CONFIDENTIAL –FOIA Exemptions Apply in U.S. 1
Status: Approved ,Date: 6 November 2020Janssen Vaccines & Prevention B.V.*
Clinical Protocol
A Randomized, Double -blind, Placebo -controlled Phase 1/2a Study for Safety and 
Immunogenicity Evaluations for Regimen Selection of Ad26.RSV.preF and/or RSV preF 
Protein Combinations Followed by [CONTACT_624652] 60 Years 
and Older
Protocol VAC18193RSV1004 ; Phase 1/2a
Amendment 6
VAC18193 (JNJ -64400141)
* Janssen Vaccines & Prevention B.V. is a Janssen pharmaceutical company  of Johnson &
Johnson and is hereafter referred to as the sponsor of the study . The sponsor is identified on the
Contact I nformation page that accompanies the protocol
This study  will be conducted under US Food & Drug Administration I NDregulations (21 CFR 
Part 312).
Status : Approved
Date : 6 November 2020
Prepared by: [CONTACT_130328] & Prevention B.V.
EDMS number: EDMS- ERI-143743616, 16.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements.
Confidentiality Statement
The information provided herein contains Company trade secrets, commercial or financial information that the Company 
customarily holds close and treats as confidential. The information is being provided under the assurance that the recipi[INVESTIGATOR_624595], regulations, rules, protective orders or 
otherwise.
[STUDY_ID_REMOVED]
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 2
Approved , Date: [ADDRESS_831961] OF IN -TEXT T ABLES A ND FIG URES ................................................................................................ 4
PROTOCOL A MENDMENTS ....................................................................................................................... 6
SYNOPSIS .................................................................................................................................................. 13
SCHEDULE OF A CTIVITI ES –COHORT 1 ............................................................................................... 28
SCHEDULE OF A CTIVITI ES –COHORT 2 ............................................................................................... 30
SCHEDULE OF A CTIVITI ES –COHORT 2 (GROUP S 14-15) LONG -TERM F OLLOW -UP 
PHASE............................................................................................................................................... 32
SCHEDULE OF A CTIVITI ES–COHORT 3 WITH ONE -DOSE REGIMEN A ND MONTH 12 A ND 
MONTH 24 BOOSTER ...................................................................................................................... 33
SCHEDULE OF A CTIVITI ES –COHORT 3 WITH T WO-DOSE REGIMEN A ND MONTH 12 
BOOSTER ......................................................................................................................................... 35
ABBREVIA TIONS ...................................................................................................................................... 38
1. INTRODUCTION ................................................................................................................................ 39
1.1. Background .................................................................................................................................... 40
1.2. Overall Rationale for the Study ...................................................................................................... 45
2. OBJECTIVES, ENDPOINT S, AND HYPOTHESIS ........................................................................... 46
2.1. Objectives and Endpoints .............................................................................................................. 46
2.2. Hypothesis ..................................................................................................................................... 49
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .49
3.1. Overview of Study .......................................................................................................................... 49
3.1.1. Study Design .............................................................................................................................. 49
3.1.2. Study Procedures ....................................................................................................................... 54
3.2. Study Design Rationale .................................................................................................................. 60
4. PARTICIPA NT POPUL ATION.......................................................................................................... 62
4.1. Inclusion Criteria ............................................................................................................................ 62
4.2. Exclusion Criteria ........................................................................................................................... 64
4.3. Prohibitions and Restrictions ......................................................................................................... 66
5. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. 66
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 68
7. VACCINE COMPLIA NCE .................................................................................................................. 69
8. PRE-STUDY A ND CONCOM ITANT THERA PY............................................................................... 69
9. STUDY PROCEDURES AND EVA LUATIONS ................................................................................. 70
9.1. Study Procedures ........................................................................................................................... 70
9.1.1. Overview ..................................................................................................................................... 70
9.1.2. Visit Windows ............................................................................................................................. 71
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 3
Approved , Date: 6 November [ZIP_CODE].1.3. Screening Phase (Day s -28to0for Cohorts 1and 2; Before Randomization on Day 1 for 
Cohort 3)..................................................................................................................................... 75
9.1.4. Randomization (Day 1) ............................................................................................................... [ADDRESS_831962]- Vaccination Follow -up........................................................................................................ 78
9.1.7. Final Visit .................................................................................................................................... 79
9.1.8. Early W ithdrawal: Early Exit Visit ................................................................................................ 79
9.1.9. Long- term Follow -up (Groups 14 and 15 from Cohort 2)........................................................... 79
9.2. Study Evaluations .......................................................................................................................... 80
9.2.1. Immunogenicity ........................................................................................................................... 80
9.2.2. RTI Procedures ........................................................................................................................... 82
9.2.3. Safety Evaluations ...................................................................................................................... 83
[IP_ADDRESS]. Adverse Events ....................................................................................................................... 83
[IP_ADDRESS]. Clinical Laboratory Tests ......................................................................................................... 85
[IP_ADDRESS]. Electrocardiogram ................................................................................................................... 87
[IP_ADDRESS]. Vital Signs ................................................................................................................................ 87
[IP_ADDRESS]. Physical Examination .............................................................................................................. 87
10. PARTICIPA NT COMPLETI ON/DISCONTINUA TION OF STUDY VA CCINE/ 
WITHDRA WAL FROM THE STUDY ................................................................................................ .88
10.1. Completion ..................................................................................................................................... 88
10.2. Discontinuation of Study Vaccine/W ithdrawal from the Study ....................................................... 88
10.3. Contraindications to Vaccination .................................................................................................... 89
11. STATISTICA L METHODS ................................................................................................................. 90
11.1. Analysis Sets .................................................................................................................................. 90
11.2. Sample Size Determination ........................................................................................................... 91
11.2.1. Initial Safety Cohort (Cohort 1) ................................................................................................... 91
11.2.2. Regim en Selection Cohort (Cohort 2) ........................................................................................ 91
11.2.3. Expanded Safety Cohort (Cohort 3) ........................................................................................... 92
11.3. Participant Information ................................................................................................................... 92
11.4. Immunogenicity Analyses .............................................................................................................. 92
11.5. Safety Analyses ............................................................................................................................. 93
11.6. Planned Analyses .......................................................................................................................... 94
11.6.1. Initial Safety Cohort (Cohort 1) ................................................................................................... 94
11.6.2. Regim en Selection Cohort (Cohort 2) ........................................................................................ 95
11.6.3. Expanded Safety Cohort (Cohort 3) ........................................................................................... [ADDRESS_831963] Quali ty.......................................................................... 106
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 4
Approved , Date: [ADDRESS_831964] ................................................. 111
16.2.3. Informed Consent ..................................................................................................................... 113
16.2.4. Privacy of Personal Data .......................................................................................................... 114
16.2.5. Long- Term Retention of Samples for Additional Future Research .......................................... 114
16.2.6. Countr y Selection ..................................................................................................................... 114
17. ADM INISTRA TIVE REQUI REM ENTS ............................................................................................ 115
17.1. Protocol Amendments .................................................................................................................. 115
17.2. Regulatory Documentation .......................................................................................................... 115
17.2.1. Regulatory Approval/Notification .............................................................................................. 115
17.2.2. Required Pre -study  Documentation ......................................................................................... 115
17.3. Participant Identification, Enrollment, and Screening Logs ......................................................... 116
17.4. Source Doc umentation ................................................................................................................. 116
17.5. Case Report Form Completion .................................................................................................... 117
17.6. Data Quality Assurance/Quality Control ...................................................................................... [ADDRESS_831965] Retention ......................................................................................................................... 118
17.8. Monitoring .................................................................................................................................... 118
17.9. Study Com pletion/Termination ..................................................................................................... 119
17.9.1. Study Com pletion/End of Study ................................................................................................ 119
17.9.2. Study Termination ..................................................................................................................... 119
17.10. On-Site Audits .............................................................................................................................. 120
17.11. Use of Information and Publication .............................................................................................. 120
18. APPENDIX 1: GUIDA NCE ON STUDY CONDUCT DU RING THE COVID- [ADDRESS_831966] OF A TTACHMENTS
Attachment 1: Toxicity Tables ............................................................................................................. [ADDRESS_831967] OF IN -TEXT TA BLES A ND FIGURES
TABLES
Table 1: Study Design: Initial Safety Cohort (Cohort 1) .......................................................................... 18
Table 2: Study Design: Regimen Selection Cohort (Cohort 2) ............................................................... 19
Table 3: Study Design: Expanded Safety Cohort (Cohort 3) with One -dose Regimen and
Month 12 and Month 24 Booster .............................................................................................. 20
Table 4: Study Design: Expanded Safety Cohort (Cohort 3) with Two- dose Regimen and 
Month 12 Booster ...................................................................................................................... 20
Table 5: Summary  of Immunogenicity Assay s (Humoral) ...................................................................... 21
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 5
Approved , Date: 6 November 2020Table 6: Summary  of Immunogenicity Assay s (Cel lular) ........................................................................ 22
Table 7: Other Ongoing Clinical Studies with Ad26.RSV.preF ............................................................... 43
Table 8: Study Design: Initial Safety Cohort (Cohort 1) .......................................................................... 52
Table 9: Study Design: Regimen Selection Cohort (Cohort 2) ............................................................... 53
Table 10: Study Design: Expanded Safety Cohort (Cohort 3) with One -dose Regimen and 
Month 12 and Month 24 Booster .............................................................................................. 54
Table 11: Study Design: Expanded Safety Cohort (Cohort 3) with Two- dose Regimen and 
Month 12 Booster ...................................................................................................................... 54
Table 12: Visit Windows: Initial Safety Coho rt (Cohort 1) ......................................................................... 72
Table 13: Visit Windows: Regimen Selection Cohort (Cohort 2).............................................................. 73
Table 14: Visit Windows: Expanded Safety Cohort (Cohort 3) -One-dose Regimen and 
Month 12 and Month 24 Booster .............................................................................................. 74
Table 15: Visit Windows: Expanded Safety Cohort (Cohort 3) -Two-dose Regimen and 
Month 12 Booster ...................................................................................................................... 75
Table 16: Summary  of Immunogenicity Assay s (Humoral) ...................................................................... 81
Table 17: Summary  of Immunogenicity Assay s (Cellular) ........................................................................ 81
Table 18: Probability of Observing at Least One Adverse Event in the Initial Safety Cohort 
(Cohort 1) at a Given True Adverse Event Rate ....................................................................... 91
Table 19: Probability of Observing at Least One Adverse Event in the Expanded Safety Cohort 
(Cohort 3) at a Given True Adverse Event Rate ....................................................................... 92
FIGURES
Figure 1: Schematic Overview of the Study for Cohort 1 ......................................................................... 57
Figure 2: Schematic Overview of the Study for Cohort 2 ......................................................................... 58
Figure 3: Schematic Overview of the Study for Cohort 3 One -dose Regimen and Month 12 and 
Month 24 Booster ...................................................................................................................... 59
Figure 4: Schematic Overview of the Study for Cohort 3 T wo-dose Regimen and Month 12 
Booster...................................................................................................................................... 60
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 6
Approved , Date: 6 November 2020PROTOCOL A MENDMENTS
Protocol Version Issue Date
Original Protocol 30 January 2018
Amendment 1 19March 2018
Amendment 2 24 September 2018
Amendment 3 28 January 2019
Amendment 4 12July 2019
Amendment 5 8 June 2020
Amendment 6 06November 2020
Amendment 6 (Issued date: 06November 2020)
The overall reason for the amendment: To further examine the immune response to revaccination at different 
time intervals , this amendment changes the Month [ADDRESS_831968] vaccination visit is also added to further examine the kinetics of the 
immune responses.
The table below gives an overview of each change and all affected sections
Rationale: For Cohort 3, participants in Group 20 w ill receive the selected regimen at Month 24 .
Synopsis: Objectives, Endpoints and Hypothesis 
Synopsis: Overview of Study Design –Expanded Safety Cohort (Cohort 3)
2.1Objectives and Endpoints
3.1.1 Study Design –Expanded Safety Cohort (Cohort 3)
5Treatment Allocation and Blindi ng
11.6.4 Final Analysis
Rationale: For Cohort 3, an additional visit 14 days after the Month 24 vaccination is added .
Schedule of Activities –Cohort 3 with One- dose Regimen and Month 12 and Month 24 Booster
3.1.1 Study Design (Figure 3)
9.1.[ADDRESS_831969]-vaccination Follow -up
Rationale: Corrections of errors in footnote numbering have been made.
Throughout the protocol
Amendment 5 (Issued date: 8 June 2020)
The overall reason for the amendment: This amendment is made to further extend the assessment of durability 
of the immune response in Groups [ADDRESS_831970] vaccination . For the one -dose 
regimen in Cohort 3, an additional revaccination at Month 24 (Day 730 )with a [ADDRESS_831971] -vaccination follow -up 
period is added .
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 7
Approved , Date: 6 November 2020The table below gives an overview of each change and all affected sections
Rationale: For Cohort 2, participants in 2 groups (Groups 14 and 15) will continue into a long -term follow -up 
phase to further extend the assessment of the long -term durability of the immune response in, and to understand 
the potential effect of a decreased dose level of Ad26.RSV.preF on long -term durability of the immune response.
During th e long -term follow -up phase, onl y SAEs related to study vaccine ,study procedures ,or non -
investigational (concomitant) Janssen products, and all AEs leading to discontinuation will be collected.
Synopsis: Objectives and Endpoints
Synopsis: Overview of Study Design
Synopsis: Safety Eval uations
Synopsis: Statistical Methods
Schedule of Activities –Cohort 2 (new table for long -term follow- up created)
2.1Objectives and Endpoints
3.1.1Study Design
3.1.2 Study Procedu res
3.2Study Design Rationale
4.2Exclusion Criteria
5Treatment Allocation and Blinding
8Pre-study and Concomitant Therapy
9.1.1 Overview
9.1.2 Visit Windows
9.1.7 Final Visit
9.1.9 Long -term Follow -up (Groups 14 and 15 from Cohort 2)
[IP_ADDRESS] Adverse Events
10.1 Completion
11.6.2 Regimen Selection Cohort (Cohort 2)
12.1.1 Adverse Event Definitions and Classificati ons
12.3.1 All Adverse Events
12.3.2 Serious Adverse Events
16.2.3 Informed Consent
17.9.1 Study Completion/End of Study
Rationale: For the one -dose regimen in Cohort 3, to add an additional revaccination at Month 24 (Day  730)with 
a 1-year post- vaccination follow -up period to a ssess the long -term durability of the immune response of the 
selected dose, and to assess the safety and immunogenicity of the selected dose after tw o annual revaccinations 
(Month 12 and Month 24).
Syno psis: Objectives and Endpoints (Cohort 3)
Synopsis: Overview of Study Design
Synopsis: Statistical Methods
Schedule of Activities –Cohort 3
2.1Objectives and Endpoints (Cohort 3)
3.1.[ADDRESS_831972]-Vaccination Follow -up
9.1.7 Final Visit
[IP_ADDRESS] Physical Examination
10.1 Completion
11.4 Immunogenicity Analyses
11.6.3 Expanded Safety Cohort (Cohort 3)
16.2.3 Informed Consent
11.8 Data Review Committee
17.9.1 Study Completion/End of Study
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 8
Approved , Date: 6 November 2020Rationale: To specify RTI follow -up will only be recorded during the first [ADDRESS_831973] participant in Cohort 1.
Synopsis: Objectives and Endpoints
Synopsis: RTI Procedures
Schedule of Activities –Cohorts 1, [ADDRESS_831974]-vaccination Follow -up
9.2.2 RTI Procedures
Rationale: To specify that eligibility for revaccination is determined by [CONTACT_624653].
4.1Inclusion Criteria
Rationale: For health and safety reasons due to the Coronavirus Disease 2019 (COVID -19), participants may not 
be able to come to the study site for scheduled procedures. Appendix 1 has been added to provide guidance to the 
investigator for managing study -related pro cedures during the COVID -19 pandemic.
Appendix 1
Rationale: Minor textual changes, clarifications and corrections have been made.
Throughout the protocol
Amendment 4(Issued date: 12July 2019)
The overall reason for the amendment: This amendm ent is made to include changes to the dosing regimen to 
obtain more data on the long -term durability of the immune response. For Cohort 2, study vaccination at the 
Month 12 visit is removed, and the 7 -day and 28 -day visits after the Month 12 visit ar e deleted .
Month 12 re- vaccination of the selected regimen is already included in Cohort 3. T he w indow  for the Month 12 
re-vaccination for Cohort 3 isamended to –[ADDRESS_831975] -dose blood sample w ould be 
available in parallel with data from the primary analysis of the proof -of-concept study VAC18193RSV2001 to 
aid decision making on Month 12 revaccination in that study .
The table below gives an overview of each change and all affected sections
Rationale: For Cohort 2, t oremo ve study vaccination from the procedures at the Month [ADDRESS_831976] vaccination for 
this cohort.
Synopsis: Objectives and Endpoints (Cohort 2)
Synopsis: Overview of Study Design
Synopsis: Statistical Methods
Synopsis: Schedule of Activities –Cohorts 1 and 2 (new table for Cohort 2 created)
2.1Objectives and Endpoints (Cohort 2)
3.1.1 Study Design
3.1.2 Study Procedures (new figure for Cohort 2 created)
3.2Study Design Rationale
9.1.1 Overview
9.1.2 Visit Windows
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 9
Approved , Date: [ADDRESS_831977]-vaccination Follow -up
9.1.7 Final Visit: [ADDRESS_831978] Vaccination (Month 12 Booster)
[IP_ADDRESS] Physical Examination
10.1 Completion
11.6.2 Regimen Selection Cohort (Cohort 2)
11.8 Data Review Committee
17.9.1 Study Completion/End of Study
Rationale: To amend the visit w indow  for the Month 12 vaccination in Cohort 3 from ±2 months to –2 months ; 
and to align the visit windows for Visits 10, 11 and 12 in Cohort 2 to ± 1month.
Synopsis: Schedule of Activities –Cohort 2
Synopsis: Schedule of Activities –Cohort 3
9.1.2 Visit Windows
Rationale: Clarification that participants discontinued from study vaccine should be m onitored for 
immunogenicity, if this does not result in safety risks for the participant, as well as safety, and /orfor other 
procedures (eg, RTI follow -up).
10.2Discontinuation of Study Vaccine/Withdrawal from the Study 
Amendment 3(Issued date: 28January 2019)
The overall reason for the amendment: To investigate the durability of the immune response both with and 
without revaccination at Month [ADDRESS_831979] the 63 in the subset of Cohort 3 participants .No change is 
made for the collection of blood for c ellular immunogenicity assessment s.
The table below gives an overview of the rationale for each change and all affected sections
Rationale: To allow  collection of blood samples for humoral immunogenicity assessments from all [ADDRESS_831980] the 63 in the Cohort 3 subset .
Synopsis: Objectives and Endpoints (Cohort 3) ; Immunogenicity Evaluations
Schedule of Activities (Cohort 3)
2.1Objectives and Endpoints (Cohort 3)
3.1.2 Study Procedures
5Treatment Allocation and Blinding
9.1.1 Overview
9.2.1 Immunogenicity
Rationale: Toclarify that a participant who miss esavaccination can receive subsequent vaccinations if the 
investigator determines that the participant is eligible according to the criteria in Section 10.3.
10.2 Discontinuation ofStudy Vaccine /Withdrawal from the Study
Rationale: Clarification of the data to be used in the primary analysis of Cohort 3.
11.6.3 Expanded Safety Cohort (Cohort 3)
Rationale: Other minor changes, clarifications and corrections made throughout the protocol.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 10
Approved , Date: 6 November 2020Amendment 2(Issued date: 24September 2018)
The overall reason for the amendment: To remove the concom itant seasonal influenza vaccination for Cohort 
3, and to increase the sample size in Cohort 3 to generate sufficient safety data to support late stage development .
Also, additio nal blood sample collection for cellular and humoral immunogenicity is included for a subset of 
63participants from Cohort 3 to provide a more in -depth characterization of immune response. Furthermore, to 
ensure availability of immunogenicity data from Co hort 2 primary analysis in time to support late stage 
development decisions, assessments of RSV neutralizing antibody levels of the one -dose regimen with separate 
injections (Group 16) and the tw o-dose regimen (Group 17) have been moved from primary to sec ondary 
endpoints.
The table below gives an overview of the rationale for each change and all affected sections
Rationale: Removal of the seasonal influenza vaccination (or placebo) as timing of Cohort 3 vaccination will no
longer coincide with the influenza season.
Title
Synopsis: Objectives ,Endpoints and Hypothesis ; Overview of Study Design; Dosage and Administration;
Immunogenicity Evaluations; Statistical Methods
Schedule of Activities (Cohort 3)
1Introduction
2.1Objectives and Endpoints
2.2Hypothesis
3.1.[ADDRESS_831981]-vaccination Follow -up
9.1.8 Early Withdrawal: Early Exit Visit
9.2.1 Immunogenicity
11.1 Analysis Sets
11.2.3 Sample Size Determination (Cohort 3)
11.4 Immunogenicity Analyses
11.9 Study Vaccination Pausing Rules
12.1.1 Adverse Event Definitions and Classifications
14.1 Physical Description of the Vaccines
15Study-S pecific Materials
16.1 Study -Specific Design Considerations
Rationale: Increase in the sample size forCohort 3 to 315participant s to provide sufficient safety data on the 
selected regimen to support late stage development .
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 11
Approved , Date: 6 November 2020Synopsis: Overview of Study Design ; Immunogenicity Evaluations
1.2Overall Rationale for the Study
3.1.1 Study Design
5Treatment Allocation and Blinding
9.1.1 Overview
Rationale: Inclusion of additional blood sample collection (at additional timepoints) for cellular and humoral 
immunogenicity for a subset of 63 participants from Cohort 3 to provid e sufficient timepoints with 
immunogenicity samples which will be used for immune response modelling in preparation of Phase 3 studies.
Synopsis: Immunogenicity Evaluations
Schedule of Activities (Cohort 3)
5Treatment Allocation and Blinding
9.1.[ADDRESS_831982]-vaccination Follow -up
9.2.1 Immunogenicity
Rationale: Assessments of RSV neutralizing antibody levels of the one -dose regimen with separate injections 
(Group 16) and the tw o-dose regimen (Group 17) w ere m oved from primary to secondary endpoints to ensure 
availability of immunogenicity data from Cohort 2 prim ary analysis in time to support late stage development 
decisions.
Synopsis: Objectives, Endpoints and Hypothesis ; Overview of Study Design; Immunogenicity Evaluations; 
Statistical Methods
2.1Objectives and Endpoints
3.1.1 Study Design
9.2.1 Immunogenicity
11.6.2 Regimen Selection Cohort (Cohort 2)
Rationale: Other minor changes, clarifications and corrections made throughout the protocol.
Amendment 1 (Issued date: 19March 2018)
The overall reason for the amendment: The protocol amendment is made to change the timing of the seasonal 
influenza vaccination for Cohort 3. Changes in project timelines have resulted in the likelihood that some 
participants in this study would not receive seasonal influenza vaccination until very late in the influenza season. 
The amended vaccination regimen for Cohort [ADDRESS_831983] on Day 1 itself. Also, the sample size for Cohort 3 is 
reduced.
The table below gives an overview of the rationale for each change and all affected sections
Rationale: Retiming of the seasonal inf luenza vaccination (or placebo)
Synopsis: Objectives and Endpoints; Overview of Study Design; Immunogenicity Evaluations; Statistical 
Methods
Schedule of Activities (Cohort 3)
1.2Overall Rationale for the Study
2.1Objectives and Endpoints
3.1.1 Study Design
3.1.2 Study Procedures
3.2Study Design Rationale
4Participant Population
5Treatment Allocation and Blinding
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 12
Approved , Date: [ADDRESS_831984]-vaccination Follow -up
9.1.8 Early Withdrawal: E arly Exit Visit
9.2.1 Immunogenicity
11.1 Analysis Sets
11.2.3 Sample Size Determination (Cohort 3)
11.4.2 Immunogenicity Analyse s (Cohort 3 )
11.6.3 Planned Analyses (Cohort 3)
11.8 Data Review Committee
Rationale: Clarification that participants with a history of allergy to egg protein will be excluded from the study
4.2Exclusion Criteria
Rationale: Clarification that ,for pausing rules 1, 3 and 4, the term “related to study vaccine” exclud esseasonal 
influenza vaccine/placebo for seasonal influenza vaccine
11.9 Study Vaccination Pausing Rules
Rationale : Other clarifications and minor correc tions to remove inconsistencies
Synopsis: Dosage and Administration
Schedule of Activities
1.1Background
5Treatment Allocation and Blindi ng
6Dosage and Administration
10.2 Discontinuation of Study Vaccine
12.1.1 Adverse Event Definitions and Classifications
12.3.3 Pregnancy
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 13
Approved , Date: 6 November 2020SYNOPSIS
A Randomized, Double -blind, Placebo -controlled Phase 1/2a Study for Safety and Immunogenicity 
Evaluations for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations 
Followed by [CONTACT_624652] 60 Years and Older
A human adenovirus -vectored vaccine candidate and a pre-fusion conformation- stabilized respi[INVESTIGATOR_14256] (RSV) F protein which have shown promise in preclinical animal models of RSV will be 
assessed in this study:
Ad26.RSV.preF (JNJ-64400141), a replication -incompetent adenovirus serotype 26 (Ad26)
containing a deoxyribonucleic acid (DNA) transgene that encodes the pre-fusion conformation -
stabilized F protein (pre -F) derived from the RSV A2 strain.
RSV preF protein (JNJ -64213175) is a pre -fusion conformation- stabilized F protein derived from the 
RSV A2 strain .
This will be the first-in-human (FIH) study for RSV preF protein, and for the Ad26.RSV.preF/RSV preF 
protein combination (administered as separate injections in opposite arms ) and Ad26.RSV.preF/RSV preF 
protein mixture (administered as a single injection).
OBJECTIVE S, ENDPOINTS, AND HYPOTHESIS
Objectives and Endpoints
The current study has an adaptive design to determine a regimen for further clinical development in adults 
aged ≥[ADDRESS_831985] on cellular response compared to Ad26.RSV.preF alone.
SAFETY COHORT OBJECTIVE (COHORT 1): To determine in small numbers of participants aged 60 years and older the 
safety of intramuscular homologous two -dose regimens comprising RSV preF protein or Ad26.RSV.preF/RSV preF prot ein 
mixture on Days 1 and 57, with a booster at Month 12, or separate administration of Ad26.RSV.preF and RSV preF protein in 
opposite arms on Day 1 with a booster at Month 12, before progression to regimen selection in a larger number of participants
Objectives Endpoints
PRIMARY
To assess the safety and reactogenicity of the 
intramuscular one -and two -dose regimens, with 
abooster at Month 12Serious adverse events (S AEs)from first dose 
administration until the end of the study
Solicited local and systemic adverse events ( AEs)for 
7 days after each vaccine administration
Unsolicited AEs from the time of each vaccine 
administration through the following 28 days
SECONDARY
To assess the humoral and cellular immune responses 
elicited by [CONTACT_300092]26.RSV.preF, RSV preF protein, and the 
Ad26.RSV.preF/RSV preF protein combination and 
mixtureRSV neutralization assay, F protein binding antibodies 
(enzyme -linked immunosorbent assay [ELISA ]; pre -F 
and/or post -F), and interferon -gamma ( IFN-γ) enzyme -
linked immunospot (ELISpot) assay
EXPLORATORY
Additional exploratory analyses may be performed to 
investigate vaccine -elicited immune responses furtherAssays to be used include, but are not limited to, RSV 
strain cross -neutralization, anti -F protein antibody 
specificity and functionality characterization, adenovirus 
neutralization assays, molecular antibody 
characterization (avidity, Fc cell interaction, antibody 
isotypi[INVESTIGATOR_007], antibody sequencing for repertoire), and nasal 
antibodies to RSV, including but not limited to 
immunoglobulin (Ig )A and IgG; evaluation of the 
cellular immune response and the functional and 
memory immune response by [CONTACT_624654] (ICS) and transcriptome analysis
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 14
Approved , Date: 6 November 2020Objectives Endpoints
To evaluate symptoms of respi[INVESTIGATOR_4375] (including
respi[INVESTIGATOR_624596] )via the Respi[INVESTIGATOR_228737] (RTI) Symptoms FormDuring the RSV season: Signs and symptoms of RTI 
(including RTI due to RSV )from Day 1 until the end of 
the second RSV season of the studya
Characterization of viral or bacterial infections in the 
respi[INVESTIGATOR_4352]Assessment , typi[INVESTIGATOR_624597] ( RT-PCR )or 
response to respi[INVESTIGATOR_624598] (COHORT 2): To select a regimen for progression to evaluation in an 
expanded safety cohort (Cohort 3;see below) by [CONTACT_624655] 60 years 
andolder of intramuscular one-dose regimens of Ad26.RSV.preF, Ad26.RSV.preF/RSV preF protein mixture, or separate 
administration of Ad26.RSV.preF and RSV preF protein in opposite arms on Day 1, or a two -dose regimen of Ad26.RSV. preF/
RSV preF protein mixture on Days 1 and 57 
Objectives Endpoints
PRIMARY
To assess the safety and reactogenicity of the 
intramuscular one -and two -dose regimensSAEs from first dose administration until the end of 
thestudy
Solicited local and systemic AEs for 7 days after each 
vaccine administration
Unsolicited AEs from the time of each vaccine 
administration through the following 28 days
To assess RSV neutralizing antibody levels of the 
one-dose regimens (Groups 11to 15) containing
RSV preF protein compared to the one -dose 
Ad26.RSV.preF regimen RSV A2 neutralizing antibody levels of the one -dose 
regimens (Groups 11to 15) on Day 29b
SECONDARY
To assess RSV neutralizing antibody levels of the 
one-dose regimen with separate injections 
(Group 16) and the two -dose regimen (Group 17) 
containing RSV preF protein compared to the 
one-dose Ad26.RSV.preF regimenRSV A2 neutralizing antibody levels of:
 the one -dose regimen with separate injections
(Group 16) on Day 29
 the two -dose regimen (Group 17) on Day 85b
To assess additional humoral immune responses 
elicited by [CONTACT_300092]26.RSV.preF and the 
Ad26.RSV.preF/RSV preF protein combination 
andmixtureF protein binding antibodies (ELISA; pre-F and/or post -F)
To assess cellular immune responses by 
[CONTACT_20129]-γ ELISpot of all regimens containing RS V 
preF protein compared to the one-dose 
Ad26.RSV.preF regimen RSV F protein by [CONTACT_20129] -γ ELISpot assay
-the one -dose regimens on Day 29b(Groups 11to16)
-the two -dose regimen on Day 85b(Group 17)
EXPLORATORY
Additional exploratory analyses may be performed 
to investigate vaccine -elicited immune responses 
furtherAssays to be used include, but are not limited to, RSV strain 
cross -neutralization, anti -F protein antibody specificity and 
functionality characterization, adenovirus neutralization 
assays, molecular antibody characterization (avid ity, Fc cell 
interaction, antibody isotypi[INVESTIGATOR_007], antibody sequencing for 
repertoire), and nasal antibodies to RSV, including but not 
limited to IgA and IgG; evaluation of the cellular immune 
response and the functional and memory immune response 
by [CONTACT_624656] 1.
bSee “STATISTICAL METHODS -Immunogenicity Analyses” for details.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 15
Approved , Date: 6 November 2020Objectives Endpoints
To assess the long -term durability of the immune 
response in selected groupsAssays to be used include, but are not limited to, RSV 
neutralizing antibody levels against A and B strain, RSV F 
protein binding antibodies (ELISA; pre-F and/or post-F), 
RSV F protein specific functional antibodies, and RSV F 
protein specific IFN -γ ELISpot in Groups 14 and 15 at Days 
912and 1 095
To evaluate symptoms of respi[INVESTIGATOR_4375]
(including respi[INVESTIGATOR_624596]) via the 
RTI Symptoms For mDuring the RSV season: Signs and symptoms of RTI 
(including RTI due to RSV) from Day 1 until the end of the 
second RSV season of the studya
Characterization of viral or bacterial infections in 
the respi[INVESTIGATOR_4352]Assessment, typi[INVESTIGATOR_624599]-PCR or 
response to respi[INVESTIGATOR_624600] (COHORT 3): To determine the safety and immunogenicity of the selected 
regimen in an expanded cohort of participants aged 60 years and older; and to determine the need for a booster dose at 
Month 12and/orMonth 24
Objectives Endpoints
PRIMARY
To assess the safety and reactogenicity ofthe selected 
regimen and a booster at Month 12and/orMonth 24SAEs from first administration until the end of the study
Solicited local and systemic AEs for 7 days after each 
vaccine administration
Unsolicited AEs from the time of each vaccine 
administration through the following 28 days
SECONDARY
To assess humoral immune responses to the selected 
regimen in all participants RSV neutralization A2 strain
To assess cellular immune responses to the selected 
regimen in a subset of participantsIFN-γ ELISpot assay 
EXPLORATORY
Additional exploratory analyses may be performed to 
further investigate vaccine-elicited immune responses Assays to be used include, but are not limited to:
F protein binding antibodies (ELISA; pre-F and/or 
post-F)
Flow cytometry 
RSV cross -neutralization of B and/or other A strain
F-protein antibody specificity characterization
Cytokines/chemokines in nasal samples (if feasible)
Adenovirus neutralization assays
Functional and molecular antibody characterization
Analysis of nasal antibodies to RSV includin g, but not 
limited to IgA and IgG
To assess the long-term durability of the immune 
response in groups receiving a booster at different time 
intervals Assays to be used include, but are not limited to, RSV 
neutralizing antibody levels against A and B strain, RSV 
F protein binding antibodies (ELISA; pre-F and/or post-
F), RSV F protein specific functional antibodies, and RSV 
F protein specific IFN-γ ELISpo t at Days 758, 912 and 
1095
To evaluate symptoms of respi[INVESTIGATOR_4375] (including 
respi[INVESTIGATOR_624596]) via the RTI Symptoms 
FormDuring the RSV season: Signs and symptoms of RTI 
(including RTI due to RSV) from Day 1 until the end of 
the second RSV season of the studya
Characterization of viral or bacterial infections in the 
respi[INVESTIGATOR_4352]Assessment, typi[INVESTIGATOR_624599]-PCR or 
response to respi[INVESTIGATOR_624601] 1.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 16
Approved , Date: 6 November 2020Hypothesis
No formal statistical testing of safety and immunogenicity data is planned. Data will be analyzed 
descriptively.
OVERVIEW OF STUDY DESIGN
This is a multi -center, randomized, double -blind, placebo -controlled Phase 1/2a study for safety and 
immunogenicity evaluations for regimen selection of Ad26.RSV.preF and RSV preF protein combinations 
followed by [CONTACT_624657] ≥60
years who are in stable health .
To further extend the assess ment of the long -term durability of the immune response to the study vaccine, 
participants in Groups 14 and 15 (Cohort 2 ) will continue into a long -term follow -up phase.
The study design includes 3sequential cohorts: an initial safety cohort (Cohort 1in a total of 
64participants), a regimen selection cohort (Cohort 2 in a total of 288participants), and an expanded safety  
cohort (Cohort 3 in a total of 315 participants).
The overall total number of participants will be approximately 667.
Thestudy duration willbe approximately 730 days (2 years) per participant in Cohorts 1 and 2 (Groups 11 -
13 and Groups 16 -18), and approximately 1095 days (3 years) per participant in Coh ort 2 (Groups 14 -15) 
and Cohort 3 . The study comprises a maximum 28 -day screening period for Cohorts 1 and 2 (screening for 
Cohort 3 will be performed pre-vaccination on Day 1), study vaccination (active or placebo) with a one-
dose (on Day 1) or two-dose (on Day 1 and Day 57) regimen and a booster dose (active or placebo) at 
Month 12(Cohort 1)or at Month 12 and Month 24 (Cohort 3), a minimum 28-day follow -up period after 
each vaccination, and a follow -up period until [ADDRESS_831986] Ad26.RSV.preF or RSV preF protein 
vaccination (Cohorts 1 and 2 [Groups 11-13 and Groups 16-18]) or until [ADDRESS_831987] 
Ad26.RSV.preF or RSV preF protein vaccination (Cohort 2 [Groups 14 -15] and Cohort 3) . The end of the 
study is defined asthe last participant’s last visit 24months after the first vaccination (Cohorts 1 and 2 
[Groups 11-13 and Groups 16-18]) or the last participant’s last visit approximately 1095 days (3years) after 
the first vaccination (Cohort 2 [Groups 14 -15] and Cohort 3). 
An internal data review committee (DRC) will be established for this study to evaluate safety and 
reactogenicity data on a regular basis.
Ifanyofthe pre-specified study vaccination pausing rules is met, further study vaccination will be paused 
and a DRC meeting will be convened.
The DRC may also review unblinded immunogenicity data during the course of the study if this is deemed 
necessary for future vaccine development -related decisions.
Initial Safety Cohort (Cohort 1)
Intheinitial safety cohort, participants will be randomized progressively in 1 of 4randomizations (R1a 
through R1d) with safety checks in place before extending enrollment and progressing from one 
randomization step to the next as follows ( Table 1):
Cohort R1a. Initially 2 participants will be enrolled, 1 into Group 1 and 1 into Group 2, and will receive 
a single dose of placebo or 50g of RSV preF protein, respectively. Enrollment will be paused to 
allow for 24-hour safety assessments in these 2 sentinel participants by [CONTACT_458](s) 
(PI[s]), the sponsor’s study responsible physician/ scientist (SR P/S), and the sponsor’s medical leader 
(ML). In the absence of any clinical safety concerns over the 24-hour assessment, the remaining 
10participants will be randomized and dosed. Seven days after the last participant has received his/her 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 17
Approved , Date: [ADDRESS_831988] dose, available safety data will be reviewed by [CONTACT_978](s), SRP/S , ML, and the sponsor’s therapeutic 
area safety head (TASH) before proceeding to Cohort R1b .
Cohort R1b. Initially 3 participants will be enrolled, 1 into each of Groups 3 through 5, and will receive 
a single dose of placebo, 5×1010 viral particles (vp)Ad26.RSV.preF/50 g RSV preF protein, or 150g
RSV preF protein, respectively. Enrollment will be paused to allow for 24 -hour safety assessments in 
the 3 sentinel participants by [CONTACT_978](s), SRP/S , and ML. In the absence of any clinical safety concerns 
over the [ADDRESS_831989] participant has received his/her first dose, available safety data will be reviewed by [CONTACT_1600](s), SRP/S , ML, and TASHbefore proceeding to Cohort R1c.
Cohort R1c. Initially 2 participants will be enrolled, 1 into Group 6 and 1 into Group 7, and will receive 
a single dose of placebo or 5×1010 vp Ad26.RSV.preF/150 g RSV preF protein, respectively. 
Enrollment will be paused to allow for 24-hour safety assessments in these 2sentinel participants by 
[CONTACT_978](s), SRP/S , and ML. In the absence of any clinical safety concerns over the [ADDRESS_831990] participant has 
received his/her first dose, available safety data will be reviewed by [CONTACT_978](s), SRP/S , ML, and TASH
before proceeding to Cohort R1d.
Cohort R1d. Initially 3 participants will be enrolled, 1 into each of Groups 8 through 10, and will 
receive 2 doses of placebo (1 in each arm), or 1×1011 vp Ad26.RSV.preF/150 g RSV preF protein, 
with placebo in the opposite arm, or 1×1011 vp Ad26.RSV.preF in one arm and 150g RSV preF 
prote in in the opposite arm. Enrollment will be paused to allow 24-hour safety assessments in the 
3sentinel participants by [CONTACT_978](s), SRP/S , and ML. In the absence of any clinical safety concerns over 
the 24 -hour assessment , the remaining 17 participants will be randomized and dosed.
Seven days after the final participant inCohort 1 has received his/her first dose, all available safety 
data at that time for the whole cohort will be reviewed by [CONTACT_624658] 2.
Sentinel participants will be contact[CONTACT_5143] [ADDRESS_831991] safety information.
Progression to the regimen selection cohort will be based on acceptable safety in the initial safety cohort, 
as determined by [CONTACT_624659] 8 safety data in all participants .
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 18
Approved , Date: 6 November 2020Table 1: Study Design :Initial Safety Cohort (Cohort 1)
Group R N Day 1 Day 57 Month 12
1 R1a 4 Placebo Placebo Placebo 
2 R1a 8 RSV preF protein 50 g RSV preF protein 50 g RSV preF protein 50 g
3 R1b 4 Placebo Placebo Placebo 
4 R1b 8Ad26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/50 gAd26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/50 gAd26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/50 g
5 R1b 8 RSV preF protein 150 g RSV preF protein 150 g RSV preF protein 150g
6 R1c 4 Placebo Placebo Placebo 
7 R1c 8Ad26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/150 gAd26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/150 gAd26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/150 g
8 R1d 4Placebo
+ Placebo*Placebo Placebo
+ Placebo*
9 R1d 8Ad26.RSV.preF/
RSV preF protein mixture:
1×1011 vp/150 g
+ Placebo*Ad26.RSV.preF/
RSV preF protein mixture:
1×1011 vp/150 gAd26.RSV.preF/
RSV preF protein mixture:
1×1011 vp/150 g
+ Placebo*
10 R1d 8Separate injections : 
Ad26.RSV.preF 1×1011 vp 
+ RSV preF protein 150 g*PlaceboSeparate injections : 
Ad26.RSV.preF 1×1011 vp 
+ RSV preF protein 150 g*
R1 TOTAL: 64
N:number of participants; R :randomization; vp :viral particles
* Each injection to be given in opposite arms
Regimen Selection Cohort (Cohort 2)
In the regimen selection cohort, approximately 288 participants will be randomized in parallel to 1 of 
8groups (Groups 11 through 18; Table 2). No pauses in enrollment for safety assessments are planned.
Based on safety and immunogenicity results available at the time of primary analy sis, a sponsor committee 
will decide which regimen will be used for the expanded safety cohort (Cohort 3). In case none of the 
groups that are part of the primary objective meet internal criteria, regimen selection may be delayed until 
additional analys eswill be available. Additional factors such as data from oth er assays, manufacturability , 
and e ase of administration will be taken into account to select the regimen for the expanded safety phase.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 19
Approved , Date: 6 November 2020Table 2: Study Design :Regimen Selection Cohort (Cohort 2)
Group R N Day 1 Day 57
11 R2 24Ad26.RSV.preF 1×1011 vp
+ Placebo*Placebo
12 R2 42Ad26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/50 g
+ Placebo*Placebo
13 R2 42Ad26.RSV.preF/
RSV preF protein mixture:
1×1011 vp/50 g
+ Placebo*Placebo
14 R2 42Ad26.RSV.preF/
RSV preF protein mixture:
1×1011 vp/150 g
+ Placebo*Placebo
15 R2 42Ad26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/150 g
+ Placebo*Placebo
16 R2 36Separate injections *: 
Ad26.RSV.preF 1×1011 vp 
+ RSV preF protein 150 gPlacebo
17 R2 36Ad26.RSV.preF/
RSV preF protein mixture:
1×1011 vp/150 g
+ Placebo*Ad26.RSV.preF/
RSV preF protein mixture:
1×1011 vp/150 g
18 R2 24Placebo
+ Placebo*Placebo
R2 TOTAL: 288
N:number of participants (Note : Data from Groups 9 and 10 of Cohort 1 will be pooled with those from Groups 16 and 17 of 
Cohort 2) up to Month 12 ; R:randomization; vp :viral particles
* Each injection to be given in opposite arms
Expanded Safety Cohort (Cohort 3)
In the expanded safety cohort, approximately 315 participants will be randomized in parallel to 1 of 3
groups (Groups 19 through 21; Table 3and Table 4). No pauses in enrollment for safety assessments are 
planned.
Participants will receive the selected one -or two- dose regimen from Cohort 2 or placebo.
If the one-dose regimen is selected (Groups 11 through 16 from Cohort 2), Groups 19and20 would receive 
the selected regimen on Day 1, and a booster at Month 12(the selected regimen or placebo, respectively)
and Month 24 (the selected regimen) . Group 21 will receive placebo at all timepoints (Table 3).
If the two-dose regimen is sele cted (Group 17 of Cohort 2), Groups 19and20 would receive the selected 
regimen on Day 1andon Day 57, anda booster (the selected regimen or placebo , respe ctively ) at Month 
12. Group 21 will receive placebo atall three timepoints (Table 4).
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 20
Approved , Date: 6 November 2020Table 3: Study Design :Expanded Safety Cohort (Cohort 3) with One-dose Regimen and Month 12 and Month 24 
Booster
Group R N Day 1 Month 12 Month 24
19 R3 135 Selected Regimen Selected Regimen Selected Regimen
20 R3 135 Selected RegimenPlacebo for the Selected 
RegimenSelected Regimen
21 R3 45Placebo for the Selected 
RegimenPlacebo for the Selected 
RegimenPlacebo for the Selected 
Regimen
R3 TOTAL: 315
OVERALL 
TOTAL:667
N:number of participants; R :randomization
Table 4: Study Design :Expanded Safety Cohort (Cohort 3) with Two -dose Regimen and Month 12 Booster
Group R N Day 1 Day 57 Month 12
19 R3 135 Selected Regimen Selected Regimen Selected Regimen
20 R3 135 Selected Regimen Selected Regimen Placebo for the Selected Regimen
21 R3 45 Placebo for the Selected Regimen Placebo for the Selected Regimen Placebo for the Selected Regimen
R3 TOTAL: 315
OVERALL 
TOTAL:667
N:number of participants; R :randomization
PARTICIPANT POPULATION
Participant swillbeadult menand women, aged ≥60 years on the day of signing the informed consent form 
(ICF). Participant s will be in good or stable health (on the basis of physical examination, medical history, 
laboratory safety dataa, 12-lead electrocardiogram,aand vital signs meas urement performed at screening ).
DOSAGE AND ADMINISTRATION
Ad26.RSV.preF and RSV preF protein will be administered as a combination (ie, as separate injections in 
opposite arms) or as a mixture (ie, as a single injection) into the deltoid muscle according to the schedules 
shown in Table 1, Table 2, Table 3, and Table 4:
 Ad26.RSV.preF (JNJ-64400141) will be supplied at a concentration of 2×1011vp/1 mL in single -use 
vials. Dose levels of 5×1010 vp and 1×1011 vp will be used.
 RSV preF protein (JNJ-64213175) will be supplied at a concentration of 0.3 mg/1 mL in single use 
vials. Dose levels of 50 μg and 150 μg will be used.
 Placebo for Ad26.RSV.preF andRSV preF protein.
All injections of Ad26.RSV.preF and RSV preF protein (or corresponding placebo) will be [ADDRESS_831992] or other qualified individual will prepare the appropriate vial and /orsyringe and 
provide the syringe in a blinded manner to the vaccine administrator who will perform the injection. The 
unblinded pharmacist, or other qualified individual, may also perform vaccine administration, but will have 
no other study function following dosing. Diluent will be use das required.
                                                
aFor participants in Cohorts 1 and 2 only.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 21
Approved , Date: 6 November 2020All vaccines should be administered in the deltoid muscle:
When participants receive 2injections at any given visit, the injections will be given in opposite arms 
at the same time with no more than 45 minutes between the injections.
When participants receive a single injection per visit, eg,in Groups 1 through 7 in Cohort 1, alternating 
injection sites will be used for subsequent injections unless there is a medically justifiable reason in the 
judgment of the PI(s).
IMMUNOGENICITY E VALUATIONS
All sample collection and processing will be performed by [CONTACT_624660].
Humoral and cellular immunogenicity assays that may be used in this study (as available and applicable) 
are summarized in Table 5and Table 6below.
Blood for humoral and cellular immune responses will be drawn from all partici pants in Cohorts 1 and 2 .
In Cohort 3, blood will be drawn for humoral immune responses from all participants and for cellular 
immune responses from a subset of 63participants. Nasal samples will be used for immunogenicity 
assessments (eg, immunoglobulin or cellular immune component )and identification of the etiology of 
respi[INVESTIGATOR_18073] (if needed). Blood samples for transcriptome analysis will be collected in Cohorts 1 
and 2 only.
In addition to RT -PCR performed on nasal samples,aany immunogenicity blood sample collected from all 
participant s may be assayed by [CONTACT_44898] (including but not limited to RSV virus neutralizing antibodies 
[VNA s]or ELISA specific to RSV protein G [glycoprotein] and/or N [nucleoprotein] as available and 
applicable )for RSV exposure .
Table 5: Summary of Immunogenicity Assays (Humoral)
Assay Purpose
Primary endpoint (Regimen Selection Cohort [Cohort 2 ] –Groups 11 to 15 only)
RSV neutralization A Analysis of neutralizing antibodies to an A strain
Secondary endpoints
RSV neutralization A Analysis of neutralizing antibodies to an A strain
F protein antibodies
(ELISA; pre -F and/or post -F) Analysis of antibodies binding to RSV F protein in pre -fusion and/or post -fusion form
Exploratory endpoints
RSV strain cross -neutralization Analysis of cross -neutralizing antibodies to B and/or a different A strain(s) 
F protein antibody specificity 
characterization Pre-and post -F specificity by [CONTACT_624661], and/or competition 
ELISA. Adsorption of serum or plasma with pre -F and post -F protein before any 
antibody assay, epi[INVESTIGATOR_111050], functional VNAs
G and/or N protein antibodies 
(ELISA) Analysis of antibodies binding to RSV G and/or N protein 
Adenovirus neutralization assay Analysis of neutralizing antibodies to adenovirus
Functional and molecular antibody 
characterizationAnalysis of antibody characteristics including, but not limited to, ADCC, ADCP, avidity, 
other respi[INVESTIGATOR_624602], Ig isotype, functional VNAs to 
other respi[INVESTIGATOR_4398], and antibody assessments for antibody repertoire
ADCC :antibody -dependent cell -mediated cytotoxicity; ADCP : antibody-dependent cellular phagocytosis; ELISA :enzyme -linked 
immunosorbent assay; F :fusion; G: glycoprotein; Ig:immunoglobulin; N: nucleoprotein; RSV :respi[INVESTIGATOR_4345]; VNA :
virus neutralizing antibody
Note : Antibody analyses might be performed in nasal samples, serum and plasma.
                                                
aAll references to the collection of a “nasal sample” imply a “nasal turbinate sample or its alternative ”.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 22
Approved , Date: 6 November 2020Table 6: Summary of Immunogenicity Assays (Cellular)
Assay Purpose
Secondary endpoints
IFN-γ ELISpot T-cell IFN -γ responses to RSV F protein peptides
Exploratory endpoints
ICS Analysis of T -cell responses to RSV F protein peptide -stimulated PBMC (including, 
but not limited to, CD4+/CD8+, IL-2, IFN -γ, TNF -α, activation markers and memory)
Transcriptome analysis Regulation of genes (clusters), expression patterns, that predict specific immune 
responses after vaccination
Chemokine/cytokine analysis Levels of chemokines and cytokines in nasal samples
Sequencing of B-cells Including but not limited to sequencing of BCR (B-cell receptor) or VH/VL 
(heavy/light chain characterization) for specificity
ELISpot :enzyme-linked immunospot; F :fusion; ICS : intracellular cytokine staining; IFN-γ: interferon gamma; IL -2:
interleukin -2; PBMC: peripheral blood mononuclear cell s; RSV :respi[INVESTIGATOR_4345]; TNF-α: tumor necrosis factor 
alpha
RTI PROCEDURES
During thefirst 2RSV seasons of the study (relative to the enrollment date of the first participant in 
Cohort 1), participants should record any signs and symptoms of RTI (such asrunny nose, fever, severe 
cough, rapid breathing, or difficulty breathing) , including measurement of body temperature, on a daily 
basis using a specific RTI Symptoms Form, starting on the first day they experience symptoms, including 
the day on which the symptoms resolve.
If respi[INVESTIGATOR_624603] 2RSV seasons of the study , the following should take 
place:
Participants should contact [CONTACT_624662] .
Participants should record signs and symptoms of the RTI (including measurement of body temperature) 
daily using the RTI Symptoms Form until the day of symptom resolution .
If feasible, participants should take a nasal sample at home , preferably between 2 and 3 days after the 
onset of the RTI symptoms . The sample should be stored refrigerated and brought to the site by [CONTACT_100925] 3 to 4 days.
Alternatively, participants may go to the site preferably within [ADDRESS_831993] ed by [CONTACT_119570] 30±7 days 
(unless a planned clinic visit has occurred or will occur within 30 days). These calls will remind participants 
to complete the RTI Symptoms Form in the event of any symptoms of RTI, to contact [CONTACT_624663] m onset, and to take a nasal sample (or go to the site to have a nasal sample taken by [CONTACT_464]). 
These calls will also check for any SAEs and concomitant medications associated with SAEs since the 
previous visit or telephone contact.
The presence of RSV or any other respi[INVESTIGATOR_624604]-PCR 
diagnostics on the nasal samples , which may include viral load and RSV subtypi[INVESTIGATOR_007] .
Blood from participant swith a suspected RTI may be assayed by a serological assay (eg, protein G and/or 
N ELISA) to confirm RSV infection. ( No additional blood sampling is necessary –any serological assay 
conducted to confirm RSV infection will use blood from the existing samp les.)
Every effort should be made to collect data on the clinical course of RTIs including information on 
oxygenation status, supplemental oxygen requirements and specific drug treatments, as well as other 
concurrent respi[INVESTIGATOR_624605].
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 23
Approved , Date: 6 November 2020Any RTI that is not due to RSV infection will be reported as an AE if it occurs between the time of any 
vaccination through the next 28 days. Any RTI recorded as an AE in the eCRF will be excluded from any 
AE analysis if the central laboratory RT-PCR is subsequently found to be positive for RSV. RTIs arising 
from RSV infection will not be reported as (S)AEs in the Clinical Study Report as they are endpoints of the 
study and will be tabulate d separately.
Any RTI fulfilling the criteria of an SAE will be reported as such durin g the entire study period if RT -PCR 
indicates it is not an RSV -RTI. If the RT-PCR is positive for RSV the event should not be reported as an 
SAE. If the RT -PCR information is not available within [ADDRESS_831994] the following AEs 
via the participant diary:
Solicited local AEs: erythema (measured using the ruler supplied), swelling/induration (measured using 
the ruler supplied and graded using the functional scale ), and pain/tenderness.
Solicited systemic AEs: fatigue, headache, myalgia, arthralgia, chills, nausea ,and fever (ie, body 
temperature ≥38.0°C).
Body temperature (oral route preferred) should be measured at approximately the same time each day, 
preferably in the evening, using the thermometer supplied. All diary asses sments, including body 
temperature , 7days after each vaccination may be collected earlier in the day to coincide with the clinic
visit.
Unsolicited AEs will be collected for 28 days after each vaccination (ie, from the time of each vaccination 
through the following 28 days).aSAEs will be collected from first dose administration to the end of the 
double -blind phase of the study . During the long -term follow -up phase ( Groups 14 and 15 from Cohort 2), 
only SAEs related to study vaccine ,study procedures ,or non-investigational (concomitant) Janssen 
products, and all AEs leading to discontinuation will be collected. All AEs, including any that are ongoing 
at 28 days after each dose, will be followed until clinical resolution or stabilization. Concomitant 
medications will be collected from the time of each vaccination, through 28 days after each vaccination, 
and additionally outside these periods when associated with any SAE .During the long-term follow -up 
phase (Groups 14 and 15 from Cohort 2), only medications in conjunction with SAEs related to study 
vaccine, study procedures, or non-investigational (concomitant) Janssen products, or in conjunction with 
AEs leading to discontinuation shou ld be recorded.
All SAEs and AEs leading to discontinuation from the study/vaccination (regardless of the causal 
relationship) are to be reported from the moment of first vaccination until completion of the participant’s 
last study -related procedure, which may include contact [CONTACT_160181] -up.
                                                
aAEs that start more than 28 days after a vaccination, but that are still present at the time of the next vaccination will 
also be recorded.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 24
Approved , Date: 6 November 2020STATISTICAL METHODS
Sample Size Determination
For Cohort 1, no formal sample size calculations are done.
For Cohort 2, the objective is to compare the RSV A2 neutralizing antibody levels of all regimens 
containing RSV preF protein (Groups 12through 17)tothe one- dose Ad26.RSV.preF regimen (Group 11). 
This will be based on the GMT ratios and corresponding 95% confidence interval s (CIs ) of the VNA A2 
levels of the regimens containing RSV preF protein onDay 29 for the one-dose regimens (Groups 12 
through 16) and on Day 85 for the two -dose regimen (Group 17) versus the VNA A2 levels on Day 29 of 
the one -dose Ad26.RSV.preF regimen (Group 11). The sample size was selected to provide a precision of 
~0.53 on the log 2scale.
Note : Immunogenicity data from Groups 9 and 10 of the initial safety cohort (Cohort 1) will be combined 
with those from Groups 16and 17 ofthe regimen selection cohort (Cohort 2) .
The table below presents the resulting 95% CI sfor several observed ratios , assuming a standard deviation 
for VNA of 1 on the log 2scale and accounting for 5% dropout.
Observed Ratio Corresponding 95% CI
1 [0.69; 1.44]
1.2 [0.83; 1.73]
1.5 [1.04; 2.17]
In addition to the above, factors such as data from other assays, reactogenicity profiles, manufacturability 
and ease of administration will be considered when selecting the regimen for the expanded safety phase.
The expanded safety cohort (Cohort 3)should provide sufficient safety data on the selected regimen to 
support late stage development ifthe immunogenicity results of Cohort 2 are satisfactory.
Planned Analyses
Note : Depending on the timing, some of the planned analyses might be combined.
Initial Safety Cohort (Cohort 1) –Primary Analysis
Primary analysis: analysis of safety data [ADDRESS_831995] participant in Cohort 1 will be included in the 
analysis. This analysis will be performed on unblinded data. The blind will be maintained at the 
participant/site level .
Asimmunogenicity data from Groups 9 and 10 of the initial safety cohort (Cohort 1) will be combined with 
those from Groups 16 and 17 of the regimen selection cohort (Cohort 2),immunogenicity data from the 
initial safety cohort will be analyzed at the time of the primary analysis of the regimen selection cohort.
Initial Safety Cohort (Cohort 1) –Analysis [ADDRESS_831996] 
participant in this cohort will be included in the analysis. The blind will be maintained at the participant/site 
level .
Regimen Selection Cohort (Cohort 2) – Primary Analysis
Primary analysis: analysis of safety data [ADDRESS_831997]-dose 1. 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 25
Approved , Date: 6 November 2020 This analysis should contain allsafety data collected up to the time of the visit at [ADDRESS_831998] participant in this cohort .
 Immunogenicity data from at least Groups 11 to 15 and part of Group 18(placebo group) , up to at 
least [ADDRESS_831999]-dose 1 will be included as well.a
 This analysis will be performed on unblinded data. The blind will be maintained at the participant/site 
level .
Inthis analysis ,all available immunogenicity data of the initial safety cohort (Cohort 1) will be analyzed 
as well.
Regimen Selection Cohort (Cohort 2) –Additional Analysis
Additional analysis: analysis of immunogenicity data [ADDRESS_832000]-dose 1 for all one-dose regimens 
(including the one-dose regimen with separate injections) and [ADDRESS_832001] -dose 2 for the two- dose regimen. This analysis will be performed on unblinded data. The 
blind will be maintained at the participant/site level.
In this analysis, all available immunogenicity data of Groups 9 and10 from the initial safety cohort (Cohort 
1) and immunogenicity data of Cohort 2 included in the primary analysis will be analyzed as well.
The primary analysis of Cohort 1 and Cohort 2 and the additional analysis may be combined into one 
analysis.
Regime n Selection Cohort (Cohort 2) – Analysis [ADDRESS_832002] participant in this 
cohort will be included in the analysis. The blind will be maintained at the participant/site level.
Regimen Selection Cohort (Cohort 2 -Groups 14 and 15 ) –Analysis [ADDRESS_832003] participant in th ese
2groups will be included in the analysis. 
Expanded Safety Cohort (Cohort 3) –Primary Analysis
Primary analysis: analysis of safety and immunogenicity data up to Day [ADDRESS_832004] participant in this cohort in case a two-dose regimen is 
selected .aIf the corresponding immunogenicity data are not available at the time of database lock, they will 
be analyzed at a later timepoint. This analysis will be performed on unblinded data. The blind will be 
maintained at the participant/site level.
                                                
aAn unblinded person who is not part of the study team (or another independent party) will dictate which Day 29 samples should 
be analyzed by [CONTACT_624664]. Half of the Day 29 sam ples of Group 18 (placebo group) will be included to 
ensure th e blind at the level of the clinical immunology laboratory.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 26
Approved , Date: 6 November 2020Expanded Saf ety Cohort – Analysis [ADDRESS_832005] 
participant in this cohort will be included in the analysis. The blind will be maintained at the participant/site 
level .
Expanded Safety Cohort – Analysis [ADDRESS_832006] 
participant in this cohort will be included in the analysis. The blind will be maintained at the participant/site 
level .
Final Analysis
The final analysis at the end of the study will include safety and immunogenicity data from all cohorts.a
Data collected up to the time of the last visit for the last participant will be included in the analysis. This 
analysis will be performed on unblinded data.
Additional Interim Analyses
Additional interim analyses (blinded or, if occurring after the primary analysis of the respective cohort,
unblinded) may be performed during the study for the purpose of informing future vaccine development -
related decisions in a timely manner, or upon health authority request. If they occur, these unplanned interim  
analyses may replace planned analyses, depe nding on the timing . The results will not influence the conduct 
of the study in terms of early termination or later safety or immunogenicity endpoint assessments, and will 
only be available to a selected group of sponsor personnel.
Immunogenicity Analyses
No formal hypothesis for immunogenicity will betested. For the regimen selection cohort (Cohort 2), GMT 
ratios with corresponding 95% CI of the VNA A2 levels of the combination/ mixture regimens on Day 29 
for the one -dose regimens (Groups 12 through 16) and Day 85 for the two -dose regimen (Group 17) versus 
the Day 29 VNA A2 levels of the one-dose Ad26.RSV.preF regimen (Group 11) will be calculated. 
Therefore, a regression model will be fitted with the respective VNA A2 levels as dependent variable and 
the respective regimens and baseline levels as covariates, using Satterthwaite’s method to calculate the 
degrees of freedom and allowing different variances for the vaccines. The estimate and CIs obtained as 
such will be back -transformed (by [CONTACT_151698]) to a GMT ratio and the corresponding CI . Note that the 
effect of additional factors ,such as age and the interaction with theregimen ,might also be explored in this 
model.
Note : Immunogenicity data from Groups 9 and 10 of the initial safety cohort (Cohort 1) will be combined 
with those from Groups 16 and 17 of the regimen selection cohort (Cohort 2) .
In the expanded safety cohort (Cohort 3), the effect of the Month 12 booster will be assessed. Therefore, 
the following ratios for VNA A2 will be calcu lated:
 In the groups with an active vaccination at Month 12, the ratio of the Month 12 booster Day 29 level 
versus the prime Day 29 level with the corresponding 95% CI will be calculated.
 The groups with an active vaccination at Month 12 will be compared to corresponding groups with 
placebo vaccination at Month 12 by [CONTACT_624665] 95% CI.
Note that the above might also be repeated for other assays.
                                                
aMight be done per cohort, depending on the timing.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 27
Approved , Date: 6 November 2020In addition, for all cohorts, continuous variables will be summarized with desc riptive statistics of the actual 
values and the changes from baseline where appropriate. Graphical representations of immunologic 
parameters will be made as applicable. For categorical variables, frequency tables will be presented.
Safety Analyses
No forma l statistical testing of safety data is planned.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 28
Approved , Date: 6 November 2020SCHEDULE OF A CTIVITIES –COHORT 1
Clinic Visit # 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Visit TimingVac 1 Vac 1
+ 7 dVac 1
+ 14 dVac 1
+ 28 dVac 1
+ 56 dVac 2
+ 7 dVac 2
+ 28 dVac 1
+ 26wkVac 1
+ 12 moVac 3
+ 7 dVac 3
+ 28 dVac 3
+ 26wkVac 3
+ 12 morEarly
Exita
Visit Day (s) -28to 0 1 8bc15 29 57 64d85d183 365 372d393d547d730d
Visit Window ±2 d ±2 d ±3 d ±3 d ±2 d -3/+10 d±14 d ±2mo ±2 d ±3 d ±14 d ±1 mo
Visit Type
Screening
STUDY 
VACCINATION 
1
Safety
Safety and 
Immunogenicity
Safety and 
Immunogenicity
STUDY 
VACCINATION 
2
Safety
Safety and 
Immunogenicity
Safety and 
Immunogenicity
STUDY 
VACCINATION
3
Safety
Safety and 
Immunogenicity
Safety and 
Immunogenicity
Safety and 
Immunogenicity
Early exit
Written informed consente
Inclusion/exclusion criteria 
Demographics 
Medical history/pre -study 
medications
Physical examinationf              
Vital signsgincl. body temperature               
12-lead ECGh
Serology(HIV-1/2,hepatitis B/C) 
Randomization 
Verification of selected eligibility 
criteria i   
Contra indications to vaccination j  
Safety lab blood sample , mL 10 55 5
Cellular immunity sample, mLk50 505050 505050 50 50 50 50
Humoral immunity sample, mL 10 101010 101010 10 10 10 10
Transcriptome sample, mL 2.52.52.5
Nasal turbinate sample (or its 
alternative)      
Vaccination   
[ADDRESS_832007] -vaccination 
observationl   
SolicitedAErecording --Continuous -- --Continuous -- --Continuous -- 
UnsolicitedAErecordingm----------Continuous ---------------Continuous ------ ------Continuous ------ 
SAErecordingm-------------------------------------------Continuous ------------------------------------------
Concomitantmedicationsn-------------------------------------------Continuous ------------------------------------------
Respi[INVESTIGATOR_1092] (RTI)o,p-------------------------During the first 2 RSV seasons of the study ------------------------------- 
RTI Symptoms Form distribution ---------------------To be distributed before the start of the first [ADDRESS_832008] 2 RSV seasons of the study -------------------
Participant diary distributionq  
Participant diary review by [CONTACT_6624]   
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 30
Approved , Date: 6 November 2020SCHEDULE OF A CTIVITIES –COHORT [ADDRESS_832009]-vac FU Second Year FUs
Clinic Visit # 1 2 3 4 5 6 7 8 9 10 11 12
Visit TimingVac 1 Vac 1
+ 7 dVac 1
+ 14 dVac 1
+ 28 dVac 1
+ 56 dVac 2
+ 7 dVac 2
+ 28 dVac 1
+ 26 wkVac 1
+ 12 moVac 1
+ 18 moVac 1
+ 24 moEarly
Exita
Visit Day(s) -28 to 0 1 8c15 29 57 64 d85 d183 365 547 730 
Visit Window ±2 d ±2 d ±3 d ±3 d ±2 d -3/+10 d ±14 d ±1 mo ±1 mo ±1 mo
Visit Type
Screening
STUDY 
VACCINATION 
1
Safety
Safety and 
Immunogenicity
Safety and 
Immunogenicity
STUDY 
VACCINATION 
2
Safety
Safety and 
Immunogenicity
Safety and 
Immunogenicity
Safety and 
Immunogenicity
Safety and 
Immunogenicity
Safety and 
Immunogenicity
Early exit
Written informed consente 
Inclusion/exclusion criteria 
Demographics 
Medical history/pre -study medications 
Physical examinationf            
Vital signsgincl. body temperature             
12-lead ECGh
Serology(HIV-1/2,hepatitis B/C) 
Randomization 
Verification of selected eligibility criteria  
Contraindications to vaccination j 
Safety lab blood sample, mL 10 5 5 5
Cellular immunity sample, mLk50 50 50 50 50 50 50 50 50 50
Humoral immunity sample, mL 10 10 10 10 10 10 10 10 10 10
Transcriptome sample, mL 2.5 2.5 2.5
Nasal turbinate sample (or its alternative)      
Vaccination  
[ADDRESS_832010] -vaccination observationl 
SolicitedAErecording --Continuous -- --Continuous -- 
UnsolicitedAErecordingm----------Continuous --------- ------Continuous ------ 
SAErecordingm-------------------------------------Continuous ----------------------------------- 
Concomitantmedicationsn-------------------------------------Continuous ----------------------------------- 
Respi[INVESTIGATOR_1092] (RTI)o,p----------------------During the first 2 RSV seasons of th e study ------------------------ 
RTI Symptoms Form distribution ----------------To be distributed before the start of the first [ADDRESS_832011] 2 RSV seasons of the study --------------------
Participant diary distributionq 
Participant diary review by [CONTACT_6624]  
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 37
Approved , Date: 6 November 2020Table footnotes for all cohorts:
a. For those participants who are unable to continue participation in the study, but for whom consent is not withdrawn, an exit visit will be conduct ed as soon as possible.
b. In addition, sentinel participant s will be contact[CONTACT_5143] [ADDRESS_832012] study vaccine dose safety review come in earlier than Day 8 for Visit 3inCohorts 1 and 2, and Visit 2in Cohort 3 (allowed window is 
±2 days), a subsequent phone call will be made at the end of the diary period to collect diary card information recorded between the actu al visit and the end of the diary period on 
Day 8.
d. The tim ings of the post-vaccination visits will be determined relative to the actual day of that vaccination.
e. Signing of the Informed Consent Form ( ICF) should be done before any study -related activity. Additional written informed consent for participants in Groups 14 and 15 (Cohort 2) 
progressing into the long -term follow -up phase and participants in Cohort 3 who will receive an additional vaccination at Day 730 (Month 24 booster) will be required .
f. A full physical examination, including height and body weight , will be carried out at screening and before the Month 12 booster (Cohorts 1 and 3 ) and before the Month 24 booster 
(Day 730) (Cohort 3 only). At other visits, an abbreviated, symptom -directed examination will be performed if determined necessary by [CONTACT_093].
g. Body  temperature (oral route preferred), s upi[INVESTIGATOR_624606] d iastolic bl ood pressure, h eartrate and respi[INVESTIGATOR_624607] 5minutes re st.Vital signs are to be measured before 
blood draw s and nasal samples.
h. Supi[INVESTIGATOR_624608] ( ECG ) after at least [ADDRESS_832013] check for acute illness or body temperature ≥38.0 °C at the time of vaccination. In such cases, the participant may be vaccinated up to, and no later than [ADDRESS_832014] -vaccination. Any unsolicited, solicited local and solicited systemic AEs, and vital signs (s upi[INVESTIGATOR_624609], h eartrate,respi[INVESTIGATOR_697] ,and body temperature) will be documented by [CONTACT_3449] -site personnel following this observation period.
m. All adverse events ( AEs)and special reporting situations related to study procedures or to non -investigational (concomitant) Janssen products will be reported from ICF signature 
[CONTACT_624710]. All other AEs (unsolici ted) and special reporting situations will be reported from each vaccination through the following 28 days. All serious adverse events ( SAEs ) related 
to study procedures or to non -investigational (concomitant) Janssen products will be reported from ICF signature [CONTACT_624710]. All other SAEs will be reported f rom the first vaccination 
onwards .
n. Concomitant medications will be collected from the time o f each vaccination, through [ADDRESS_832015] 2 RSV seasons of the study (relative to the enrollment date of the first participant in Cohort 1) using the specific RTI 
Symptoms Form. Participant s will be notified of the RSV season. During the first 2 RSV season s, they will be contact[CONTACT_80077] 30±7 days (unless a prescheduled clinic 
visit has occurred or will occur within 30 days). Calls will remind participants to complete the RTI Symptoms Form in the event of any symptoms of RTI , to conta ct the site at the 
time of symptom onset, andto take a nasal sample at home preferably between 2 and 3 days after the onset of the RTI symptoms (or go to the site preferably within 2to 3days after 
the onset of the RTI to have a nasal sample taken by [CONTACT_464]). Calls will also check for any SAEs and associated concomitant medications since the previous visit or telephone 
contact . Details of the RTI procedures are provided in Section 9.2.[ADDRESS_832016] 2 RSV seasons of the study (relative to the enrollment date of the first participant in Cohort 1), e very effort should be made to collect data on the clinical course of 
RTIs including informa tion on oxygenation status, supplemental oxygen requirements and specific drug treatments, as well as other concurrent respi[INVESTIGATOR_624610].
q. Rulers and thermometers will also be distributed at these visits.
r. Vac 3+12 mo is the same as Vac 1+24 mo.
s. Participants in Groups 14 and 15 will continue into the long -term follow -up phase (see Cohort 2 long -term follow -up phase Time and Events Schedule ).
t. During the long -term follow -up phase, only SAEs related to study vaccine, study procedures, or non -investigational (concomitant) Janssen products, and all AEs leading to 
discontinuation will be collected during the long -term follow -up phase
u. During the long -term follow -up phase, o nly medications in conjunction with SAEs related to study vaccine, study procedures, or non -investigational (concomitant) Janssen products, 
or in conjunction with AEs leading to discontinuation should be recorded.
v. Visit 13 ([ADDRESS_832017] vaccination) is not required for any Cohort [ADDRESS_832018] vaccination.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 38
Approved , Date: 6 November 2020ABBREVIA TIONS
Ad26 adenovirus serotype 26
Ad35 adenovirus serotype 35
AE adverse event
CDC Clinical Development Committee
CI confidence interval
CS circumsporozoite
DNA deoxyribonucleic acid
DRC Data Review Committee
ECG electrocardiogram
eCRF electronic case report form 
eDC electronic data capture
ELISA enzyme -linked immunosorbent assay
ELISpot enzyme -linked immunospot (assay)
ERD enhanced respi[INVESTIGATOR_3765]
F protein fusion protein
FA full analysis (set)
FA2 fusion protein of the RSV A2 strain
FDA [LOCATION_002] Food and Drug Administration
FI formalin -inactivated
FIH first-in-human
G protein glycoprotein
GCP Good Clinical Practice
GMT geometric mean titer
HIV human immunodeficiency virus
ICF informed consent form
ICH International Council for Harmonisation
ICS intracellular cytokine staining
IEC Independent Ethics Committee
IFN-γ interferon gamma
Ig immunoglobulin
IL interleukin
IRB Institutional Review Board
IWRS interactive web response system
ML medical leader
N protein nucleoprotein
NSAID non-steroidal anti -inflammatory drug
PBMC peripheral blood mononuclear cell s
PI [INVESTIGATOR_160143]-protocol RSV immunogenicity (set)
pre-F pre-fusion
post-F post-fusion
PQC Product Quality Complaint
RSV respi[INVESTIGATOR_624611]-PCR reverse transcriptase polymerase chain reaction
SAE serious adverse event
SRP/S study responsible physician/ scientist
S[LOCATION_003]R suspected unexpected serious adverse reaction
TASH therapeutic area safety head
Th T-helper (cell)
TNF -α tumor necrosis factor alpha
VNA virus neutralizing antibody
vp viral particles
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 39
Approved , Date: 6 November [ZIP_CODE]. INTRODUCTION
A human adenovirus -vectored vaccine candidate and a pre-fusion conformation- stabilized 
respi[INVESTIGATOR_227899] (RSV) F protein which have shown promise in preclinical animal 
models of RSV will be assessed in this study :
Ad26.RSV.preF (JNJ-64400141), a replication -incompetent adenovirus seroty pe 26 (Ad26) 
containing a deoxy ribonucleic acid (DNA) transgene that encodes the pre-fusion 
conformation -stabilized F protein (pre -F) derived from the RSV A2 strain.
RSV preF protein (JNJ-64213175), a pre-fusion conformation- stabilized F protein derived 
from the RSV A2 strain .
Different naming conventions are being used for clinical studies. The first part of the study 
identifier is one of the following, depending on the vaccine and study  population:
VAC18192 (used for studies to test the Ad26.RSV.FA2 vaccine in the adult population)
VAC18193 (used for studies to test the Ad26.RSV.preF vaccine in the adult and elderl y 
populations)
VAC18194 (used for studies to test the Ad26.RSV.preF vaccine in the pediatric population)
Studies are given a suffix of a 4-digit number preceded by [CONTACT_624666] (for ‘Respi[INVESTIGATOR_624612]’).
The following sponsor RSV vaccine studies are referenced in this protocol :
Study Identifier Clinical Phase Vaccine Study Population
VAC18192RSV1001 1 Ad26.RSV.FA2 Adults aged 18 to 50 years
VAC18192RSV1003 1 Ad26.RSV.FA2 Adults aged 18 to 50 years
VAC18193RSV1003 1 Ad26.RSV.preF vaccine Adults aged 60 years and older
Current study :
VAC18193RSV1004 1/2a Ad26.RSV.preF vaccine Adults aged 60 years and older
VAC18193RSV2002 2a Ad26.RSV.preF vaccine Adults aged 18 to 50 years
VAC18193RSV2003 2a Ad26.RSV.preF vaccine Adults aged 60 years and older
VAC18194RSV2001 1/2a Ad26.RSV.preF vaccine Adults aged [ADDRESS_832019]-in-human (FIH) study  for RSV preF protein, and for the Ad26.RSV.preF/ 
RSV preF protein combination (administered as separate injections in opposite arms) andthe
Ad26.RSV.preF/RSV preF protein mixture (administered as a single inject ion).
Forthemost comprehensive nonclinical information regarding Ad26.RSV.preF, refer to the late st 
version of the Investigator’s Brochure for Ad26.RSV.preF .17
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 40
Approved , Date: [ADDRESS_832020] 
version of the Investigator’s Brochure for RSV preF protein.18
The term “sponsor ”used throughout this document refers to the entities listed in the Contact 
[CONTACT_23774](s), which will be provided as a separate document.
1.1. Background
Back ground
RSV is an important cause of serious respi[INVESTIGATOR_624613] y, immunocompromised, 
and those with underl ying chronic cardiopulmonary  conditions.8Although most adults mount a 
long-lasting fullyprotective immune response, waning immune responses in the elderl y might
contribute to increased susceptibility  to severe disease after RSV infection causing significant 
morbidity  and mortality . In long -term care facilities, RSV is estimated to infect 5 %to 10% of the 
residents per year with significant rates of pneumonia (10% to 20%) and death (2% to 5%) .9In an
epi[INVESTIGATOR_624614], it was estimated that 11,[ADDRESS_832021] important cause of serious acute respi[INVESTIGATOR_624615] 5 years of age: worldwide in 2005, RSV caused an estimated 33.[ADDRESS_832022] vaccine 
candidate for use in young children, which consisted of formalin -inactivated RSV (FI -RSV), was 
associated with enhanced respi[INVESTIGATOR_23715] (ERD) upon infection with RSV .21Although the 
mechanisms for ERD are not fully underst ood, it is thought that FI -RSV failed to induce adequate 
neutralizing antibod y titers and CD8+priming, and induced a T -helper (Th)[ADDRESS_832023] is not expected to be a concern in this study .6
Adenoviral- vectored Vaccines
Itis thought that an efficacious RSV vaccine should induce high levels of neutralizing antibodies, 
antigen -specific CD8+T-cell responses, and Th1- type CD4+T-cells.2The Ad26.RSV. preF 
candidate RSV vaccine being evaluated in this protocol is based on theAdVac®platform which 
has been shown to promote a strong antibod y response as well as CD8+T-cell and Th1 -type CD4+
T-cell responses.
The immunogenicity  profile of adenoviral vectors, with particular emphasis on Th1 responses, is 
illustrated by [CONTACT_624667]26 -vectored human 
immunodeficiency  virus (HIV) vaccine (Ad26.ENVA.01), and immunization of adults and infants 
with an adenovirus serotype 35 (Ad35) -vectored tuberculosis (TB) vaccine (Ad35.TB -S). These 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 41
Approved , Date: 6 November 2020data demonstrate predominantly  interferon gamma (IFN -γ) and tumor necrosis factor alpha (TNF -
α) production in CD4+and CD8+T-cells.1,5,31
Ad26.RSV.FA2 Clinical Data
Ad26 encoding for a wild-type RSV F protein of the RSV A2 strain (FA2) has been evaluated in 
studies VAC18192RSV1001 and VAC18192RSV1003 (N=48 and N=32, respectivel y, of which 
35 and 24participant s, respectively , received Ad26.RSV.FA2) in healthy  adults at doses of 5×1010
viral particles ( vp). Both studies have been completed.
The r esults indicate that there have been no safet y concerns following vaccination in either study . 
After vaccination with Ad26.RSV.FA2, local reactogenicit y comprised almost exclusively  mild to 
moderate pain of median duration [ADDRESS_832024] commonly  experienced solicited systemic 
adverse events (AEs ) (heada che, fatigue, chills, and myalgia) were also mostly  mild to moderate 
in severity , with a median duration of 1 to3 days; most unsolicited AEs and most laboratory
toxicities were mild to moderate in severity . No serious adverse events ( SAEs) were reported a nd 
no AEs led to withdrawal from study  vaccine.19,20
Single vaccination with 5 ×1010vp of Ad26.RSV.FA2 raised both humoral and cellular immunity . 
Anincrease in RSV neutralizing antibody  titers was observed ;RSV -specific T-cell responses were 
also increased.
FA2 and preF RSV Vaccines
The clinical studies VAC18192RSV1001 (FIH for Ad35.RSV.FA2) and VAC18192RSV1003 
(FIH for Ad26.RSV.FA2) have been comple ted with Ad26.RSV.FA2 and Ad35.RSV.FA2 (a 
similar recombinant, replication -incompetent vaccine using an Ad35 vector), in which Ad26 and 
Ad35, respectively , encode for a wild -type RSV F protein of the RSV A2 strain.
The adenoviral vectors Ad26 and Ad35 are derived from Group B and D seroty pe adenoviruses 
and have been similarl y modified to be replication -incompetent; expression of the antigen is 
controlled by [CONTACT_624668]. An Ad26 -based RSV vaccine was chosen for further clinical 
development over the Ad35-based counterpart based on a better immunogenicity  profile from 
nonclinical data, a similar safety  and immunogenicity  profile but at half the Ad35 dose from 
clinical data, and a better manufacturing profile.
The F protein of RSV undergoes a conformational transition from a metastable pre-fusion 
conformation to a stable post -fusion conformation. Neutralizing sensitive epi[INVESTIGATOR_624616], but recent evidence indicates that those epi[INVESTIGATOR_624617] -F protein seem to be 
more potent th an those previously  identified and present on the post -F protein .11,12This evidence 
resulted in the design of the candidate RSV vaccine (Ad26.RSV.preF) in which the adenoviral 
vector encodes a full length RSV F protein stabilized in the pre-F protein conformation. The full 
length membrane -bound RSV F protein in a pre- F confi guration encoded by [CONTACT_624669] 5amino acids from the wild-type used in the FA2 construct.24This change in the transgene 
confers more stability  to the pre-fusion form of the molecule before it undergoes its natural 
transition to the post-fusion form .24This change also induce s higher immune responses against 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 42
Approved , Date: 6 November 2020pre-fusion epi[INVESTIGATOR_624618]-fusion protein 
conformation .25,29For these reasons, it is anticipated that the Ad26.RSV.preF vaccine candidate 
will generate more neutralizing antibodies relative to the Ad26.R SV.FA2 vaccine .16
Ad26.RSV.preF and RSV preF Protein Preclinical Data
Preclinical studies were performed in naïve and RSV pre-exposed animals. Ad26.RSV.preF is 
immunogenic in mice and cotton rats, with humoral responses that include the induction of RSV 
neutralizing antibodies. In addition, in mice it was shown that Ad26.RSV .preF elicit scellular 
responses, characterized by [CONTACT_624670] F-specific CD8+IFN-γ+T-cells. The immune 
response following Ad26.RSV.preF immunization was Th1 -biased.
RSV preF protein induced virus neutralizing antibody  (VNA) titers in mice, cotton rats, and non -
human primates. Furthermore, prime -boost immunization with non-adjuvanted RSV preF protein
gave partial protection from RSV infection in the lung in cotton rats. In RSV pre-exposed mice, 
high neutralizing antibody  titers were boosted by a single administration of RSV preF protein; 
RSV preF protein induced low RSV F -specific cellular responses in pre -exposed mice , in contrast 
to Ad26.RSV.preF which induced high cellular responses.
The mixture of Ad26.RSV.preF and RSV preF protein induced both high VNA titers and a cellular 
response in mice, maintaining the advantage of each vaccine component. RSV preF protein boost -
immunization, after Ad26.RSV.preF prime, induced high virus neutralizing titers, and the cellular 
responses induced by [CONTACT_624671] .In RSV pre-exposed non-human 
primates, the mixture of Ad26.RSV.preF and RSV preF protein induced both cellular responses 
and high VNA titers b y single administration.16
The RSV preF protein has been evaluated in a single dose pi[INVESTIGATOR_624619] 250 μ g. No clinically significant toxicological changes were noted. In afollow -up good 
laboratory practice (GLP)toxicology  study  in the rabbit, RSV preF protein was evaluated at 250μg 
per injection, either alone in a prime -boost regimen with Ad26.RSV.preF (1×1011vp) or in a single 
injection mixture with Ad26.RSV.preF for 3dosing days with 2-week intervals. Test article -related 
mortality  was not observed, and no effects were noted on clinical observations, dermal scores, 
body  weight, hematology, ophthalmology, and body temperature. All vaccine regimens were well 
tolerated and without adverse effects.
Ad26.RSV.preF and RSV preF Protein Clinical Data
Ad26.RSV.preF :
Ad26.RSV.preF is currently  under evaluation in four other ongoing studies: one Phase 1 study  
(VAC18193RSV1003), two Phase 2a studies (VAC18193RSV2002 and VAC18193RSV2003) 
and one Phase 1/2a stud y (VAC18194RSV2001) ( Table 7).
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 43
Approved , Date: 6 November 2020Table 7: Other Ongoing Clinical Studies with Ad26.RSV.preF
Study IdentifierClinical 
PhaseVaccine N Planned Study Population
VAC18193RSV1003 1 Ad26.RSV.preF 72 Adult participants aged 60 years and older
VAC18193RSV2002 2a Ad26.RSV.preF 44-70 Adult participants aged 18 to 50 years
VAC18193RSV2003 2a Ad26.RSV.preF 180 Adult participants aged 60 years and older
VAC18194RSV2001 1/2a Ad26.RSV.preF 12 adults
48 toddlersAdult participants aged 18 to 50 years and 
RSV -seropositive toddlers aged 12 to 
24months
In oneof these studies, interim safet y and immunogenicity  data are available , as follows :
VAC18193RSV1003: This is an ongoing single -center, randomized, placebo -controlled, double -
blind, FIH, Phase [ADDRESS_832025] receiv ed
2 intramuscular injections as follows:
Group 1 : 5×1010vp Ad26.RSV.preF on Day 1 and 1year*later
Group 2 : 5×1010vp Ad26.RSV.preF on Day 1 and placebo 1year later
Group 3 : 1×1011vp Ad26.RSV.preF on Day 1 and 1year later
Group 4 : 1×1011vp Ad26.RSV.preF on Day 1 and placebo 1year later
Group 5 :placebo on Day 1 and 1 year later.
* Window of - 2 months to +1 month
Safety  and immunogenicity  data from the unblinded ( at the study  group level) analysis 28days 
post-Dose 1 from all 72 participant s who received Ad26.RSV.preF (5×1010vp or 1×1011vp) or 
placebo confirmed thatthe 1 ×1011vp dose of Ad26.RSV.preF was more immunogenic compared 
with the 5×1010vp dose. Data from this ongoing study , which is still blinded, show that the 
Ad26.RSV.preF vaccine is immunogenic and that there is a favorable Th1/Th2 profile .No safet y 
concerns were revealed; the reactogenicit y of both doses was comparable.
In study VAC18194RSV2001, first 12 male and female adult s,and then 48male and female RSV -
seropositive toddlers, are randomized to receive 2 intramuscular injections as follows:
Adults ( aged ≥18 to ≤50 years ):
Group 1: 1×1011 vp Ad26.RSV.preF on Day 1 and Day  29
Group 2: plac ebo on Day 1 and Day  29
RSV -seropositive toddlers (aged 12 to 24 months):
Group 3: 5×1010 vp Ad26.RSV.preF on Day 1 and Day  29
Group 4: placebo on Day 1 and Day  29
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 44
Approved , Date: [ADDRESS_832026] been dosed prior to the start of the current study .
In study  VAC18193RSV2002, more than 44 (and up to 70) healthy  male and female participant s 
aged [ADDRESS_832027] been prescreened for susceptibility  to RSV infection receive a single 
intramuscular injection with Ad26.RSV.preF 1×1011vp or placebo, followed by [CONTACT_624672] -A Memphis 37b virus within [ADDRESS_832028] been dosed prior to the start of the current study .
In study VAC18193RSV2003, 180 male and female participant s aged ≥60 years in stable health 
arerandomized to 1 of 2 groups. Participant s in Group 1 receive Ad26.RSV.preF 1×1011vp on 
Day 1  administered at the same time as a commerciall y available seasonal influenza vaccine
(Fluarix®Quadrivalent), and placebo onDay 29. Participant s in Group 2 receive placebo on Day 1, 
administered at the same time as a commercially  available seasonal influenza vaccine (Fluarix
Quadrivalent), and Ad26.RSV.preF 1×1011vp on Day 29. All vaccines are given b y intramuscular 
injection . The primary  analy sis for safet y and immunogenicity  at [ADDRESS_832029] been completed prior to the start of the current study .
In study  VAC18193RSV1003, Ad26.RSV.preF was provided in a different formulation buffer 
(Formul ation Buffer 1a) from the one used in the current study  and studies VAC18194RSV2001, 
VAC18193RSV2002 and VAC18193RSV2003 (Formulation Buffer 2b).
RSV preF Protein:
To date,RSV preF protein has not been tested in humans. This is the FIH study  for RSV preF 
protein, and for the Ad26.RSV.preF/RSV preF protein combination (administered as separate 
injections in opposite arms) and Ad26.RSV.preF/RSV preF protein mixture (administered as a 
single injection) .
Safety Data Supporting the Ad26.RSV.preF Dose Selection
The dose levels for Ad26.RSV.preF used in the current study  are supported by [CONTACT_624673]26 -based vaccines encoding for different antigens (including EnvA [in 
Ad26.ENVA.[ADDRESS_832030] HIV];4,5circumsporozoite (CS) protein [inAd26.CS.[ADDRESS_832031] malaria] ;34
and Ebola gly coprotein [in Ad26.ZEBOV against Ebola virus]27).
In completed clinical studies, the safet y of Ad26.ENVA.01, Ad26.CS.01, and Ad26.RSV.FA2 has 
been evaluated in 584 adults, of whom 519 (88.9%) received Ad26 at a dose level of 5×1010vp 
and 25 (4.3%) were vaccinated with Ad26 at the highest dose level tested (1×1011vp).
                                                
CCI
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 45
Approved , Date: 6 November 2020In addition, 17 clinical studies with Ad26 vaccines (Ad26.RSV.preF, Ad26.Mos[4].HI V, and 
Ad26.ZEBOV) are ongoing. At least 4,[ADDRESS_832032] onevaccination with an Ad26 -based vaccine 
(mainly  5×1010vp) up to [ADDRESS_832033] been observed based upon the transgene 
used.14,15
Overall, these clinical data are supportive of dosing Ad26.RSV.preF at 5×1010vp and 1×1011vp 
in the current stud y.
1.2. Overall Rationale for the Study
Despi[INVESTIGATOR_624620], no licensed vaccine is available fo r RSV.
The current study  has an adaptive design to determine a regimen for further clinical development 
in adults aged ≥[ADDRESS_832034] on cellular response scompared with
Ad26.RSV.preF alone .
The potential use of RSV preF protein as a component of an RSV vaccine will be assessed by 
[CONTACT_624674]26.RSV.preF, RSV 
preF protein, thecombination or mixture of Ad26.RSV.preF and RSV preF protein , or placebo.
Approximately  667male and female participant saged ≥60 years will be randomized in 3cohort s 
as outlined in Table 8, Table 9, Table 10, and Table 11, respectivel y.
The current study  will be the FIH study  for the RSV preF protein, and for the Ad26.RSV.preF/
RSV preF protein combination and mixture .
Theinitial safety  cohort (Cohort 1) is designed to assess the safety  and immunogenicit y of 2dose
levels of RSV preF protein (50 μ g and150 μ g). The s afety  of RSV preF protein at each dose will
be checked before administration ofthe combination or mixture of Ad26.RSV.preF and RSV preF 
protein.
The dose selection rationale is provided in Section 3.2.
An internal data review committee (DRC) will be established for this study to evaluate safety and 
reactogenicity data on a regular basis.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 46
Approved , Date: 6 November [ZIP_CODE]. OBJECTIVES , ENDPOINTS, AND HYPOTHESIS
2.1. Objectives and Endpoints
SAFETY COHORT OBJECTIVE (COHORT 1) :
To determine in small numbers of participant s aged 60 years and older the safety of intramuscular homologous 
two-dose regimens comprising RSV preF protein or Ad26.RSV.preF/RSV preF protein mixture on Days 1 and 57, 
with a booster at Month 12, or separate a dministration of Ad26.RSV.preF and RSV preF protein in opposite arms 
on Day 1 with a booster at Month 12, before progression to regimen selection in a larger number of participant s
Objectives Endpoints
PRIMARY
To assess the safety and reactogenicity ofthe 
intramuscular one -and tw o-dose regimens, 
with abooster at Month 12SAEs from first dose administration until the end 
of the study
Solicited local and systemic AEs for 7 days after 
each vaccine administration
Unsolicited AEs from the time of each vac cine 
administration through the follow ing 28 days
SECONDARY
To assess the humoral and cellular immune 
responses elicited by [CONTACT_300092]26.RSV.preF, RSV 
preF protein ,and the Ad26.RSV.preF/RSV 
preF protein combination and mixtureRSV neutralization assay, F protein binding 
antibodies ( enzyme -linked immunosorbent assay 
[ELISA]; pre-F and /orpost-F), and IFN- γ 
enzyme -linked immunospot (ELISpot) assay
EXPLORATORY
Additional exploratory analyses may be 
performed to investigate vaccine -elicited 
immune responses furtherAssays to be used include, but are not limited to, 
RSV strain cross -neutralization, anti -F protein 
antibody specificity and functionality 
characterization, adenovirus neutralization assays, 
molecular antibody characterization (avidity, Fc 
cell inte raction, antibody isotypi[INVESTIGATOR_007] , antibody 
sequencing for repertoire ), and nasal antibodies to 
RSV, including but not limited to immunoglobulin 
(Ig)A and IgG; evaluation of the cellular immune 
response and the functional and memory immune 
response by [CONTACT_624675] (ICS) 
and transcriptome analysis
To evaluate symptoms of respi[INVESTIGATOR_4375]
(including respi[INVESTIGATOR_624596]) via the 
Respi[INVESTIGATOR_59398] (RTI) Symptoms 
FormDuring the RSV season: Signs and symptoms of 
RTI (includi ng RTI due to RSV) from Day 1 until 
the end of the second RSV season of the studya
Characterization of viral or bacterial infections 
inthe respi[INVESTIGATOR_4352]Assessment , typi[INVESTIGATOR_624621] 
(RT-PCR )or response to respi[INVESTIGATOR_624622] 1.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 47
Approved , Date: 6 November 2020REGIMEN SELECTION COHORT OBJECTIVE (COHORT 2):
To select a regimen for progression to evaluation in an expanded safety cohort (Cohort 3;see below ) by 
[CONTACT_624676] s aged 60 years and older of intramuscular one-dose 
regimens of Ad26.RSV.preF, Ad26.RSV.preF/RSV preF protein mixture, or separate administration of 
Ad26.RSV.preF and RSV preF protein in opposite arms on Day 1, or a two -dose regimen of Ad26.RSV.preF/RSV 
preF protein mixture on Days 1 and 57 
Objectives Endpoints
PRIMARY
To assess the safety and reactogenicity of the 
intramuscular one -and tw o-dose regimensSAEs from first dose administration until the end 
of the study
Solicited local and systemic AEs for 7 days after 
each vaccine administration
Unsolicited AEs from the time of each vaccine 
administration through the follow ing 28 days
To assess RSV neutralizing antibody levels of
the one -dose regimens (Groups 11to 15)
containing RSV preF protein compared to the 
one-dose Ad26.RSV.preF regimen RSV A2 neutralizing antibody levels ofthe 
one-dose regimens (Groups 11 to 15) on Day 29a
SECONDARY
To assess RSV neutralizing antibody levels of 
the one-dose regimen with separate injections
(Group 16) and the tw o-dose regimen
(Group 17)containing RSV preF protein 
compared to the one -dose Ad26.RSV.preF 
regimenRSV A2 neutralizing antibody levels of :
 the one -dose regimen with separate injections
(Group 16) on Day 29
 the two -dose regimen (Group 17)on Day 85a
To assess additional humoral immune responses 
elicited by [CONTACT_300092]26.RSV.preF and the 
Ad26.RSV.preF/RSV preF protein combination 
and mixtureF protein binding antibodies (ELISA; pre -F and/or 
post-F)
To assess cellular immune responses by 
[CONTACT_20129]-γ ELIS potof all regimens containing
RSV preF protein compared to the one -dose 
Ad26.RSV.preF regimen RSV F protein by [CONTACT_20129]-γ ELISpot assay
-the one -dose regimens on Day 29a
(Groups 11 to 16)
-the two -dose regimen on Day 85a(Group 17)
EXPLORATORY
Additional exploratory analyses may be 
performed to investigate vaccine -elicited 
immune responses furtherAssays to be used include, but are not limited to, 
RSV strain cross -neutralization, anti -F protein 
antibody specificity and functionality 
characterization, adenovirus neutralization assays, 
molecular antibody characterization (avidity, Fc 
cell interaction, antibody isotypi[INVESTIGATOR_007] , antibody 
sequencing for repertoire ), and nasal antibodies to 
RSV, incl uding but not limited to IgA and IgG; 
evaluation of the cellular immune response and the 
functional and memory immune response by [CONTACT_624677] “STATISTICAL METHODS - Immunogenicity Analyses” for details.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 48
Approved , Date: 6 November 2020Objectives Endpoints
To assess the long -term durability of the 
immune response in selected groupsAssays to be used include, but are not limited to, 
RSV neutralizing antibody levels against A and B 
strain, RSV F protein binding antibodies (ELISA; 
pre-F and/or post -F), RSV F protein specific 
functional antibodies, andRSV F protein specific 
IFN- γ ELISpot in Groups 1 4 and 15 at Days 912 
and 1095
To evaluate symptoms of respi[INVESTIGATOR_4375] 
(including respi[INVESTIGATOR_624596]) via the 
RTI Symptoms FormDuring the RSV season: Signs and symptoms of 
RTI (including RTI due to RSV) from Day 1 until 
the end of the seco nd RSV season of the studya
Characterization of viral or bacterial infections 
inthe respi[INVESTIGATOR_4352]Assessment, typi[INVESTIGATOR_624623]-PCR or response to respi[INVESTIGATOR_624624] (COHORT 3):
To determine the safety and immunogenicity of the selected regimen in an expanded cohort of participant s aged 
60 years and older; and to determine the need for a booster dose at Month 12 and/orMonth 24
Objectives Endpoints
PRIMARY
To assess the safety and reactogenicity of the 
selected regimen and a booster at Month 12
and/orMonth 24SAEs from first administration until the end of 
the study
Solicited local and systemic AEs for 7 days after 
each vaccine administration
Unsolicited AE s from the time of each vaccine 
administration through the follow ing 28 days
SECONDARY
 To assess humoral immune responses to the 
selected regimen in all participants RSV neutralization A2 strain
 To assess cellular immune responses to the 
selected regimen in a subset of participantsIFN- γ ELISpot assay 
EXPLORATORY
Additional exploratory analyses may be 
performed to further investigate vaccine -elicited 
immune responses Assays to be used include, but are not limited to:
F protein binding antibodies (ELISA; pre- F 
and/or post -F)
Flow  cytom etry
RSV cross -neutralization of B and/or other A 
strain
F-protein antibody specificity characterization
Cytokines/chemokines in nasal samples (if 
feasible)
Adenovirus neutralization assays
                                                
aThe second RSV seas on of the study is defined relative to the enrollment date of the first participant in Cohort 1.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 49
Approved , Date: 6 November 2020Objectives Endpoints
Functional and m olecular antibody 
characterization
Analysis of nasal antibodies to RSV including, 
but not limited to IgA and IgG
To assess the long -term durability of the immune 
response in groups receiving a booster at different 
time intervals Assays to be used include, but are not limited to, 
RSV neutralizing antibody levels against A and B 
strain, RSV F protein binding antibodies (ELISA; 
pre-F and/or post-F), RSV F protein specific 
functional antibodies, and RSV F protein specific 
IFN- γ ELISpo tat Days 758, 912 and 1095
To evaluate symptoms of respi[INVESTIGATOR_4375] 
(including respi[INVESTIGATOR_624596]) via the 
RTI Symptoms FormDuring the RSV season: Signs and symptoms of 
RTI (including RTI due to RSV) from Day 1 until 
the end of the second RSV season of the studya
Characterization of viral or bacterial infections in 
the respi[INVESTIGATOR_4352]Assessment, typi[INVESTIGATOR_624623]-PCR or response to respi[INVESTIGATOR_624625] 9.2for evaluations related to endpoints.
2.2. Hypothesis
No formal statistical testing of safet y and immunogenicity  data is planned.
Data will be analy zed descriptively .
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study
3.1.1. Study Design
This is a multi -center, randomized, double -blind, placebo- controlled Phase 1/2a study  for safet y 
and immunogenicit y evaluations for regimen selection of Ad26.RSV.preF and RSV preF protein 
combinations fol lowed by [CONTACT_624678] ≥60years who are in stable health.
To further extend the assessment of the long -term durability  of the immune response to the study 
vaccine, participants in Groups 14 and 15in Cohort 2 willcontinue into a long-term follow -up 
phase.
Thestudy  design includ es3 sequential cohort s: an initial safety  cohort (Cohort 1 in a total of 
64participant s), a regimen selection cohort (Cohort 2 in a total of 288participant s),and an
expanded safet y cohort (Cohort 3 in a total of 315participant s).
                                                
aThe second RSV season of the study is defined relative to the enrollment date of the first participant in Cohort 1.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 50
Approved , Date: 6 November 2020The overall total number of participant s will be approximately  667.
This study  will be the FIH study  for RSV preF protein, and for the Ad26.RSV.preF/RSV preF 
protein combination (administered as separate injections in opposite arms) and Ad26.RSV.preF/
RSV preF protein mixture (administered as a single injection).
Thestudy duration willbe approximately  730 days (2years) perparticipant in Cohorts 1 and 2
(Groups 11-13 and Groups 16-18), and approximately  1095 days (3years) per participant in 
Cohort 2 (Groups 14 -15) and Cohort 3 . The stud y comprises a maximum 28-day screening period
for Cohorts 1 and 2(screening for Cohort 3 will be done pre-vaccination onDay 1), study
vaccination (active or placebo) with a one-dose (on Day 1) or two-dose (on Day 1 and Day 57) 
regimen and a booster dose (active or placebo) at Month 12 (Cohort 1 ) or at Month 12 and Month 
24 (Cohort 3),a minimum 28-day follow -up period after each vaccination, and a follow -upperiod 
until 2years after the first Ad26.RSV.preF or RSV preF protein vaccination (Cohorts 1 and 2 
[Groups 11-13 and Groups 16-18]) or until [ADDRESS_832035] Ad26.RSV.preF or RSV preF 
protein vaccination (Cohort 2 [Groups 14-15] and Cohort 3). The end of the study  is defined asthe 
last participant ’s last visit 24months after the first vaccination (Cohorts 1 and 2[Groups 11-13 
and Groups 16-18]) or the last participant’s last visit approximately  1095 days (3years) after the 
first vaccination ( Cohort 2 [Groups 14 -15] and Cohort 3) .
Ifany ofthe pre -specified study vaccination pausing rule sis met, further study  vaccination will be 
paused and a DRC meeting will be convened. For details on the pausing rules, see Sect ion 11.9.
Initial Safety Cohort (Cohort 1)
Intheinitial safet y cohort , participant s will be randomized progressively  in 1 of 4randomizations 
(R1a through R1d) with safet y checks in place before extending enrollment and progressing from 
one randomization step to the next as follows (see also Table 8):
Cohort R 1a.Initially  2 participant s will be enrol led, 1 into Group 1 and 1 into Group 2,and 
will receive a single dose of placebo or 50g of RSV preF protein, respectively . Enrollment 
will be paused to allow for 24-hour safet y assessments in these 2 sentinel participant s by [CONTACT_28824] (s)(PI[s]),the sponsor’s study  responsible physician/ scientist ( SRP/ S), 
and the sponsor’s medical leader (ML). In the absence of an y clinical safety concerns over the 
24-hour assessment , the remaining [ADDRESS_832036] participant has received his/her first dose, available safet y data will be reviewed 
by [CONTACT_978](s),SRP/S , ML, and the sponsor’s therapeutic area safet y head (TASH) before 
proceeding to Cohort R 1b.
Cohort R1b. Initially  3 participant s will be enrol led, 1 into each of Groups 3 through 5, and 
will receive a single dose of placebo, 5×1010 vp Ad26.RSV.preF/50 g RSV preF protein, or 
150gRSV preF protein, respectively. Enrollment will be paused to allow for 24- hour safet y 
assessments in the 3 sentinel participant s by [CONTACT_978] (s),SRP/S , and ML . In the absence of an y 
clinical safet y concerns over the 24-hour assessment , the remaining [ADDRESS_832037] participant has received his/her first dose, 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 51
Approved , Date: 6 November 2020available safet y data will be reviewed by  [CONTACT_978] (s),SRP/S ,ML,and TASH before proceeding 
to Cohort R1c.
Cohort R 1c.Initially  2 participant s will be enrol led, 1 into Group 6 and 1 into Group 7, and 
will receive a single dose of placebo or 5×1010 vp Ad26.RSV.preF/150 g RSV preF protein, 
respectivel y. Enrollment will be paused to allow for 24-hour safet y assessments in these 
2 sentinel participant s by [CONTACT_978](s),SRP/S , and ML. In the absence of any clinical safety 
concerns over the [ADDRESS_832038] participant has received his/her first dose, availab le safet y data 
will be reviewed b y the PI (s),SRP/S , ML ,and TASH before proceeding to Cohort R1d.
Cohort R1d. Initially 3 participant s will be enrolled, 1 into each of Groups 8 through 1 0, and 
will receive 2 doses of placebo (1 in each arm), or1×1011 vp Ad26.RSV.preF/150 g RSV 
preF protein, with placebo in the opposite arm, or 1×1011 vp Ad26.RSV.preF in one arm and 
150g RSV preF protein in the opposite arm. Enrollment will be paused to allow 24-hour 
safet y assessments in the 3 sentinel participant s by [CONTACT_978](s),SRP/S , and ML . In the absence 
of any clinical safety  concerns over the 24-hour assessment , the remaining 17participant s will 
be randomized and dosed .
Seven days after the final participant inCohort 1 has received his/her first dose, all availa ble 
safet y data at that time for the whole cohort will be reviewed by [CONTACT_624679] 2.
Sentinel participant s will be contact[CONTACT_5143] [ADDRESS_832039] safety 
information.
Progression to the regimen selection cohort will be based on acceptable safety  in the initial safety 
cohort , as determined b y DRC review of Day  8 safety  data in all participants.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 52
Approved , Date: 6 November 2020Table 8: Study Design :Initial Safety Cohort (Cohort 1)
Group R N Day 1 Day 57 Month 12
1 R1a 4Placebo Placebo Placebo 
2 R1a 8RSV preF protein 50 g RSV preF protein 50 g RSV preF protein 50 g
3 R1b 4Placebo Placebo Placebo 
4 R1b 8Ad26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/50 gAd26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/50 gAd26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/50 g
5 R1b 8RSV preF protein 150 g RSV preF protein 150 g RSV preF protein 150 g
6 R1c 4Placebo Placebo Placebo 
7 R1c 8Ad26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/150 gAd26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/150 gAd26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/150 g
8 R1d 4Placebo
+ Placebo*Placebo Placebo
+ Placebo*
9 R1d 8Ad26.RSV.preF/
RSV preF protein mixture:
1×1011 vp/150 g
+ Placebo*Ad26.RSV.preF/
RSV preF protein mixture:
1×1011 vp/150 gAd26.RSV.preF/
RSV preF protein mixture:
1×1011 vp/150 g
+ Placebo*
10 R1d 8Separate injections : 
Ad26.RSV.preF 1×1011 vp 
+ RSV preF protein 150 g*PlaceboSeparate injections : 
Ad26.RSV.preF 1×1011 vp 
+ RSV preF protein 150 g*
R1 TOTAL: 64
N:number of participants; R :randomization; vp :viral particles
*Each injection to be given in opposite arm s
Regimen Selection Cohort (Cohort 2)
In the regimen selection cohort , approximately  288participant s will be randomized in parallel to 
1 of 8 groups (Groups 1 1through 18;Table 9). No pauses in enrollment for safet y assessments are 
planned.
Based on safet y and immunogenicit y results available at the time of primary  analysis, a sponsor 
committee will decide which regim en will be used for the expanded safety  cohort (Cohort 3). In 
case none of the groups that are part of the primary  objective meet internal criteria, regimen 
selection may be delay ed until additional analy seswill be available. 
The sponsor committee will consist of the Clinical Development Committee (CDC), Head of 
Clinical Development, Senior Advisors on Clinical Development, Head of Regulatory Affairs,
Senior Statistician, Head of Biomarkers, Representative of Chemistry , Manufacturing Control, 
Head of Early Development and Translational Medicine, Head of Late Development, and other 
Senior Functions from the CDC. Additional factors such as data from other assay s, 
manufacturability ,and ease of administration will be taken into account to select the regimen for 
the expanded safet y phase. More details will be described in the Statistical Analy sis Plan.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 53
Approved , Date: 6 November 2020Table 9: Study Design :Regimen Selection Cohort (Cohort 2)
Group R N Day 1 Day 57
11 R2 24Ad26.RSV.preF 1×1011 vp
+ Placebo*Placebo
12 R2 42Ad26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/50 g
+ Placebo*Placebo
13 R2 42Ad26.RSV.preF/
RSV preF protein mixture:
1×1011 vp/50 g
+ Placebo*Placebo
14 R2 42Ad26.RSV.preF/
RSV preF protein mixture:
1×1011 vp/150 g
+ Placebo*Placebo
15 R2 42Ad26.RSV.preF/
RSV preF protein mixture:
5×1010 vp/150 g
+ Placebo*Placebo
16 R2 36Separate injections *: 
Ad26.RSV.preF 1×1011 vp 
+ RSV preF protein 150 gPlacebo
17 R2 36Ad26.RSV.preF/
RSV preF protein mixture:
1×1011 vp/150 g
+ Placebo*Ad26.RSV.preF/
RSV preF protein mixture:
1×1011 vp/150 g
18 R2 24Placebo
+ Placebo*Placebo
R2 TOTAL: 288
N:number of participant s (Note : Data from Groups 9 and 10 of Cohort 1 will be pooled with those from Groups 16 and 17 of 
Cohort 2 up to Month 12 ); R:randomization; vp :viral particles
*Each injection to be given in opposite arms
Expanded Safety Cohort (Cohort 3)
In the expanded safet y cohort , approximately  315participant swill be randomized in parallel to
1 of 3 groups (Groups 1 9through 21;Table 10andTable 11). No pauses in enrollment for safety 
assessments are planned.
Participant s will receive the selected one-or two -dose regimen f rom Cohort 2 or placebo.
If theone-dose regimen is selected (Groups 11through 16from Cohort 2), Groups 19and20
would receive the selected regimen on Day 1, and a booster at Month 12 (the selected regimen or 
placebo, respectivel y) and Month 24(the selected regimen) . Group 21 will receive placebo atall
timepoints (Table 10).
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 54
Approved , Date: 6 November 2020If thetwo-dose regimen isselected (Group 17 of Cohort 2), Groups 19and20 would receive the 
selected regimen on Day 1and Day 57, and a boost er(the selected regimen or placebo , 
respectivel y) at Month 12 . Group 21 will receive placebo atall three timepoints (Table 11).
Table 10: Study Design :Expanded Safety Cohort ( Cohort 3) with One- dose Regimen and Month 12 and 
Month 24 Booster
Group R N Day 1 Month 12 Month 24
19 R3 135 Selected Regimen Selected Regimen Selected Regimen
20 R3 135 Selected RegimenPlacebo for the Selected 
Regimen Selected Regimen
21 R3 45Placebo for the Selected 
RegimenPlacebo for the Selected 
RegimenPlacebo for the Selected 
Regimen
R3 TOTAL: 315
OVERALL 
TOTAL:667
N:number of participants; R :randomization
Table 11: Study Design :Expanded Safety Cohort (Cohort 3)with Two -dose Regim enand Month 12 
Booster
Grou
pR N Day 1 Day 57 Month 12
19 R3 135 Selected Regimen Selected Regimen Selected Regimen
20 R3 135 Selected Regimen Selected RegimenPlacebo for the Selected 
Regimen
21 R3 45Placebo for the Selected 
RegimenPlacebo for the Selected 
RegimenPlacebo for the Selected 
Regimen
R3 TOTAL: 315
OVERALL 
TOTAL:667
N:number of participants; R :randomization
3.1.2. Study Procedures
After each vaccination, participant s will be closely  observed for a minimum of [ADDRESS_832040]-
vaccination to monitor for the development of any acute reactions, or longer if deemed necessary 
by [CONTACT_093]. Any  unsolicited, solicited local or solicited systemic AEs will be documented 
by [CONTACT_624680]. Participant s will be given a thermometer, 
ruler and daily  assessment ( participant ) diary  with instructions for the proper recording of events. 
Each participant will record solicited local (at injection site) and solicited systemic AEs and body 
temperatures, beginning on the evening of each vaccine dosing day and on a daily  basis for the 
following 7 days. Body temperatures (oral route preferred) should be taken at approximately  the 
same time each day.aStudy-site personnel will collect and review participant diary  information 
and confirm the entries at subsequent site visits.
                                                
aTemperature 7 days after each vaccinati on m ay be collected earlier in the day to coincide w ith the clinic visit.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 55
Approved , Date: [ADDRESS_832041] dose administration until the end of the
double -blind phase of thestudy . During the long-term follow -up phase (Groups 14 and 15from 
Cohort 2), only SAEs related to study  vaccine ,study  procedures ,or non-investigational 
(concomitant) Janssen products, and all AEs leading to discontinuation will be collected. All AEs, 
including an y that are ongoing at [ADDRESS_832042] ed and recorded in the electronic case report 
form (eCRF )from time of each vaccine administration through 28 days after each vaccination , and 
additionally  outside of these periods when associated with an SAE. During the long -term follow -
up phase (Groups 14 and 15 from Cohort 2), only medications in conjunction with SAEs related 
to study  vaccine, study  procedures, or non-investigational (concomitant) Janssen products, or in 
conjunction with AEs leading to discontinuation should be recorded.
All SAEs and AEs leading to discontinuation from the study /vaccination (regardless of the causal 
relationship) are to be reported from the moment of first vaccination until completion of the 
participant’s last study -related procedure, which may  include contact [CONTACT_233858] -up.
For participants in Cohorts 1 and 2, blood will be collected for serology  and for laboratory safet y 
assessments at the screenin g visit. Additionally , for participants in Cohorts 1 and 2 , blood will be 
collected for laboratory safet y assessments on Day 1 (pre-vaccination ) and Day 8 (or at the exit 
visit if early exit is within [ADDRESS_832043] vaccination and the participant terminates without 
withdraw ingconsent).
Blood for humoral and cellular immune responses will be drawn from all participants in Cohorts 
1 and 2. In Cohort 3, blood will be drawn for humoral immune responses from all participants and 
for cellular immune respon ses from a subset of 63participants, as specified in the Schedule of 
Activities.
Transcriptome analysis will be performed on samples collected on Day 1 (prior to vaccination) , 
Day 8,and Day 15in Cohorts 1 and 2 only.
Nasal samples will be collected for immunogenicity  assessment sas specified in the Schedule of 
Activities.
Note : All references throughout the protocol to the collection of a “nasal sample” imply  a “nasal 
turbinate sample or its alternative”.
During the first 2 RSV seasons of the study (relat ive to the enrollment date of the first participant 
in Cohort 1), participants should record any signs and symptoms of RTI (eg, runny nose, fever, 
severe cough, rapid breathing, or difficult y breathing) on a daily basis using astudy -specific RTI 
                                                
aAEs that start more than 28 days after a vaccination, but that are still present at the time of the next vaccination will 
also be recorded.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 56
Approved , Date: [ADDRESS_832044] 2RSV season sof the study , participants will be contact[CONTACT_80077]  30±7 
days (unless a planned clinic visit has occurred or will occur within 30 days). Calls will remind 
the participants to complete the RTI Symptoms Form in the event of any symptoms of RTI, to 
contact [CONTACT_160198], and to take a nasal sample at home prefera bly 
between 2 and 3 days after the onset of the RTI  symptoms (or go to the site preferabl y within 2to 
3days after the onset of the RTI to have a nasal sample taken by [CONTACT_34450] y staff). Calls will also check 
for any SAEs and associated concomitant medications since the previous visit or telephone contact.
Unscheduled visits may  be performed based on investigator’s clinical judgment and may include 
further evaluations, as needed.
A diagram of the stud y design is provided in Figure 1, Figure 2 , Figure 3, and Figure 4.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 57
Approved , Date: 6 November 2020Figure 1: Schematic Overview of the Study for Cohort 1
* In addition, sentinel participants in Cohort 1will be contact[CONTACT_5143] [ADDRESS_832045] safety 
information .Safety –[ADDRESS_832046] study vaccination *Screening: 
Days -28 to 0
Study Vaccination 1 : Day 1
Study Vaccination 3: Month 122
3
5
6
71VISIT
Safety –[ADDRESS_832047] study vaccination
Safety and I mmunogenicity –[ADDRESS_832048] study vaccination8
9Safety and I mmunogenicity –[ADDRESS_832049] study vaccination
10
114
Safety and Immunogenicity –[ADDRESS_832050] study vaccination
Safety and I mmunogenicity –12months post-third study vaccination12
13
14Safety and I mmunogenicity –14days post -first study vaccination
Safety –[ADDRESS_832051] -second study vaccinationStudy Vaccination 2: Day 57
Safety and I mmunogenicity –[ADDRESS_832052] -second study vaccination
Safety and I mmunogenicity –26weeks post -first study vaccination
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 58
Approved , Date: 6 November 2020Figure 2: Schematic Overview of the Study for Cohort 2
* Participants in Groups 14 and 15 w ill continue into the long -term follow -up phase.

VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 59
Approved , Date: 6 November 2020Figure 3: Schematic Overview of the Study for Cohort 3 One- dose Regim en and Month 12 and Month 24
Booster
*Visit 13 ([ADDRESS_832053] vaccination) is not required for any Cohort [ADDRESS_832054] vaccination.Safety : [ADDRESS_832055] study vaccinationScreening + Study Vaccination 1 : 
Day 1
Study Vaccination 3: Month 2 41
2
4
5
6
Safety *: [ADDRESS_832056] study vaccination
Safety and I mmunogenicity: [ADDRESS_832057] study vaccination7
8Safety and I mmunogenicity: [ADDRESS_832058] study vaccination
9
103
Safety and Immunogenicity: [ADDRESS_832059] study vaccination
Safety and I mmunogenicity: 36months post-first study vaccination11
12
13Safety and I mmunogenicity: 14days post -first study vaccination
Safety : [ADDRESS_832060] -second study vaccinationStudy Vaccination 2: Month 12 
Safety and I mmunogenicity: [ADDRESS_832061] -second study vaccination
Safety and I mmunogenicity: 26weeks post -second study vaccinationSafety and I mmunogenicity: 12weeks post -first study vaccinationSafety and I mmunogenicity: 56days post -first study vaccination
Safety and I mmunogenicity: 26weeks post -first study vaccination
Safety and I mmunogenicity: 14days post -third study vaccination 14
15
16
17
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 60
Approved , Date: 6 November 2020Figure 4: Schematic Overview of the Study for Cohort 3 Two -dose Regim enand Month 12 Booster
3.2. Study Design Rationale
Vector Selection
The rationale behind the selection of the Ad26 vector is described in Section 1.1.
Dose Selection
The 5×1010vp dose is the most commonly  used dose in previous RSV vaccine studies and other 
programs , and has good safety  and immunogenicity  profiles. Moreover, in study 
VAC18193RSV1003, the 1×1011vpdose of Ad26.RSV.preF was well-tolerated in adults aged 
≥60 years and was found to induce higher humoral immune responses than the 5×1010vp dose

VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 61
Approved , Date: [ADDRESS_832062] maintaining good cellular responses . As the current study  is FIH for the Ad26 .RSV.preF/
RSV preF protein combination (separate injections in opposite arms ) and Ad26.RSV.preF/RSV 
preF proteinmixture (single injection ), both the 5×1010vp and 1×1011vpAd26.RSV.preF doses 
will be assessed.
The dose levels of 50 μg and 150 μg of RSV preF protein to be used were chosen based on the 
supposition that half log intervals in dose response are biologically meaningful for vaccines. Dose 
levels of 15 μg, 50 μg, 150 μg, and 500 μg would correspond to such a series. I t was decided that 
the 15 μg dose would be too low , while the 500 μg dose did not appear to be feasible at this time. 
Therefore, the 50μgand 150 μgwere chosen for initial exploration. These doses are comparable
todoses utilized by [CONTACT_624681].3,7,30
Regimen Selection
In the initial safet y cohort (Cohort 1) , RSV preF protein dosing is increased from 50 μg to150μg 
for initial safet y assessment. Safety of protein at each dose is assessed before dosing of the
Ad26.RSV.preF/RSV preF protein combination or mixture. The dose of the mixture willalso be
increased from a protein/adeno dose of 50 μg/5× 1010vp to a protein/adeno dose of 150μg/1×1011
vp for initial safet y assessment.
In Group 10 of Cohort 1 (Ad26.RSV.preF /RSV preF protein 1×1011vp/150 μg combination given 
as separate injections inopposite arms on Day 1and at Month 12), no active boost vaccination will 
be administered onDay57asthecombination will not be investigated furt her for immunogenicit y 
in the regimen selection ( Cohort 2).
In the regimen selection cohort (Cohort 2), regimens under consideration include dose ranging 
with all dose combinations of the mixture , including high dose Ad26.RSV.preF with high dose 
RSV preF protein; a 2-month prime -boost regimen with a mixture of high dose Ad26.RSV.preF 
with high dose RSV preF protein; and separate administration (inopposite arms) of high dose 
Ad26.RSV.preF and high dose RSV preF protein.
In Cohort 2, only Group 17 (Ad26.RSV.preF/RSV preF protein mixture 1×1011vp/150 μg given 
as a single injection on Day 1andDay 57) will include an active boost vaccination on Day 57, 
because it is anticipated that if a Day [ADDRESS_832063] dose combination 
of Ad26.RSV.preF and RSV preF protein.
All Cohort 1 and 3 regimens include a Month 12 booster dose to assess the need for a yearly 
revaccination. Additionally , the Cohort 3 one- dose regimen includes a Month 24 bo oster dose to 
assess the long- term durability  ofthe immune response to the selected dose.
Screening Period
The study  includes a maximum 28-day screening period for Cohorts 1 and 2, including but not 
limited to safety  laboratory  testing and a 12 -lead ECG. As the screening period of participants for 
Cohorts 1 and 2 will generate sufficient safet y data before the start of Cohort 3, screening of 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 62
Approved , Date: 6 November 2020participants for Cohort 3 will be performed on Day 1 without safety laboratory  testing and a 
12-lead ECG.
Blinding, Control, Study Phase/Periods, Vaccine Groups
Placebo control swill be used to establish the frequency  and magnitude of changes in endpoints 
that may occur in the absence of active vaccine. Randomization will be used to minimize bias in 
the assignment of participants to vaccine groups, to increase the likelihood that known and 
unknown participant attributes (eg, demographic s,baseline characteristics) are evenly  balanced 
across vaccine groups, and to enhance the validity  of statistical comparisons across vaccine groups. 
Blinded treatment will be used to reduce potential bias during data collection and evaluation of 
endpoints.
4. PARTICIP ANT POPULA TION
Screening for eligible participant s in Cohorts [ADDRESS_832064] consult with the appropriate sponsor representative and resolve any issues before 
enroll ing a participant in the study .Waivers are not allowed .
Note : Investigators should ensure that all study  enrollment criteria have been met at screening. If 
a participant ’s clinical status changes (including any available laboratory results or receipt of 
additional medical records) after screening but before the fir st dose of stud y vaccine is given such 
that he or she no longer meets all eligibility criteria, then the participant should be excluded from 
participation in the study . Section 17.4, Source Documentation, describes the required 
documentation to support meeting the enrollment criteria.
4.1. Inclusion Criteria
Each potential participant must satisfy  all of the following criteria to be enroll ed in the study :
1.Each participant must sign an informed consent form (ICF)indicating that he or she 
understands the purpose of and procedures required for the study , is willing to participate in 
the study  and attend all scheduled visits, and is willing and able to comply with all study  
procedures and adhere to the prohibitions and restrictions specified in this protocol.
2.Participant must be a man or woman, ≥[ADDRESS_832065] be:
postmenopausal (postmenopausal state is defined as no menses for 12 months without 
an alternative medical cause); and
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 63
Approved , Date: 6 November 2020not intending to conceive by  [CONTACT_130362].
Note : Hysterectomized women are also eligible for the study .
4.Criterion amended per Amendment 5
4.1 In the investigator’s clinical judgment, participant must be either in good or stable 
health. Participant s may have underl ying illnesses such as hypertension, type [ADDRESS_832066] 12 weeks preceding vaccination and 
expected to remain stable for the duration ofthe study . Participant s will be included 
on the basis of physical examination, medical history , vital signsa, and 12-lead 
electrocardiogram ( ECG )bperformed at screening.
Note : To determine eligibility for revaccination, signs and symptoms of potential 
underlying illnesses should be medically stable in the weeks pr eceding r evaccination.
Participants with changes in medication [ADDRESS_832067] signs or symptoms of the underlying illness.
5.For participants in Cohorts 1 and 2 only : Participant must be healthy  on the basis of clinical 
laboratory tests performed at screening. If the results of the laboratory screening tests are 
outside the central laboratory normal reference ranges and additionally  within the limits of 
toxicity  Grade 2according to the US Food and Drug Administration (FDA) toxicity  tables (ie, 
for tests in the FDA tablec), the participant may be included only if the inv estigator judges the 
abnormalities or deviations from normal to be not clinicall y significant and appropriate and 
reasonable for the population under study . This determination must be recorded in the 
participant ’s source documents and initialed by  [CONTACT_20603].
Note : If laboratory screening tests are out of central laboratory normal ranges and deemed 
clinically significant, repeat of screening tests is permitted once ,using an unscheduled visit 
during the screening period to assess eligibility. Screening laboratory tests are to be done 
within [ADDRESS_832068] the investigator during the study .
                                                
aParticipant s can be enroll ed with Grade 1 or Grade 2 values for vital signs measurements.
bFor participants in Cohorts 1 and 2 only.
cFor the FDA toxicity grading tables, see Attachment 1: FDA Guidance document “Toxicity Grading Scale for 
Healthy Adult and Adolescent Volunteers Enroll ed in Preventive Vaccine Clinical Trials” (September 2007) .
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 64
Approved , Date: 6 November [ZIP_CODE].2. Exclusion Criteria
Any potential participant who meets any of the following criteria will be excluded from 
participating in the stud y:
1.Participant hasacute illness (this does notinclude minor illnesses such as diarrhea) or body  
temperature ≥38.[ADDRESS_832069] dose of study  vaccine . In such a 
situation, the participant may be vaccinated up to, and no later than 10 days after the scheduled 
vaccination .
Note : For participants in Cohorts 1 and 2, safety laboratory tests should be repeated if 
vaccination is postponed and thetime between the safety laboratory tests and vaccination 
exceeds 28 days.
2.Participant has a serious chronic disorder, including severe chronic obstructive pulmonary 
disease or clinicall y significant congestive heart failure, requirement for supplemental oxygen, 
end-stage renal disease with or without dialy sis, clinicall y unstable cardiac disease, 
Alzheimer’s disease, or has any condition for which, in the opi[INVESTIGATOR_871], 
participation would not be in the best interest of the participant (eg, compromise well- being) 
or that could prevent, limit, or confound the protocol- specified assessments .
3.Participant has history  of malignancy  within 5years before screening (exceptions are 
squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or 
malignancy , which is considered cured with minimal risk of recurrence ).
4.Participant has had major surgery  (per the investigator’s judgment), within [ADDRESS_832070] dose of 
study  vaccine.
Note : Participant s with planned surgical procedures to be conducted under local or 
locoregional anesthesia and not judged as major by [CONTACT_233843] .
5. Per serology  testing inCohorts 1 and 2and per medical history  in Cohort 3: Participant has 
chronic active hepatitis B or hepatitis C infection, documented by  [CONTACT_971] B surface antigen 
and hepatitis C antibody , respectivel y.
6.Per serology  testing in Cohorts 1 and 2 and per medical history  in Cohort 3: Participant has 
HIV type 1 or t ype 2 infection.
7.Participant has had major psychiatric illness and/or drug or alcohol abuse which in the 
investigator ’s opi[INVESTIGATOR_130242] ’s safet y and/or compliance with the 
study  procedures .
8.Participant has a known allergy , or history  of anaphy laxis or other serious adverse reactions 
to vaccines or vaccine components (including an y of the constituents of the study  vaccine) .
9.Participant has a history  of chronic urticaria (recurrent hives), ecze ma and/or atopic dermatitis .
10.Participant has a history  of acute pol yneuropath y (eg, Guillain -Barré s yndrome).
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 65
Approved , Date: 6 November 202011. Criterion amended per Amendment 2:
11.1 Participant has abnormal function of the immune system resulting from:
Clinical conditions (eg, autoimmune disease or immunodeficiency)
Chronic (longer than 10 days) or recurrent use of systemic corticosteroids during the 
study  and within [ADDRESS_832071] administration of study  vaccine (Note : Ocular, 
topi[INVESTIGATOR_327865]; intra-articul ar steroid injections are not 
allowed.)
Administration of antineoplastic and immunomodulating agents or radiotherap y 
during the study  and within [ADDRESS_832072] dose of study 
vaccine or has an y plans to receive such treatment during the stud y.
13. Criterion amended per Amendment 2:
13.1 Participant is in receipt of, or planning to receive, licensed live attenuated vaccine 
within 28days of each study  vaccination (ie, before andafter); other licensed vaccines (ie, not 
live: eg, influenza, tetanus, hepatitis A orB,rabies ) should be given at least 14 days before or 
14 days after each study  vaccination .
14. Criterion amended per Amendment 5:
14.[ADDRESS_832073] dose of study  vaccine or is currently  enroll ed 
or plans to participate in another investigational study  during the course ofthe double -
blind phase of this study .
Note : Participation in an observational clinical study (ie, with no intervention) is allowed 
upon approval of the sponsor.
Note : During the long-term follow -up period (Groups 14 and 15 from Cohort 2 only) , 
participation in another investigational study is allowed only upon approval of the sponsor.
15.Participant has a contraindication to intramuscular injections and blood draws, eg, bleeding 
disorde rs.
16. Criterion deleted per Amendment 2.
17.Participant has received RSV vaccine ina previous RSV vaccine study  at any time prior to 
randomization.
18.Participant who, in the opi[INVESTIGATOR_871], is unlikely  to adhere to the requirements of 
the study , or is unlikel y to complete the full course of vaccination and observation.
19.Participant cannot communicate reliabl y with the investigator.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 66
Approved , Date: [ADDRESS_832074] be willing and able to adhere to the following prohibitions and 
restrictions during the course of the stud y to be eligible for participation:
1. See Section 8regarding prohibited and restricted therapi[INVESTIGATOR_624626] .
2.Agree to follow all requirements that must be met during the study  as noted in the inclusion 
and exclusion criteria (Section 4.1and Section 4.2, respectivel y).
5. TREA TMENT ALLOCA TION AND BLINDING
Study Vaccine Allocation
Central randomization will be implemented in this study . Participant s will be randomly  assigned 
to a vaccination group based on a computer -generated randomization schedule prepared before the 
study  by [CONTACT_43754]. The randomization will be balanced by [CONTACT_624682].
In the initial safet y cohort (Cohort 1), the randomization ratio in Cohorts R1a and R1c is 1:2, in 
Cohorts R1b and R1d the ratio is 1:2:2. In each of those cohorts, 1 sentinel participant from each 
group (each active group and the placebo group to maintain the blind) will initially  be enrolled to 
monitor for any  unexpected severe adverse reaction. Therefore, the randomization will be phased 
to accommodate this and to end up with the overall randomization ratios specified above. No 
stratification will be applied.
In the regimen selection cohort (Cohort 2), the random ization ratio is 4:7:7:7:7:6:6:4. No 
stratification will be applied.
In the expanded safet y cohort (Cohort 3), stratification will be applied: participant s will be 
assigned to 1of 2 strata prior to randomization, depending on the blood mononuclear cell (PBMC)
sampling capability  and capacit y of the site. One stratum will contain a maximum of 
63participant s from whom blood samples to assess humoral and cellular (PBMC samples ) 
immunogenicit ywill be collected. The other stratum will contain the remaining participant s, from 
whom blood samples will be collected only for humoral immunogenicity  assessments, to reach the 
target of a total of 315 participants in Cohort 3 . Within each stratum, participant s will be 
randomized 3:3:1 ratio to one of the respective groups.
The interactive web response system (IWRS) will assign a unique code, which will dictate the 
group assignment for the participant . The requestor must use his or her own user identification and 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 67
Approved , Date: [ADDRESS_832075] dose of study  vaccine
is administered, additional participant s may be recruited to replac e these participant s at the 
discretion of the sponsor. Any replacement participant will be assigned to the same group as the 
original (discontinued) participant . The replacement participant ’s randomization number will 
equal the randomization number of the discontinued participant [PHONE_3548] (eg,participant 0001 would 
be replaced by [CONTACT_3445] 1001). These additional participant s should also be randomized through 
IWRS.
In the initial safety  cohort (Cohort 1), any randomized participant who is withdrawn from the study 
for reasons other than due to an AE after the first dose but before the second dose might be replaced 
at the discretion of the sponsor. Any replacement participant will be randomized through IWRS. 
The replacement participan t’s randomization number will equal the randomization number of the 
discontinued participant [PHONE_10364].
In the regimen selection cohort (Cohort 2), no replacements or additional randomizations will be 
done for withdrawals after the first dose .
Blinding
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality  to allow the investigator to break the blind for an 
individual participant .
At the sponsor level, unblinding (at the particip antlevel) will occur at the time of the primary  
analysis for each cohort. After the primary  analy sis, group level results may  be shared as needed ;
however, efforts will be made to preserve the blinding to the individual participant allocation until 
the ti mepoints specified below .
While the responsibility  to break the study  vaccine allocation code in emergency  situations resides 
solely  with the investigator, it is recommended that the investigator contact [CONTACT_624683], before breaking the blind. Telephone contact [CONTACT_624684] [ADDRESS_832076] be retained with the participant ’s source documents in a secure manner.
For Cohorts [ADDRESS_832077] or qualified staff 
member with primary  responsibility  for stud y vaccine preparation and dispensing.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 68
Approved , Date: [ADDRESS_832078] or qualified s taff member with primary 
responsibility  for study  vaccine preparation and dispensing. By [CONTACT_624685]-term 
follow -up phase of the study , clinical staff, the investigator and eligible participants from Groups 
14 and 15 (Cohort 2), will be parti ally unblinded to their treatment received (ie, will be informed 
that they were randomized to either Group 14 or 15)prior to full unblinding after the database lock 
of the final analysisat the end of the long-term follow -up phase (Day  1095).The pharmacy  and 
the preparation of study  vaccines will be monitored by [CONTACT_624686] (see also 
Section 17.8).
Note : The unblinded pharmacist, or other qualified individual, may  also perform administration of 
the vaccine, but will have no other stud y function following dosing.
If the randomization code is broken by [CONTACT_373418] -site personnel, the participant
must discontinue further study vaccine administration and must be followed as appropriate (see 
Section 10.2 for details). If the randomization code is broken by [CONTACT_576673] y reporting 
purposes, the participant should not discontinue further vaccine administration and may remain in 
the study  (if the randomization code is still blinded to the study -sitepersonnel and the participant ).
6. DOSA GE A ND A DMINISTR ATION
Ad26.RSV.preF and RSV preF protein will be administered either as acombination (as separate 
injections in opposite arms) or as a mixture ( a single injection) into the deltoid muscle according 
to the schedules shown in Table 8, Table 9, Table 10and Table 11:
Ad26.RSV.preF (JNJ-64400141): will be supplied at a concentration of 2×1011vp/1 mL in 
single -use vials. Dose levels of 5×1010 vp and 1×1011 vp will be used .
RSV preF protein (JNJ-64213175): will be supplied at a concentration of 0.3mg/1 mL in 
single use vials. Dose levels of 50 μg and 150 μg will be used.
Placebo forAd26.RSV.preF andRSV preF protein .
All injections of Ad26.RSV.preF and RSV preF protein (or corresponding placebo) will be [ADDRESS_832079], or other qualified individual, will prepare the appropriate vial and/or
syringe and provide the syringe in a blinded manner to the vaccine administrator who will perform 
the injection. The unblinded pharmacist, or other qualified individual, may also perform vaccine 
administ ration, but will have no other study  function following dosing. Diluent will be usedas 
required. 
Full details of vaccine preparation, including mixing of Ad26.RSV.preF and RSV preF protein,
areprovided in the Investigational Product Preparation I nstruct ions.
All vaccines should be administered in the deltoid muscle :
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 69
Approved , Date: 6 November 2020When participant s receive 2injections at any given visit, these injections will be given in 
opposite arms at the same time with no more than 45 minutes between the injections.
When participant s receive a single injection per visit, eg,in Groups 1 through 7 in Cohort 1, 
alternating injection sites will be used for subsequent injections unless there is a medicall y 
justifiable reason in the judgment of the PI(s).
No local or topi[INVESTIGATOR_624627].
For each injection, a record should be made in the eCRF of which arm was injected.
7. VACCINE COMPLI ANCE
Study  vaccine (active or placebo) will be administered intramuscularly by a blinded vaccine 
administrator ( a trained and qualified study  nurse, medical doctor, or otherwise qualified 
healthcare professional ). The unblinded pharmacist, or other qualified individual, may also 
perform vaccine administration, but will have no other study  function following dosing. The date 
and time of each study  vaccine administration will be recorded in the eCRF .
8. PRE-STUDY AND CONCOMIT ANT THE RAPY
Pre-study therapi[INVESTIGATOR_624628]/antipy retic medications andnon-steroidal anti-inflammatory  
drugs (NSAIDs) usedup to [ADDRESS_832080] be recorded in the 
eCRF during screening .
Concomitant therapi[INVESTIGATOR_624629] 28 days after each vaccination , and additionally  outside of these periods 
when associated with an ySAE that meets the criteria outlined in Section 12.3.2 .During the long -
term follow -up phase (Groups 14 and 15 from Cohort 2), only concomitant therapi[INVESTIGATOR_624630], study  procedures, or non-investigational 
(concomitant) Janssen products, or in conjunction with AEs leading to discontinuation should be 
recorded.
Information on concomitant use of herbal supplements or vitamins will not be collected.
Use of experimental medication s (including experimental vaccines other than the study  vaccine) 
during the study  is not allowed. Note : During the long-term follow -up period (Groups 14 and 15 
from Cohort 2 only), use of experimental medications during participation in another 
investigational study is allowed only upon approval of the sponsor.
Analgesic/antip yretic medications and NSAID smay be used post-vaccination only in case of 
medical need (eg, fever or pain) and their use must be documented. Use of these medications as 
routine proph ylaxis prior to study  vaccine administration is discouraged.
Chronic (longer than 10 days) or recurrent use of systemic corticosteroids is prohibited during the 
study and within [ADDRESS_832081] administration of study  vaccine (ocular, topi[INVESTIGATOR_624631] ; intra-articular steroid injections are not allowed ). Antineoplastic and 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 70
Approved , Date: [ADDRESS_832082] 
administration of study  vaccine and during the study .
If chronic use of prohibited therapi[INVESTIGATOR_624632] , the sponsor should be contact[INVESTIGATOR_530].
Vaccination wi th live attenuated vaccines within 28 day s of a vaccination in this study  (ie, before 
and after) is prohibited. Other licensed vaccines (ie, not live: eg, influenza, tetanus, hepatitis A, 
hepatitis B,rabies) should be given at least [ADDRESS_832083]-exposure setting (eg, rabies or tetanus), it must take priority  over the vaccine s 
in this study .
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapi[INVESTIGATOR_23730].
9. STUDY PROCEDURES A ND EV ALUATIONS
9.1. Study Procedures
9.1.1. Overview
Evaluation of the safet yand reactogenicit ywill include laboratory assessments (Cohorts 1 and 2 
only), measurements of vital signs, phy sical examination by [CONTACT_3449] -site personnel, and participant
reports on signs and s ymptoms post-vaccination. Additional study  visits may  be required if, in the 
investigator’s opin ion, further clinical or laboratory evaluation is needed.
All p articipant swillbeprovided with athermometer, aruler and a participant diary  to measure and 
record bod y temperature ,solicited local AEs (at the injection site) ,and solicited systemic AEs.
Thediary  includes instructions on how to capture data and grading scales to assess the severit y of 
thesymptoms. Study  staff are responsible for providing appropriate training to the participant to 
avoid any missing or incorrect data. The diary card will be reviewed b y the study -sitepersonnel at 
visits indicated in the Schedule of Activities . If the diary card review is missed, the diar y card will
bereviewed at the next visit. If a participant misses a vaccination, the diary  card covering the 
period after the missed vaccination does not have to be completed.
During the first 2 RSV seasons of the study (relative to the enrollment date of the first participant 
in Cohort 1), participants will be contact[CONTACT_80077]  30±7 days (unless a planned visit 
has occurred or will occur within 30 days). These calls will remind participants to complete the 
RTI Symptoms Form in the event of any symptoms of RTI, to contact [CONTACT_624687], and to take a nasal sample at home preferabl y between 2 and 3 days after the onset
of the RTI symptoms (or go to the site preferabl y within 2to 3days after the onset of the RTI to 
have a nasal sample taken by [CONTACT_34450] y staff). These calls will also check for any SAEs and associated 
concomitant medications since the previous visit or telephone contact.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 71
Approved , Date: 6 November 2020The Schedule of Activities summarizes the frequency  and timing of safety  and immunogenicit y 
assessments applicable to this study .The total blood volume to be collected over the entire study 
from each participant will be:
In Cohort 1 :approximately  627.5mL. The maximum volume of blood to be drawn at any 
given visit will be 6 7.5mL.
In Cohort 2(Groups 11-13 and Groups 16-18): approximately  567.5 mL. The maximum 
volume of blood to be drawn at an y given visit will be 67.5 mL .
In Cohort 2 participants in Groups 14 and 15 whocontinue into the long-term follow -up phase: 
approximately  687.5 mL. The maximum volume of blood to be drawn at any  given visit will 
be 67.5 mL .
In therandomly  selected subset of 63participant s in Cohort 3 with blood draws for humoral 
as well ascellular responses: approximately 840mL. The maximum volume of blood to be 
drawn at an y given visit will be 60 mL.
In the remaining [ADDRESS_832084]-vaccination visits will be 
calculated from the imputative vaccination date according to protocol.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 72
Approved , Date: 6 November 2020Table 12: Visit Windows: Initial Safety Cohort (Cohort 1) 
VISIT Visit Day Window Prim ary Purpose
Visit [ADDRESS_832085] STUDY VACCINATION
Visit 3 Day 8 ±[ADDRESS_832086] study vaccination safety only visit
Visit 4 Day 15 ±[ADDRESS_832087] study vaccination safety and
immunogenicity visit
Visit 5 Day 29 ±[ADDRESS_832088] study vaccination safety and 
immunogenicity visit
Visit 6 Day 57 ± 3 days SECOND STUDY VACCINATION
Visit 7 Day 64
(Vac 2
+7 days )±[ADDRESS_832089] -second study vaccination safety only visit
Visit 8 Day 85
(Vac 2
+28 days )3 days /[ADDRESS_832090] -second study vaccination safety and 
immunogenicity visit
Visit 9 Day 183
(Vac 1
+26weeks)±14days 26- week post -first study vaccination safety and 
immunogenicity visit
Visit 10 Day 365 ±2months THIRD STUDY VACCINATION
(MONTH 12 BOOSTER)
Visit 11 Day 372
(Vac 3
+7 days )±[ADDRESS_832091] study vaccination safety only visit
Visit 12 Day 393
(Vac 3
+28 days )±[ADDRESS_832092] study vaccination safety and
immunogenicity visit
Visit 13 Day 547
(Vac 3
+26weeks)±[ADDRESS_832093] study vaccination safety and 
immunogenicity visit
Visit 14 Day 730
(Vac 3
+12 months )±1 month FINAL VISIT: 12-month post -third study vaccination 
safety and immunogenicity visit
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 73
Approved , Date: 6 November 2020Table 13: Visit Windows: Regim en Selection Cohort (Cohort 2)
VISIT Visit Day Window Prim ary Purpose
Visit [ADDRESS_832094] STUDY VACCINATION
Visit 3 Day 8 ±[ADDRESS_832095] study vaccination safety only visit
Visit 4 Day 15 ±[ADDRESS_832096] study vaccination safety and 
immunogenicity visit
Visit 5 Day 29 ±[ADDRESS_832097] study vaccination safety and 
immunogenicity visit
Visit 6 Day 57 ±3 days SECOND STUDY VACCINATION
Visit 7 Day 64
(Vac 2 
+7 days)±[ADDRESS_832098] -second study vaccination safety only visit
Visit 8 Day 85
(Vac 2
+28 days)3 days/ [ADDRESS_832099] -second study vaccination safety and 
immunogenicity visit
Visit 9 Day 183
(Vac 1
+26 w eeks)±[ADDRESS_832100] study vaccination safety and 
immunogenicity visit
Visit 10 Day 365
(Vac 1
+12 months)±1month 12-month post -first study vaccination safety and 
immunogenicity visit
Visit 11 Day 547
(Vac 1
+18 months)±1month 18-monthpost-first study vaccination safety and 
immunogenicity visit
Visit 12 Day 730
(Vac 1
+24 months)±1month FINAL VISIT for Groups 11 -13 and Groups 16 -18: 
24-month post -first study vaccination safety and 
immunogenicity visit
Visit 13* Day 912
(Vac 1
+911 days )±30days 30-month post -first study vaccination immunogenicity 
visit
Visit 14* Day 1095
(Vac 1
[PHONE_12987] days )±30days FINAL VISIT: [ADDRESS_832101] study vaccination 
immunogenicity visit
*Visits during long -term follow -up phase for participant s inGroups 14 and 15 only.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 74
Approved , Date: 6 November 2020Table 14: Visit Windows: Expanded Safety Cohort (Cohort 3) -One-dose Regimen and Month 12and 
Month 24 Booster
VISIT Visit Day Window Prim ary Purpose
Visit 1 Day 1 – FIRST STUDY VACCINATION 
Visit 2 Day 8 ±[ADDRESS_832102] study vaccination safety only visit
Visit 3 Day 15 ±[ADDRESS_832103] study vaccination safety and 
immunogenicity visit
Visit 4 Day 29 ±[ADDRESS_832104] study vaccination safety and 
immunogenicity visit
Visit 5 Day 57 ±3days 56-day post -first study vaccination safety and 
immunogenicity visit
Visit 6 Day 85 
(Vac 1
+12 w eeks)-3/+[ADDRESS_832105] study vaccination safety and 
immunogenicity visit
Visit 7 Day 183
(Vac 1
+26 w eeks)±[ADDRESS_832106] study vaccination safety and 
immunogenicity visit
Visit 8 Day 365 –2 months SECOND STUDY VACCINATION
(MONTH 12 BOOSTER)
Visit 9 Day 372
(Vac 2
+7 days)±[ADDRESS_832107] -second study vaccination safety only visit
Visit 10 Day 393
(Vac 2
+28 days)±[ADDRESS_832108] -second study vaccination safety and 
immunogenicity visit
Visit 11 Day 547
(Vac 2
+26 w eeks)±[ADDRESS_832109] -second study vaccination safety and 
immunogenicity visit
Visit 1 2 Day 730
(Vac 1
+729 days )±[ADDRESS_832110] STUDY VACCINATION
(MONTH 24 BOOSTER)
Visit 13 Day 737
(Vac 3
+7 days)±[ADDRESS_832111] study vaccination safety only visit
Visit 14 Day 744
(Vac 3
+14days)±2days 14-day post -third study vaccination safety and 
immunogenicity visit
Visit 15 Day 758
(Vac 3
+28 days)±[ADDRESS_832112] study vaccination safety and 
immunogenicity visit
Visit 1 6 Day 912
(Vac 3
+182 days )±[ADDRESS_832113] study vaccination safety and 
immunogenicity visit
Visit 1 7 Day 1095
(Vac 1
[PHONE_12987] days )±30 days FINAL VISIT: [ADDRESS_832114] study vaccination 
safety and immunogenicity visit
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 75
Approved , Date: 6 November 2020Table 15: Visit Windows: Expanded Safety Cohort (Cohort 3) -Two -dose Regim enand Month 12 Booster
VISIT Visit Day Window Prim ary Purpose
Visit 1 Day 1 – FIRST STUDY VACCINATION
Visit 2 Day 8 ±[ADDRESS_832115] study vaccination safet y only visit
Visit 3 Day 15 ±[ADDRESS_832116] study vaccination safety and 
immunogenicity visit
Visit 4 Day 29 ±[ADDRESS_832117] study vaccination safety and 
immunogenicity visit
Visit 5 Day 57 ±3 days SECOND STUDY VACCINATION 
Visit 6 Day 64
(Vac 2
+7 days)±[ADDRESS_832118] -second study vaccination safety only visit
Visit 7 Day 85 (Vac 2
+28 days)-3/+[ADDRESS_832119] -second study vaccination safety and 
immunogenicity visit
Visit 8 Day 183
(Vac 1
+26 w eeks)±[ADDRESS_832120] -firststudy vaccination safety and 
immunogenicity visit
Visit 9 Day 365 –[ADDRESS_832121] STUDY VACCINATION
(MONTH 12 BOOSTER)
Visit 10 Day 372
(Vac 3
+7 days)±[ADDRESS_832122] study vaccination safety only visit
Visit 11 Day 393
(Vac 3
+28 days)±[ADDRESS_832123] study vaccination safety and 
immunogenicity visit
Visit 12 Day 547
(Vac 3
+26 w eeks)±[ADDRESS_832124] study vaccination safety and 
immunogenicity visit
Visit 13 Day 730
(Vac 3
+12 months)±1 month FINAL VISIT: [ADDRESS_832125] study vaccination 
safety and immunogenicity visit
9.1.3. Screening Phase ( Days -28to0for Cohort s 1and 2 ; Before 
Randomization on Day 1 for Cohort 3)
Only  participant s in good or stable health without acute illness or fever and comply ing with the 
inclusion and exclusion criteria as specified in Section s4.1and 4.2will be included in the study . 
The investigator will provide detailed infor mation on the study to the participants and will obtain 
written informed consent prior to each participant ’s participation in the study . All the procedures 
described in the Schedule of Activities will only  take place after the written informed consent has 
been obtained.
The following evaluations will be performed to determine eligibility  requirements as specified in 
the inclusion and exclusion criteria:
Demographic information
Medical history
Review of pre -study  medications
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 76
Approved , Date: 6 November 2020Review of inclusion/exclusion criteria
Full physical examination including vital signs measurement (respi[INVESTIGATOR_2842], heart rate, 
supi[INVESTIGATOR_624633] ,and body  temperature) and height and weight
The following evaluations will additionally  be performed for participants in Cohorts 1 and 2:
12-lead ECG
Serology  testing (HIV t ype 1 or type 2, hepatitis B, hepatitis C)
Blood sampling for laboratory safet y testing (hematology  and biochemistry)
Study  participant s who qualify  for inclusion in Cohorts [ADDRESS_832126] vaccination (Visit 2) within 28 day s.If necessary , the screening visit may 
be split into several visits.
Participant s in Cohorts 1 and 2 with laboratory values or vital signs (eg, elevated blood pressure) 
not meeting eligibility  criteria atthe screening visit may  have [ADDRESS_832127] been reviewed for completeness and adherence to the inclusion and exclusion 
criteria, the participant can be deemed eligible for the study .
SAEs (and any concomitant medications associated with SAEs ) will be collected from first dose 
administration until the end of the study . Unsolicited AEs will be recorded on the Adverse Event 
page of the eCRF from the time of each vaccination through the following 28 day s, together with 
information on any concomitant medications.aAdditionally , (S)AEs that are related to the study  
procedures or to non-investigational (concomitant) Janssen products will be colle cted from ICF 
signature [CONTACT_624710].
9.1.4. Randomization (Day  1)
Cohorts 1 and 2: After verification of selected inclusion and exclusion criteria ,babbreviated 
physical examination (at the discretion of the investigator) ,andmeasurement ofvital signs, eligible 
participants will be randomized as described in Section 5.If the medical status and/or physical
examination suggest thatsignificant changes have occurred since screening, the safety  laboratory 
                                                
aAEs that start more than 28 days after a vaccination, but that are still present at the time of the next vaccination will 
also be recorded.
bInclusion criteria 4and 5, and exclusion criteria 1, 4, 12, 13,and14.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 77
Approved , Date: 6 November 2020tests will be repeated and the randomization visit re-scheduled, or the participant excluded from 
the study  if he or she fails to meet the inclusion and exclusion criteria.
Cohort 3: Afterverification of all inclusion and exclusion criteria, physical examination, and
measurement of vital signs, eligible participants will be randomized as described in Section 5.
All eligible participants will receive their first vaccination following the procedures as described 
in Section 9.1.[ADDRESS_832128] -vaccination :
Pre-vaccination, verification of selected inclusion/exclusion criteria,aphysical examination ,b
and measurement of vital signs will be performed for all participants.
Pre-vaccination, blood and nasal samples will be collected for immunogenicity  assessments.
In Cohorts 1 and 2, pre -dose blood samples will be taken onDay1fortranscriptome analysis
andsafet y laboratory tests (hematology  and biochemistry ).
Pre-vaccination ,theinvestigator must check for any  symptoms of acute illness or fever ( body 
temperature ≥38.0 °C). In such a situation, the participant may be vaccinated up to, and no 
later than 10 days after the scheduled vaccination, or withdrawn from further vaccination at 
the discretion of the investigator.
Post-vaccination, participants will be closel y observed for at least 30 minutes to monitor for 
development of any acute reactions, or longer if deemed necessary  by [CONTACT_093]. Vital 
signs measurement will be performed. Any unsolicited orsolicited AEs and vital signs will 
be documented in the eCRF by  [CONTACT_3449] -site personnel following this observation period.
All participants will be provided with a participant diary , thermometer, and ruler to measure 
and record body  temperature, and solicited local and solicited systemic AEs for [ADDRESS_832129] -
vaccination.
Nasal swab kits and RTI Symptoms Forms will be distributed to all participants before the 
start of the first 2 RSV season sof the study (relative to the enrollment date of the first 
participant in Cohort 1); during theseRSV seasons, participants should record signs and 
symptoms of RTI using the RTI  Symptoms Form.
                                                
aTo include receipt of any routine immunizations.
bA full physical examination, including height and body weight, will be carried out at scree ning, and before final 
vaccination. At other vaccination visits, an abbreviated, symptom -directed examination will be performed if 
determined necessary by [CONTACT_093].
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 78
Approved , Date: [ADDRESS_832130] safety  information (solicited and unsolicited AEs, SAEs ,and concomitant 
medications).
The 7-daypost-vaccination visitsinclude an abbreviated phy sical examination (at the discretion 
oftheinvestigator), measurement of vital signs, and recording of any AEs/SAEs, concomitant 
medications and RTIs.a,bThe participant diary  will be reviewed and collected. If the visit occurs 
before the end of the diary  period after the vaccination, review of the diary  will still take place, but 
the diary  will be returned by [CONTACT_624688].In Cohorts 1 and 2, blood 
samples for transcriptome anal ysis and for safet y laboratory  tests (hematology  and biochemistry ) 
will be collected (after the first dose onl y, not applicable to subsequent doses) .
The14-daypost-vaccination visit (post-dose [ADDRESS_832131]- dose 3 ) includes an abbreviated phy sical
examination (at the discretion of the investigator), measurement of vital signs, and recording of
unsolicited AEs/SAEs, concomitant medications and RTIs.aBlood and nasal samples for 
immunogenicit y assessm entswill be collected. Blood samples for transcriptome anal ysis will also 
be taken (in Cohorts 1 and 2 only ).
The28-daypost-vaccination visit sinclude anabbreviated ph ysical examination (at the discretion 
oftheinvestigator), measurement of vital signs, and recording of unsolicited AEs/SAEs, 
concomitant medications, andRTIs.aBlood andnasalsamples for immunogenicity  assessments 
will be collected.
The56-daypost-vaccination visit (post-dose 1 in Cohort 3 with one -dose regimen only) include s
anabbreviated physical examination and vital signs measurement (both at the discretion ofthe
investigator), and recording of any SAEs andconcomitant medications, andRTIs.aBlood andnasal
samples for immunogenicity  assessments will be collected.
The12-week post-vaccination visit (post -dose 1 in Cohort 3 with one-dose regimen only) includes
anabbreviated physical examination and vital signs measurement (both at the discretion ofthe
investigator), and recording of any SAEs andconcomitant medications, andRTIs.aBlood andnasal
samples for immunogenicity  assessments will be collected.
The26-week post-vaccination visits include an abbreviated ph ysical examination and vital signs 
measurement (both at the discretion of the investigator) and recording of any SAEs and associated
concomitant medications, and RTIs.aBlood samples for immunogenicit y assessments will be 
collected.
                                                
aRTIs will only be recorded during the first 2 RSV seasons of the study  (relative to the enrollment date of the first participant in 
Cohort 1).
bVisit 13 ([ADDRESS_832132] vaccination) is not required for any Cohort [ADDRESS_832133] vaccination.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 79
Approved , Date: [ADDRESS_832134] vaccination visit includes an abbreviated physical examination and vital 
signs measurement (both at the discretion of the investigator) and recording of any SAEs and 
associated concomitant medications, and RTIs.aBlood andnasalsamples for immunogenicit y 
assessments will be collec ted.
The18-month post-first vaccination visit (Cohort 2 only) includes an abbreviated physical 
examination and vital signs measurement (both at the discretion of the investigator) and recording 
of any SAEs and associated concomitant medications, and RTIs .aBlood samples for 
immunogenicit y assessments will be collected .
9.1.7. Final Visit
For Cohorts 1 and 2(Groups 11-13 and Groups 16-18), t he visit at 24months after the first
vaccination will be the final visit and include an abbreviated physical examination and vital signs 
measurement (both at the discretion of the investigator) , and recording of any SAEs and associated 
concomitant medications, and RTIs.aBlood samples for immunogenicit y assessments will be 
collected. Participants in Groups 14 and 15 (Cohort 2)will continue into along-term follow -up 
phase . Their final visit will be the visit at [ADDRESS_832135] vaccination.
For Cohort 3, the visit at 36 months after the firstvaccination will be the final visit and include an 
abbreviated physical examination and vital signs measurement (both at the discretion of the 
investigator), and recording of an y SAEs and associated concomitant medications .Blood samples 
for immunogenicit y assessments will be collected.
9.1.8. Early  Withdrawal : Early  Exit Visit
For participant s who are unable to continue participation in the study , but who do not withdraw 
consent, an earl y exit visit will be conducted as soon as possible. In the event of early  withdrawal 
from the study , all procedures as required at the final visit (see Section 9.1.7 ) will be performed. 
Blood samples for safety laboratory assessments (hematology  and biochemistry ; Cohorts 1 and2 
only) will be collected if the earl y exit is within [ADDRESS_832136] within 7 days of the previous vaccination, solicited AEs will be 
recorded; if the earl y exit visit takes place within 28 day s of the previous vaccination, unsolicited 
AEs will be recorded.
9.1.9. Long -term Follow -up(Groups 14 and 15 from Cohort 2)
Participants in Groups [ADDRESS_832137] 2RSV seasons of the study (relative to the enrollment date of the first participant 
in Cohort 1) .
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 80
Approved , Date: 6 November 2020Participants will make follow -up visits at the clinic every 6 months (26 weeks) until the final visit 
at Day 1095 . Each visit includes recording of any SAEs related to study  vaccine, study  procedures, 
or non-investigational (concomitant) Janssen products, recording of any AEs leading to 
discontinuation ; recording of concomitant medications in conjunction with SAEs related to study 
vaccine, study  procedures, or non-investigational (concomitant) Janssen products, or in 
conjunction with AEs leading to discontinuation; and collection of samples for cellular and 
humoral immunogenicit y assay s.
9.2. Study Evaluations
9.2.1. Immunogenicity
Venous blood samples of approximately  10 mL and 50 mL will be collected for determination of 
humoral and cellular immune responses, respectively , at the timepoints shown in the Schedule of 
Activities, or at the early exit visit if the participant prematurel y terminates without withdrawing 
consent (ifthe earl y exit is at least 14 days after the previous immunogenicity blood draw ).
Venous blood samples (2.5 mL ) for transcriptome analysis will b e collected on Day  1 (pre -dose), 
Day 8,and Day 15in Cohorts [ADDRESS_832138] a pre -existing immune response due to previous RSV 
exposure.
The h umoral and cellular immunogenicit y assay s that may  be used in this study  (as available and 
applicable) are summarized in Table 16and Table 17below .
Blood for humoral and cellular immune responses will be drawn from all participant s in Cohorts 1 
and 2.In Cohort 3, blood will be drawn for humoral immune responses from all participants and 
for cellular immune responses from a subset of 63 participant s.
Immunogenicit y samples will be prioritized as outlined in the Laborator yManual.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 81
Approved , Date: 6 November 2020Table 16: Summary of Immunogenicity Assays (Hum oral)
Assay Purpose
Prima ry endpoint (Regimen Selection C ohort [Cohort 2] –Groups 11 to 15 only)
RSV neutralization A Analysis of neutralizing antibodies to an A strain
Secondary endpoints
RSV neutralization A Analysis of neutralizing antibodies to an A strain
F protein antibodies
(ELISA; pre -Fand/or post -F) Analysis of antibodies binding to RSV F protein in pre -fusion and/or 
post-fusion form
Exploratory endpoints
RSV strain cross -neutralization Analysis of cross -neutralizing antibodies to B and/or a different A 
strain(s)
F protein antibody specificity 
characterization Pre-and post -F specificity by [CONTACT_624661], 
and/or competition ELISA. Adsorption of serum or plasma with pre- F 
and post -F protein before any antibody assay, epi[INVESTIGATOR_111050], 
functional VNA s
G and/or N protein antibodies
(ELISA) Analysis of antibodies binding to RSV G and/or N protein 
Adenovirus neutralization assay Analysis of neutralizing antibodies to adenovirus
Functional and molecular antibody 
characterizationAnalysis of antibody characteristics including, but not limited to, ADCC, 
ADCP, avidity, other respi[INVESTIGATOR_624634], 
Igisotype, functional VNAs to other respi[INVESTIGATOR_4398], and antibody 
assessments for antibody repertoire
ADCC :antibody -dependent cell -mediated cytotoxicity; ADCP : antibody-dependent cellular phagocytosis; ELISA :enzyme -
linked immunosorbent assay; F :fusio n; G:glycoprotein; Ig:immunoglobulin; N:nucleo protein ; RSV :respi[INVESTIGATOR_4345]; 
VNA :virus neutralizing antibody
Note : Antibody analyses might be performed in nasal samples, serum and plasma.
Table 17: Summary of Immunogenicity Assays (Cellular)
Assay Purpose
Secondary endpoints
IFN-γ ELISpot T-cell IFN -γ responses to RSV F protein peptides
Exploratory endpoints
ICS Analysis of T -cell responses to RSV F protein peptide -stimulated PBMC 
(including, but not limited to, CD4+/CD8+, IL-2, IFN -γ, TNF -α, 
activation markers and memory)
Transcriptome analysis Regulation of genes (clusters), expression patterns, that predict specific 
immune responses after vaccination
Chemokine/cytokine analysis Levels of chemokine s and cytokines in nasal samples
Sequencing of B- cells Including but not limited to sequencing of BCR (B -cell receptor) or 
VH/VL (heavy/light chain characterization) for specificity
ELISpot :enzyme-linked immunospot; F :fusion; ICS : intracellular cytokine staining; IFN-γ: interferon gamma; IL -2:
interleukin -2; PBMC: peripheral blood mononuclear cell s; RSV :respi[INVESTIGATOR_4345]; TNF-α: tumor necrosis factor 
alpha
Nasal samples , collected at the timepoints indicated in the Schedule of Activities, will be used for 
immunogenicit y assessments (for example ,immunoglobulin or cellular immune component )and 
identification of the etiology  of respi[INVESTIGATOR_121875] (if needed).
In addition to RT -PCR performed on nasal samples, any  immunogenicit y blood sample collected 
from all participant s may also be assay ed by  [CONTACT_44898]  (including but not limited to RSV VNA or 
ELISA specific to RSV protein G [glycoprotein] and/or N [nucleoprotei n] as available and 
applicable ) for RSV exposure .
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 82
Approved , Date: [ADDRESS_832139] beunder the specified, 
and where applicable, controlled temperature conditions as indicated in the Laboratory Manual.
9.2.2. RTI Procedures
Participants will be informed of the timing of the start and end of the RSV season in accordance 
with the country /region -specific RSV local surveillance s ystem.
During the first 2 RSV seasons of the study (relative to the enrollment date of the first participant 
in Cohort 1), participants should record any signs and symptoms of RTI(such as runny nose, fever, 
severe cough, rapid breathing, difficult y breathing), including measurement ofbody  temperature ,
on a daily  basisuntil symptoms have resolved using a specific RTI Symptoms Form. Signs and 
symptoms of RTI recorded on the RTI Symptoms Form will be transferred onto the RTI Symptoms 
page in the eCRF. RTI Symptoms Form swill be the primary  source for RTI monitoring. 
Participants should complete a new form on each day they experience symptoms, including the day 
onwhich the sy mptoms resolve. Completed RTI  forms can either be mailed to the site or brought 
to the site at the next visit.
If respi[INVESTIGATOR_624635] [ADDRESS_832140]:
Participants should co ntact the site as soon as possible to notify  the site of an RTI .
Participants should record signs and symptoms of the RTI (including measurement of body 
temperature) dail y using the RTI  Symptoms Form until the day  of symptom resolution .
If feasible, participants should take a nasal sample at home , preferabl y between 2 and 3 day s 
after the onset of the RTI symptoms .The sample should be stored refrigerated and brought to 
the site by  [CONTACT_78772] 3 to 4 days.
Alternativel y, participants may goto the site preferabl y within [ADDRESS_832141] 2RSV seasons of the study , participants will be contact[CONTACT_80077]  30±7 
days (unless a planned visit has occurred or will occur within 30 days). These calls will remind 
participants to complete the RTI Symptoms Form in the event of an y sym ptoms of RTI, to contact 
[CONTACT_160198], and to take a nasal sample (or go to the site to have a nasal 
sample taken by [CONTACT_464]). These calls will also check for an y SAEs and associated concomitant 
medications since the previous visit or te lephone contact.
The presence of RSV or any other respi[INVESTIGATOR_624636]-PCR 
diagnostics on the nasal samples, which may  include viral load and RSV subty pi[INVESTIGATOR_007].
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 83
Approved , Date: 6 November 2020Blood from participant swith a suspected RTI may  be a ssayed by a serological assay  (eg, protein 
G and/or N ELISA) to confirm RSV infection. (No additional blood sampling is necessary  –any 
serological assay  conducted to confirm RSV infection will use blood from the existing samp les.)
Every effort should be made to collect data on the clinical course of RTIs including information 
onoxygenation status, supplemental ox ygen requirements and specific drug treatments, as well as 
other concurrent respi[INVESTIGATOR_624637].
Any RTI  that is not due to RSV infection will be reported as an AE if it occurs between the time 
of any vaccination through the following 28 days. Any RTI recorded as an AE in the eCRF will 
be excluded from any AE analysis if the central laboratory  RT-PCR is subsequently  found to be 
positive for RSV. RTIs arising from RSV infection will not be reported as (S)AEs in the Clinical 
Study  Report as they  are endpoints of the study  and will be tabulated separately .
Any RTI fulfilling the criteria of an SAE will be reported as such during the entire study period if 
RT-PCR indicates it is not an RSV -RTI. If the RT-PCR is positive for RSV the event should not 
be reported as an SAE. If RT-PCR information is not available within [ADDRESS_832142] b e recorded inthe eCRF.
Any clinicall y significant abnormalities, including abnormalities persisting at the end of the study
or at early withdrawal, will be followed by [CONTACT_624689] a clinicall y stable 
endpoint is reached.
The study includes the following evaluations of safety  and reactogenicity  ontimepoints provided 
in the Schedule of Activities.
[IP_ADDRESS]. Adverse Events
All AEs will be reported as specified in Section 12, Adverse Event Reporting. All SAEs will be 
collected until the end of the double -blind phase; only SAEs related to study  vaccine ,study 
procedures , or non-investigational (concomitant) Janssen products , and all AEs leading to 
discontinuation will be collected during the long-term follow -up phase (Groups 14-15 in 
Cohort 2).
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 84
Approved , Date: 6 November 2020Unsolicited AEs
Unsolicited AEs will be reported by  [CONTACT_624690] 28 days, or early  discontinuation.aRelatedness of theAEs should be determined by  [CONTACT_1275]. Additionally , AEs that are related to the study procedures or to non-investigational 
(concomitant) Janssen products will be reported from I CF signature [CONTACT_624710].
Solicited AEs
Information related to solicited AEs defined below , will be recorded by  [CONTACT_10132] a diary  for 
7 days after each vaccinatio n. Each participant will be provided with a diary and instructions on 
how to complete the diary  (Section 9.1.1 ). There will be a minimum 30-minute post-vaccination 
assessment of solicited events at the site. Diary information will be transcribed by [CONTACT_1758] -site
personnel in the appropriate diary  pages of the eCRF. Once a solicited symptom from a diary  is 
considered to be of severity  Grade 1 or above, it will be referred to as a solicited AE.
Injection Site (Local) Adverse Events
Participant s will be asked to note in the diary  occurrences of pain/tenderness, indurat ion/swelling 
and ery thema at the vaccine injection site dail y for [ADDRESS_832143]-vaccination. The extent ( ie, largest 
diameter) ofanyerythema and induration/swelling should be measured (using the ruler supplied ),
graded (using the functional scale ) and reco rded daily .
Injection Site Pain/Tenderness
Injection site pain (eg, stinging, burning) is an unpleasant sensory  and emotional experience 
associated with actual or potential tissue damage and occurring at the immunization site (with 
or without involvement o f surrounding tissue). Injection site tenderness is a painful sensation 
localized at the injection site upon palpation or movement of the limb. Due to the subject ive 
nature of the reaction, the severity  assessment of pain/tenderness is self-reported (if a 
participant is unable to provide self-report, other reporters include a healthcare provider or 
caregiver ).10
Injection Site Erythema
Injection site erythema is a redness of the skin caused by [CONTACT_624691][INVESTIGATOR_495770]. I t can best be described b y looking and measuring.
Injection Site Swelling/Induration
Injection site swelling is a visible enlargement of an injected limb. It may be soft (typi[INVESTIGATOR_1306] y) 
or firm (less ty pi[INVESTIGATOR_2855]). Injection siteinduration isa palpable thickening, firmness, or hardening 
of soft tissue, usually  has well -demarcated palpable borders, can be visible (raised or sunken 
compared to surrounding skin), is often ‘woody ’ to touch, and has a flat shape. As
differentiation between swelling and induration may be difficult without ahealthcare
                                                
aAEs that start more than 28 days after a vaccination, but that are still present at the time of the next vaccination will 
also be recorded.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 85
Approved , Date: 6 November 2020professional’s assessment, both symptoms have been combined to allow self-assessment by 
[CONTACT_2299] s. Swelling and induration can best be described b y looking and measuring.
Note : Any other injection site events not meeting the above case definitions should be reported 
separately  as unsolicited AEs.22,[ADDRESS_832144] temperature of that day 
will be used in the eCRF.
Fever is define d as an endogenous elevation of body  temperature ≥38.0°C, as recorded in at least 
onemeasurement .[ADDRESS_832145] daily in the diary  for 7days 
after each vaccination symptoms of the following events : fatigue, headache, myalgia, arthr algia, 
chills, and nausea. Severity  of these event will be graded by [CONTACT_624692] 12.1.[ADDRESS_832146] 
symptoms and maximum severit y in the diary after resolution.
[IP_ADDRESS]. Clinical Laboratory Tests
InCohorts 1and2, blood samples for bio chemistry and hematology  will be collected at screening, 
on Day 1,and at [ADDRESS_832147] vaccination (or at the exit visit if early exit is within 8 day s 
of the vaccination and the participant terminates from the study  without withdrawing consent) .
The following tests will be performed b y a central laboratory (*parameters will only be measured 
at screening ):
Hematology Panel
hemoglobin
white blood cell (WBC) count with differential
platelet count
prothrombin time *
activated partial thromboplastin time *
                                                
aAll diary assessments, including body temperature ,7 days after each vaccination may be collected earlier in the day 
to coincide w ith the clinic visit.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 86
Approved , Date: 6 November 2020Biochemistry Panel
sodium
potassium
creatinine
blood urea nitrogen 
aspartate aminotransferase (AST)
alanine aminotransferase (ALT)
Review and Grading of Laboratory Data
The investigator must review each laboratory result, document thisreview ,and systematicall y 
assess any clinical significance. The laboratory reports must be filed with the source documents.
Laboratory values will be initially  evaluated by [CONTACT_20616] r according to central laboratory
criteria. Abnormal values outside the central laboratory range of normal will be graded according 
to the FDA Guidance document “Toxicity  Grading Scale from Health y Adult and Adolescent 
Volunteers Enroll ed in Preventive Vaccine Clinical Trials” (Attachment 1). Laboratory values 
within central laboratory normal limits will not be FDA graded and will be considered as normal.
Reporting Laboratory Abnormalities as A dverse Events
Any clinically  significant abnormal laboratory value within [ADDRESS_832148] be repeated at the next scheduled visit or sooner based on investigator ’sjudgment , 
however Grade 3and above abnormalities should be retested within 48 hours. Any clinically 
significant abnormalities (includi ng those persisting at the end of the study  or early withdrawal)
will be followed by  [CONTACT_624689] a clinicall y stable endpoint is reached.
Screening Procedures (Cohorts 1 and 2 Only)
For entry into the study , each participant must be healthy  on the basis of clinical laboratory tests
performed at screening. Enroll ment ofa participant with clinical laboratory values outside of the 
central laboratory normal range representing FDA toxicity  Grade 2is allowed if the investigator 
considers the values reasonable for the population under study and not clinically significant.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 87
Approved , Date: 6 November 2020Additional clinical laboratory assessments to be performed at screening include serology  testing 
(HIV t ype 1 or type 2, hepatitis B, hepatitis C).
[IP_ADDRESS]. Electrocardiogram
In Cohorts 1 and 2, supi[INVESTIGATOR_050] 12-lead ECGs will be performed at screening and interpreted locally ; 
ECGs willonly be performed thereafter during the study  if clinically  indicated based on signs and 
symptoms.
For [ADDRESS_832149] 5 minutes.
Enroll ment of a participant is allowed even with abnormal ECG results as long as the investigator 
feels that these are not clinically  significant and appropriate for the population.
[IP_ADDRESS]. Vital Signs
Blood pressure and pulse/heart rate measurements should be preceded b y at least [ADDRESS_832150] 
in a quiet setting without distractions (eg, television, cell phones).
Vital signs are to be measured before blood draw sand nasal sample s.
The following measurements will be performed:
Heart rate (beats per minutes), respi[INVESTIGATOR_2842] (breaths per minute), supi[INVESTIGATOR_221378] (mmHg) and supi[INVESTIGATOR_119232] (mmHg)
Body temperature (oral route preferred, or in accordance with the local standard of care)
Confirmatory  vital signs measurement can be doneif inconsistent with a prior measurement. If 
any clinically  significant changes in vital signs are observed , they will be reported as an AE and 
followed to resolution, or until reaching a clinically  stable endpoint.
[IP_ADDRESS]. Physical Examination
A full physical examination, including height and body  weight, will be carried out at screening
and before the Month 12 booster (Cohorts 1 and 3) and before theMonth 24 booster (Cohort 3
only). At all other visits, an abbreviated, s ymptom -directed examination will be pe rformed b y the 
investigator based on clinically relevant issues, clinically relevant s ymptoms and medical history . 
Symptom -directed physical examination may be repeated if deemed necessary  by [CONTACT_093].
Physical examinations will be performed by  [CONTACT_624693]. 
Any clinically  relevant abnormalities or changes in severit y observed during the review of body  
systems should be documented in the eCRF as an AE .
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 88
Approved , Date: 6 November 202010. PARTICIP ANT COMPLETION/DISCONTINUA TION OF STUDY V ACCINE/ 
WITHDRA WAL FROM THE STUDY
10.1. Completion
A participant will be considered to have completed study  vaccination if he or she has received all
vaccinations. A participant will be considered to have completed the study  if he or she completed 
assessments at the final visit 24months (Cohort 1 and Cohort 2[Groups 11-13 and Groups 16-18]) 
or 36 months ( Cohort 2 [Groups 14 and 15] and Cohort 3) after the firstvaccination.
10.2. Discontinuation of Study Vaccine/Withdrawal from the Study
Discontinuation of Any Study Vaccine
A participant will not be automatically  withdrawn from the study  if he or shehasto discontinue 
from study  vaccination before the end of the study vaccine regimen.
Participant swillbediscontinued from vaccination for the reasons listed below. These participant s 
must notreceive any additional dose of any  study  vaccine but should continue to be monitored for 
safet y and, if this does not result in safet y risks for the participant, for immunogenicit y (if the 
reason for discontinuation is not because of impa ired functioning of the immune system) and/or 
other study  procedures (eg, RTI follow -up). Additional unscheduled visits may be performed for 
safet y/reactogenicit y reasons, if needed.
In the event of questions, the investigator is encouraged to contact [CONTACT_456] :
Anaph ylactic reaction post vaccination, not attributable to causes other than vaccination
An SAE or other potentially  life-threatening (Grade 4) event that is determined to be related 
to study  vaccine
Any related AE, worsening of health status or intercurrent illness that, in the opi[INVESTIGATOR_1070], requires study  vaccine discontinuation
Chronic or recurrent use of immunosuppressants (after discussion with the sponsor)
Unblinding on the participant level that, in the opi[INVESTIGATOR_37021] , would compromise the 
integrit y of the data
Participants who miss avaccination, not due to the reasons above, can receive subsequent 
vaccinations if, at the time of administration, the investigator determines that they are eligible to 
receive the vaccina tion according to the criteria in Section 10.3. In the event of questions, the 
investigator is encouraged to contact [CONTACT_456].
Withdrawal from the Study
Each participant has the right to withdraw from the study  at any time for any reason without 
affecting the right to treatment by [CONTACT_093]. The investigator should make an attempt to 
contact [CONTACT_233850] -up.Although participant sare
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 89
Approved , Date: 6 November 2020not obliged to give a reason for withdrawing prematurel y, the investigator should make a 
reasonable effort to ascertain the reason(s) while fully  respecting the participant ’s rights.
A participant will be withdrawn from the study for any  of the following reasons:
Lost to follow -up
Withdrawal of consent
Death
Repeated failure to comply  with protocol requirements
Decision by [CONTACT_3211], investigator, or local regulatory  authorities and Institutional Review 
Board/Independent Ethics Committee (IRB/IEC)
If a participant is lost to follow -up, every  reasonable effort must be made by [CONTACT_1758] -site 
personnel to contact [CONTACT_478059]/withdrawal. The 
measures taken to follow -up must be documented.
When a participant withdraws before completing the study , the reason for withdrawal is to be 
documented in the eCRF and in the source document. Study vaccine assigned to the withdrawn 
participant may not be assigned to another participant . In general, participants who withdraw will 
not be replaced, unless th eparticipant was randomized but did not receive any  study  vaccine.
In Cohort 1, anyrandomiz ed participant withdrawn from the study  for reasons other than (an)
AE(s)after the first dose but before the second dose might be replaced at the discretion of the 
sponsor .In Cohort 2, no replacements or additional randomizations will be done for withdra wals 
after the first dose. I n Cohort 3, if randomized participants are withdrawn from vaccination before 
the first dose of the selected regimen is administered, additional participants may be recruited to 
replace these participants at the discretion of the sponsor.
Ifaparticipant withdraws prematurel yfrom the study , assessments for earl y withdrawal should be 
obtained ( see also Section 9.1.8 ).Participant s who wish to withdraw consent from participation in 
the study  will be offered a single exit visit for safety  follow -up (prior to formal withdrawal of 
consent). They  have the right to refuse.
Withdrawal from the Use of Samples in Future Research
Theparticipant may withdraw consent for use of samples for future research ( see Section 16.2.5 ). 
In such a case, samples will be destroy ed after they are no longer needed for the clinical study . 
Details of the sample retention for research are presented in the main I CF.
10.3. Contraindications to Vaccination
The following events constitute a contraindication to vaccination at that point in time. If any of
these events occur at the scheduled time for vaccination, the participant may be vaccinated up to 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 90
Approved , Date: 6 November 202010days bey ond the scheduled vaccination, or be withdrawn from vaccination at the discretion of
the investigator and after consultation with the sponsor:
Severe acute illness at the time of vaccination. This does not include minor illnesses such as 
diarrhea.
Fever ( body  temperature ≥38.0 °C) at the planned time of vaccination.
Medically -indicated vaccines should be given at least 14 days before or 14 days after study  
vaccine administration (see Section 8).
11. STATISTICA L METHODS
Statistical analy sis will be done by [CONTACT_43758]. A general 
description of the statistical methods to be used to analy ze the immunogenicity and safet y data is 
outlined below. Specific details will be provided in the St atistical Analy sis Plan.
Planned anal yses are described in Section 11.6.
11.1. Analysis Sets
Vaccine assignment will follow the as -treated principle.
The Full Analy sis (FA) Setwill include all participant s who were randomized and received atleast 
onedose of vaccine (active or placebo) , regardless of the occurrence of protocol deviations or the 
type of vaccine (ie, Ad26.RSV.preF , RSV preF protein, Ad26.RSV.preF/RSV preF protein
combination or mixture ). All safety  and participant information analy ses will be based on the FA 
set.
The Per-protocol RSV Immunogenicit y (PPI) Set will include all participant s who were
randomized and received the complete first dose, andfor whom immunogenicity  data are available, 
excluding participant s with major protocol deviations expecting to impact the immunogenicity  
outcomes.
In addition, the following samples will not be included in the PPI [CONTACT_55866]:
For participant s who experience a natural RSV infection (based on RT-PCR, or other sources), 
samples collected after the natural infection will not be taken into account in the assessment 
of the immunogenicit y of the selected regimen.
If a participant misses one or more active dose(s) of the selected regimen but continues the 
planned visit schedule, samples after the missed active dose(s) will not be taken into account.
The analysis of all secondary  and exploratory  immunogenicit y endpoints related to RSV will be 
based on the PPI [CONTACT_55866].Depending on the number of samples excluded, a post-hoc exploratory 
analysis might be performed, including the excluded samples. To visualize excluded samples, 
participant profiles from several assay s might be repeated, indicating the excluded sam ples.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 91
Approved , Date: 6 November 202011.2. Sample Size Determination
11.2.1. Initial Safety  Cohort (Cohort 1)
The number of participants chosen for theinitial safet y cohort will provide a preliminary  safety 
assessment. Placebo recipi[INVESTIGATOR_111072] y purposes and will provide
additional control specimens for immunogenicity assay s.
While mild to moderate vaccine reactions (local injection site,systemic responses) are expected, 
AEs that preclude further vaccine administration or more serious ones that would limit product 
development are not anticipated.
Table 18shows the probabilities of observing at least oneAE in the initial safety  cohort at given 
true AE rates. In the analy sis of theinitial safety  cohort (Cohort 1), placebo recipi[INVESTIGATOR_624638].
Table 18: Probability of Observing at Least One Adverse Event in the Initial Safety Cohort (Cohort 1) at 
a Given True Adverse Event Rate
True Adverse Probability of Observing at Least One Adverse Event in N Participant s
Event Rate N=4 N=8 N=16
0.5% 2% 4% 8%
1% 4% 8% 15%
2.5% 10% 18% 33%
5% 19% 34% 56%
10% 34% 57% 81%
25% 68% 90% 99%
50% 94% 100% 100%
11.2.2. Regimen Selection Cohort (Cohort 2)
The objective is to compare the RSV A2 neutralizing antibody  levels of all regimens containing 
RSV preF protein (Groups 12 through 17) to the one-dose Ad26.RSV.preF regimen (Group 11). 
This will be based on the estimation of GMT ratios and corresponding 95 % confidence intervals 
(CIs) of the VNA A2 levels of the regimens containing RSV preF protein on Day 29 for the one -
dose regimens (Groups 12through 16) and onDay85 for the two- dose regimen (Group 17) versus 
the VNA A2 levels on Day 29 of the one -dose Ad 26.RSV.preF regimen (Group 11). The sample 
size was selected to provide a precision of ~0.53 on the log 2scale.
Note : Immunogenicit y data from Groups 9 and 10 of the initial safety  cohort (Cohort 1) will be 
combined with those from Groups 16 and 17 ofthe regimen selection cohort (Cohort 2).
The table below presents the resulting 95% CIsfor several observed ratios , assuming a standard 
deviation for VNA of 1 on the log 2scale and accounting for 5% dropout.
Observed Ratio Corresponding 95% CI
1 [0.69; 1.44]
1.2 [0.83; 1.73]
1.5 [1.04; 2.17]
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 92
Approved , Date: [ADDRESS_832151] ingthe regimen for 
the expanded safet y phase. A more detailed rule will be described in the Statistical Analy sis Plan .
11.2.3. Expanded Safety  Cohort (Cohort 3)
The expanded safet y cohort (Cohort 3) should provide sufficient safet y data on the selected 
regimen to support late stage development if the immunogenicity  results of Cohort [ADDRESS_832152] one AE in the expanded safet y cohort at 
given true AE rates. This table shows that the current numbers give a reasonable probability  to 
also observe less frequent events in the active groups in this cohort.
Table 19: Probability of Observing at Least One Adverse Event in the Expanded Safety Cohort (Cohort 3)
at a Given True Adverse Event Rate
True Adverse Probability of Observing at Least One Adverse Event in N Participants
Event Rate N=45 N=135 N=270
0.5% 20% 49% 74%
1% 36% 74% 93%
2.5% 68% 97% 100%
5% 90% 100% 100%
10% 99% 100% 100%
25% 100% 100% 100%
11.3. Participant Information
For all participant s, demographic characteristics (eg, age, height, weight, body  mass index, race, 
and gender), and other baseline characteristics (eg, physical examination, medical history , and 
concomitant diseases) will be tabulated and summarized with descriptive statistics. This will be 
done per cohort.
11.4. Immunogenicity  Analyses
No formal hypothesis on immunogenicit y will be tested. Descriptive statistics (geometric mean 
and 95% CIfor ELISA and RSV neutralization assay ; median and quartiles forIFN-γELISpot and 
ICS) will be calculated for continuous immunologic parameters at all timepoints. For the humoral 
assay s, geometric mean fold rises from ba seline and corresponding 95% CI s might additionally  be 
calculated. Baseline is considered as the last available assessment before the first vaccination. 
Graphical representations of immunologic parameters will be made as applicable.
For categorical variabl es, frequency  tables will be presented.
In addition, for the regimen selection cohort (Cohort 2), GMT ratios with corresponding 95% CI 
of the VNA A2 levels of the combination/ mixture regimens on Day 29 for the one-dose regimens 
(Groups 12through 16) and Day85 for the tw o-dose regimen (G roup 17) versus the D ay 29 VNA 
A2 levels of the one-dose Ad26 .RSV.preF regimen (Group 11) will be calculated. Therefore, a 
regression model will be fitted with the respective VNA A2 levels as dependent variable and the 
respective regimens and baseline levels as covariates, using Satterthwaite’s method to calculate 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 93
Approved , Date: 6 November 2020the degrees of freedom and allowing different variances for the vaccines. The estimate and CIs
obtained as such will be back -transformed (by [CONTACT_151698]) to a GMT ratio and the 
corresponding CI.Note that the effect of additional factors ,such asage and the interaction with 
the regimen, might also be explored in this model.
Note : Immunogenicit y data from Groups 9 and 10 of the initial safety  cohort (Cohort 1) will be 
combined with those from Groups 16 and 17 ofthe regimen selection cohort (Cohort 2).
The same model might be repeated for other assays.
In the expanded safet y cohort (Cohort 3), the effect of the Month 12 and Month 24booster will be 
assessed. The refore, the following ratios for VNA A2 will be calculated:
In the groups with an active vaccination at Month 12/Month 24, the ratio of the 
Month 12/Month 24booster Day 29 level versus the prime Day 29 level with the 
corresponding 95% CI will be calculated.
The groups with an active vaccination at Month 12/Month 24will be compared to 
corresponding groups with placebo vaccination at Month 12/Month 24by [CONTACT_624694] 95% CI .
Note that the above might also be repeated for other assay s.
The primary  anal ysis set for the above is the PPI  [CONTACT_55866].As a sensitivity  analy sis, key tables may also 
be based on the FA set. Depending on their occurrence, the effect of natural infections might be 
further explored .
11.5. Safety  Analyses
No formal statistical testing of safet y data is planned. Per cohort, all safety  data will be analyzed 
descriptivel y by [INVESTIGATOR_24858].
Adverse Events
The verbatim terms used in the eCRF by [CONTACT_624695] (MedDRA). All reported AEs with onset during the 
active phase (ie, AEs occurring after vaccination up to [ADDRESS_832153]-vaccination), and all SAEs 
will be included in the analysis. For each AE, the number and percentage of participant s who 
experience at least oneoccurrence of the given event will be summarized by  [CONTACT_19313].
Summaries, listings, datasets, or participant narratives may  be provided, as appropriate, for those 
participant s who die, who discontinue study  vaccine due to an AE, or who experience a severe AE 
or an SAE.
Summaries and/or listings may be provided separatel y for AEs with onset outside the above 
defined timeframe (ie, beyond [ADDRESS_832154]-vaccination) and that were reported pre-dose at the 
time of subsequent vaccinations for stu dies using multiple doses.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 94
Approved , Date: 6 November 2020Solicited local (at injection sites) and solicited systemic AEs will be summarized descriptivel y. 
The overall frequencies per vaccine group as well as frequencies according to severity  and duration 
will be calculated for solicite d AEs. In addition, the number and percentages of participant s with 
at least onesolicited local (at the injection site) or solicited systemic AE will be presented. 
Frequencies of unsolicited AEs, separatel y for all and vaccin e-related only, will be presen ted by 
[CONTACT_39960] .
Any RTI recorded as an AE in the eCRF that is subsequently  determined to be RSV -positive by 
[CONTACT_624696]-PCR will be excluded from the safet y anal ysis and tabulated separatel y.
Clinical Laboratory Tests
For participants in C ohort s 1and 2, laboratory abnormalities will be determined according to the 
FDA toxicity  grading tables (see Attachment 1),or in accordance with the normal ranges for the 
clinical laboratory parameter if no grades are available . Any laboratory value shown as a “graded” 
value in the FDA table that is within central laboratory normal ranges will not be graded for 
severit y.
Vital Signs
A tabulation of the distribution of body  temperatures per half degree intervals will be provided. 
For systolic and diastolic blood pressures, pulse rate and respi[INVESTIGATOR_2842], the percentage of 
participant s with values bey ond clinicall y relevant limits will be summarized.
Electrocardiogram (ECG)
For Cohorts 1 and 2, any abnormalities in ECG parameters (at screening) will be listed.
Physical Examination
Physical examination abnormalities will be reported as AEs, according to the investigator .
11.6. Planned A nalyses
Note : Depending on the timing, some of the planned anal ysesmight be combined.
11.6.1. Initial Safety  Cohort (Cohort 1)
Primary Analysis
Primary  analysis: analysis of safet y data [ADDRESS_832155] participant in Cohort 1 will be 
included in the analysis. This analy sis will be performed on unblinded data. The blind will be 
maintained at the participant /site level.
As immunogenicit y data from Groups 9 and 10 of the initial safety  cohort (Cohort 1) will be 
combined withthose from Groups 16 and 17 of the regimen selection cohort (Cohort 2), 
immunogenicit y data from the initial safety  cohort will be analy zed at the time of the primary  
analysis of the regimen selection cohort.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 95
Approved , Date: [ADDRESS_832156] participant in this cohort will be included in the analysis. The blind will be 
maintained at the participant /site level.
11.6.2. Regimen Selection Cohort (Cohort 2)
Primary Analysis
Primary  analysis: analy sis of safet y data [ADDRESS_832157] -dose 1. 
This analy sis should contain allsafet y data collected up to the time of the visit at 28days after 
the second dose for the last participant in this cohort.
Immunogenicit y data from at least Groups 11 to 15 and part of Group 18 (placebo group) , up 
to at least [ADDRESS_832158]-dose 1 will be included as well.a
This analy sis will be performed on unblinded data. The blind will be maintained at the 
participant/site level .
Inthis analy sis,all available immunogenicity  data of the initial safet y cohort (Cohort 1) will be 
analyzed as well.
Additional Analysis
Additional analy sis: analy sis of immunogenicity data [ADDRESS_832159]-dose 1 for all one-dose 
regimens (including the one-dose regimen with separate injections) and [ADDRESS_832160]-dose 2 for the two-dose regimen. This analysis will be performed on 
unblinded data. The blind will be maintained at the participant/site level.
In this analysis, all available immunogenicit y data of Groups 9 and 10 from the initial safet y cohort 
(Cohort 1) and immunogenicity data of Cohort 2 included in the p rimary  analysis will be analyz ed 
as well.
The primary  analysis of Cohort 1 and Cohort 2 and the additional anal ysis may  be combined into 
one anal ysis.
                                                
aAn unblinded person who is not part of the study team (or another independent party) will dictate which Day 29 
samples should be analyzed by [CONTACT_624664]. Half of the Day 29 samples of Group 18 (placebo 
group) w ill be included to ensure the blind at the level of the clinical immunology laboratory.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 96
Approved , Date: [ADDRESS_832161] 
participant in this cohort will be included in the analysis. The blind will be maintained at the 
participant /site level.
Analysis [ADDRESS_832162] Vaccination (Groups 14 and 15)
This analy sis will include immunogenicit y data, and will be performed on unblinded data. Data 
collected up to the time of the visit at [ADDRESS_832163] 
participant in these 2 g roups will be included in the anal ysis.
11.6.3. Expanded Safety  Cohort (Cohort 3)
Primary A nalysis
Primary  anal ysis: analysis of safet y and immunogenicity  data up to Day  [ADDRESS_832164] participant in this 
cohort in case a two-dose regimen is selected .aIf the corresponding immun ogenicity data are not 
available at the time of database lock, they will be anal yzed at a later timepoint. This analy sis will 
be performed on unblinded data. The blind will be maintained at th e participant /site level.
Analysis [ADDRESS_832165]-Month 12 Booster
This analysis will include safet y and immuno genicity data, and will be performed on unblinded 
data. Data collected up to the time of the visit at 28 day s after the Month 12 booster dose of study 
                                                
aAn unblinded person who is not part of the study team (or another independ ent party ) will dictate which Day 85 
samples should be analyzed. All Day 85 samples of the two- dose regimen will be included and some Day 85 samples 
of each of the other groups to ensure the blind at the level of the clinical immunology laboratory.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 97
Approved , Date: [ADDRESS_832166] participant in this cohort will be included in the analysis. The blind will be 
maintained at the participant /site level.
Analysis [ADDRESS_832167] participant in this cohort will be included in the analysis. The blind will be 
maintained at the participant/site level. 
11.6.4. Final Analysis
The final analysis at the end of the study , to be conducted on a per-cohort basis, willinclude safety  
and immunogenicit y data.Data collected up to the time of the last visit for the last participant will 
be included in the analy sis.This analy sis will be performed on unblinded data.
11.7. Additional Interim A nalyses
Additional interim analyses (blinded or, if occurring after the primary  analysis of the respective 
cohort, unblinded) may be perfor med during the study for the purpose of informing future vaccine
development -related decisions in a timely manner, or upon health authorit y request. If they  occur, 
these unplanned interim analyses may replace planned analyses, depending on the timing . The 
results will not influence the conduct of the study in terms of early termination or later safet y or 
immunogenicit y endpoint assessments, and will only be available to a selected group of sponsor
personnel.
11.8. Data Review  Committee
Data Review Committee
Aninternal DRC will be commissioned for this study . The DRC will consist of sponsor personnel 
not directl y involved in the conduct of the study andwho have expertise in clinical study  conduct 
and vaccines, at least one medical expert [INVESTIGATOR_233877],at least one statistician ,
andasafet yexpert .The DRC will convene, according to their charter, to discuss any  safet y issues 
and any situation meeting a specific study  pausing rule (Section 11.9). The PI(s)and SRP/S will 
inform the DRC of an y AE of concern.
In addition, the DRC will review all safet y data collected up to the time the f inal participant in the 
initial safety  cohort (Cohort 1) had his/her Day  8 visit.
It will also be possible for the DRC toreview unblinded immuno genicit ydata during the course 
of the study if this is deemed necessary for future vaccine development -related decisions. I fthis is 
the case, a biomarker representative (not involved in the conduct of the study ) will be part of the 
DRC. 
After these reviews, the DRC will make recommendations regarding the continuation of the study . 
Conclusions of the DRC will be communicated to the investigators, the IRB/I EC and the national 
regulatory  authorities as appropriate. Details will be provided in a separate DRC charter.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 98
Approved , Date: [ADDRESS_832168] randomization codes and review 
unblinded d ata, if applicable.
Safety  data from the primar y anal yses and from the analyses at 28 da ys after the Month 12 booster 
dose (in Cohort s 1 and 3 ) and the Month 24 booster dose (Cohort 3 onl y)will be shared with the 
DRC.
11.9. Study Vaccination Pausing Rules
The PI(s) and the SRP/S will monitor the study  vaccination pausing rules. If study  vaccination is 
considered to raise significant safet y concerns, further study  vaccination of participant s will be 
suspended until DRC review is carried out and subsequent communication between the sponsor 
and the investigator takes place.
The occurrence of any of the following events will lead to pause infurther study  vaccination and 
trigger a meeting of the DRC to discuss study  suspension, adaptation or discontinuation of further 
vaccination. The list is only applicable for concerned AEs that occur up to 4 weeks after each 
vaccination and to concerned SAEs :
1.One or more participant s per cohort experience an SAE or other potentially  life-threatening 
(Grade 4) event that is d etermined to be related to study  vaccine; OR
2.One or more participant sper cohort experience anaphy laxis clearl y not attributable to other 
causes than vaccination with any study  vaccine; OR
3.Two or more participant s per cohort experience a Grade 3or 4unsol icited AE of the same 
type, determined to be related to study  vaccine, that persists for 72 hours or longer; OR
4.Two or more participant sper cohort experience a Grade 3 or 4 solicited systemic AE of the 
same ty pe, determined to be related to study  vaccine, that persists for 72 hours or longer; OR
5.Two or more participant sper cohort (in Cohorts 1 and 2 only) experience a persistent (upon 
repeat testing) Grade 3 or 4 laboratory abnormality related to the same laboratory parameter 
and considered related to study  vaccine, that persists for 72 hours or longer ; OR
6.Death of a nyparticipant , considered related to any study  vaccine or if the causal relationship 
to study  vaccine cannot b e excluded .
Note : All cases of death will be sent to the DRC . Upon their review, the DRC will decide 
whether a stud y pause is required.
After the first DRC meeting triggered by [CONTACT_172719] a given pausing rule, the DRC will 
convene thereafter for each additional participant meeting that pausing rule.
The DRC will review blinded data first, but is entitled to and has the right to require submission 
of unblinded data if deemed necessary .
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 99
Approved , Date: 6 November 2020To enable prompt response to a situation that would trigger pausing rule 3, 4or 5, the investigator 
should update the eCRF with information on any  Grade 3 or 4 AE on the same day  that the AE is 
reporte d.
Also, the investigator should notify  the sponsor’s medical monitor (and fax/email the SAE Form 
to Global Medical Safet y Operations, if applicable), immediately  and no later than 24 hours after 
becoming aware of any related AE of Grade 3 or above (and update the eCRF with relevant 
information on the same day the AE information is collected). A thorough anal ysis of all Grade 3 
cases will be carried out by  [CONTACT_456]’s medical monitor, irrespective of whether the criteria for 
pausing the study  are met. Bas ed on the pausing criteria, the sponsor’s medical monitor will then 
decide whether a study  pause is warranted. All sites will be notified immediately  in the event of a 
study  pause. The sponsor’s medical monitor is responsible for the immediate notification of the 
DRC and coordination of a DRC meeting in the event of a study  pause.
Vaccinations for an individual participant may  be suspended for safet y concerns other than those 
described inthepausing criteria, atthediscretion ofthe investigator if he/she feels the participant ’s 
safet y may be threatened. The sponsor’s medical monitor or the PI (s) (upon consultation with the 
sponsor’s medical monitor) may initiate a DRC review for any single event or combination of 
events which, in their professional opi[INVESTIGATOR_3078] n, could jeopardize the safet y of the participants or the 
reliability  of the data.
Vaccinations forthe study  may be suspended for safet y concerns other than those described above, 
or before pausing rules are met, if, in the judgment of the DRC, participan t safety  may be 
threatened.
Resumption of vaccinations will start only  upon receipt by [CONTACT_624697]. The clinical site(s) will be allowed to resume activities upon receipt of a written 
notification from the sponsor. These communications from the DRC will be forwarded by [CONTACT_421905]/IEC and by  [CONTACT_624698] .
12. ADVERSE EVENT REPORT ING
Timely, accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of participant s, investigators, and the sponsor, and are mandated by 
[CONTACT_23824]. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by [CONTACT_43765].
Method of Detecting Adverse Events and Serious A dverse Events
Care will be taken not to introduce bias when detecting AEs or SAEs. Open -ended and non-leading 
verbal questioning of the participant is the preferred method to inquire about AE occurrence.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 100
Approved , Date: 6 November 2020Solicited Adverse Events
Solicited AEs are pre-defined local (at the injection site) and systemic events for which participant s
are specificall y questioned and which are noted b y participant s in their diary  (see Section 9.1.1 ).
Unsolicited Adverse Events
Unsolicited AEs are all AEs for which participant sare specificall y not questioned in the participant
diary .
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An AEis any untoward medical occurrence in a clinical study  participant administered a medicinal 
(investigational or non-investigational) product. An AEdoes not necessarily  have a causal 
relationship with the vaccines used in this study . An AEcan therefore be any unfavorable and 
unintended sign (including an abnormal finding), symptom, or disease temporally associated with 
the use of a medicinal (investigational or non-investigational) product, whether or not related to 
that medicinal (investigational or non-investigational) product (Definition per International 
Council forHarmonisation [I CH]) .
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory test 
abnormalities.
Note : The sponsor collects AEs, whether serious or non -serious, related to the study procedures or 
non-investigational (concomitant) Janssen products from ICF signature [CONTACT_624710] . All other non-
serious AEs and special reporting situations will be reported from each vaccination through the 
following 28 day s on the Adverse Event eCRF pagea(seeSection 12.3.[ADDRESS_832169] AE recording). All other serious AEs will be reported from the first vaccination 
onwards. Clinically  relevant medical events, occurring between ICF signa ture and time of first 
vaccination, are collected on the medical history  eCRF page as pre -existing conditions. During the 
long-term follow -up phase for participants from Groups 14 and 15 in Cohort 2, only SAEs related 
to study  vaccine, study  procedures (ie , blood draws), or non-investigational (concomitant) Janssen 
products, and all AEs leading to discontinuation will be collected.
Note : For all cohorts , AE reporting starts from Day  1 onwards. Clinically  relevant medical events 
before the vaccination on Day 1 should be reported as medical history . 
                                                
aAEs t hat start more than 28 days after a vaccination, but that are still present at the time of the next vaccination will 
also be recorded.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 101
Approved , Date: 6 November 2020Any RTI  that is not due to RSV infection will be reported as an AE if it occurs between the time 
of any vaccination through the following 28 days. Any RTI recorded as an AE in the eCRF will 
be excluded from any AEanalysis if the central laboratory  RT-PCR is subsequently  found to be 
positive for RSV. RTIs arising from RSV infection will not be reported as (S)AEs in the Clinical 
Study  Report as they  are endpoints of the study  but will be tabulated separately .
Serious Adverse Event
An SAE based on ICH and European Union Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any  untoward medical occurrence that at an y dose:
Results in death
Is life -threatening
(The participant was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe .)
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or signi ficant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important *
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events t hat may not be immediatel y 
life-threatening or result in death or hospi[INVESTIGATOR_90762]. These 
should usually  be considered serious.
If a serious and unexpected AEoccurs for which there is evidence suggesting a causal relationship 
between the vaccine and the event (eg, death from anaph ylaxis), the event must be reported as a 
suspected unexpected serious adverse reaction (S[LOCATION_003]R) by [CONTACT_624699]/IEC according to regulatory  and local requirements.
Any RTI fulfilling the criteria of an SAE will be re ported as such during the entire study period if 
RT-PCR indicates it is not an RSV -RTI. If the RT-PCR is positive for RSV the event should not 
be reported as an SAE. If RT-PCR information is not available within 24 hours of knowledge of 
the event, the even t will be reported as an SAE, but will be subsequently  downgraded from SAE 
status if it later turns out to be RT -PCR positive for RSV .
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An AEis considered unlisted if the nature or severity is not consistent with the applicable product 
reference safet y information. For Ad26.RSV.preF and RSV preF protein, expectedness of an AE
will be determined b y whether or not it is listed in the respective Investigator ’s Brochure .17,18
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 102
Approved , Date: 6 November 2020Adverse Event Associated With the Use of Vaccine
An AEis considered associated with the use of the vaccine sif the attribution is related by [CONTACT_624700] 12.1.2 .
12.1.2. Attribution Definitions
Every  effort should be made by  [CONTACT_111166], ie, to administration of the vaccine or to alternative causes (eg, natural history  of the 
underly ing diseases, concomitant therapy ). This applies to all AEs (serious or non- serious ).
Causality  of AEs should be assessed b y the investigator based on the following:
Related : there is suspi[INVESTIGATOR_177872] a relationship between the vaccine and the AE (without 
determining the extent of probability ); there is a reasonable possibility  that the vaccine contributed 
to the AE.
Unrelated : there is no suspi[INVESTIGATOR_177872] a relationship between the vaccine and the AE ; there 
are other more likel y cau ses and administration of the vaccine is not suspected to have contributed 
to the AE.
By [CONTACT_108], all solicited AEs at the injection site (local) will be considered related to vaccine
administration.
12.1.3. Severity Criteria
All AEs and laboratory data reported as AEs will be coded for severit y using the toxicity  grading 
table in Attachment 1. Note : Laboratory values within central laboratory normal ranges (even if 
within a toxicity  grade range), or laboratory values outside normal ranges that are not clinicall y 
significant in the judgment of the investigator, should not be recorded as AEs.
For AEs not identified in the toxicity  grading table, the following guidelines will be applied:
Mild (Grade 1) : Awareness ofsymptoms that areeasily  tolerated, causing 
minimal discomfort and not interfering with everyday  activities.
Moderate (Grade 2) : Sufficient discomfort is present to cause interference with 
normal activity .
Severe (Grade 3) : Extreme distress, causing significant impairment of functioning  
or incapacitation. Prevents normal every day activities.
Potentially life -threatening
(Grade 4) : Symptoms causing inability to perform basic self-care functions, 
OR
Medical oroperative intervention indicated to prevent permanent 
impairment, persistent disability .
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the participant (eg,laboratory abnormalities).
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 103
Approved , Date: 6 November 2020The toxicity  grading scale used for laboratory assessments is based on the FDA toxicity  grading 
table (see Attachment 1), consistent with the assessment grading used throughout the protocol. If 
a laboratory value falls within thegrading as specified in the FDA table, but also within the 
laboratory normal limits, the value is considered as normal. For hemoglobin, both the actual value 
and the change from reference will be graded.
The severit y of solicited AEs will be graded in the diary  by [CONTACT_624701] y 
assessment provided in the diary  and then verified by [CONTACT_624702] (see Attachment 1 ).
12.2. Special Reporting Situations
Safety  events of interest on a sponsor study  vaccine that may require expedited reporting or safet y 
evaluation include, but are not limited to:
Suspected abuse/misuse of a sponsor study  vaccine
Accidental or occupational exposure to a sponsor study  vaccine
Medication error involving a sponsor product (with or without participant /patient exposure to 
the sponsor study  vaccine , eg, name [CONTACT_2976])
Exposure to a sponsor study  vaccine from breast -feeding
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a nSAE should be recorded on the SAE page of the eCRF.
12.3. Procedures
12.3.1. All Adverse Events
All AEs and special reporting situations, whether serious or non-serious, that arerelated to 
study -related procedures or that are related to non -investigational (concomitant) Janssen products 
will be reported from the time a signed and dated ICF is obtained onwards.
All other AEs and special reporting situations will be reported until 28 days (including relevant 
visit window, if applicable) after first dose of vaccine and thereafter, pre -dose on the vaccination 
day, and for 28 days (including relevant visit window, if applicable) following each subsequent 
vaccination . Unsolicited AEs with the onset date outside the time frame defined above (>28 day s 
after previous vaccination), which are ongoing on the day of the subsequent vaccination, should 
be recorded on the eCRF AE page.
All SAEs and AEs leading to discontinuation from the study /vaccination (regardless of the causal 
relationship) are to be reported from the moment of first vaccination until completion of the 
participant ’s last study -related procedure, which may  include contact [CONTACT_233858] -up.
Clinically  relevant medical event s occurring between ICF signature [CONTACT_624711] -existing conditions.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 104
Approved , Date: 6 November 2020Solicited AEs will be recorded by [CONTACT_624703] 7 days after each 
vaccination . The investigator will review each participant’s diary  at the subsequent in -clinic visit
and discuss the information from the diary  with the participant. The diary information will be 
transcribed b y the stud y-sitepersonnel in the diary  forms in the eCRF.
Thesponsor will evaluate an y safety information that is spontaneously  reported b y an investigator  
beyond the time frame specified in the protocol.
The investigator will monitor and check the study  data,including all AE and clinical laboratory
data,as they  become available and will make determinations regarding the severit y of the adverse 
experiences and their relation to vaccine. All AEs will be deemed related to vaccine or not related 
to vaccine, according to Section 12.1.[ADDRESS_832170] be 
recorded using medical terminology  in the source document and the eCRF. Whenever possible,
diagnoses should be given when signs and symptoms are due to a common etiology  (eg,cough, 
runny  nose, sneezing, sore throat, and head congestion should be reported as “upper respi[INVESTIGATOR_28945] ”). Investigators must record in the eCRF their opi[INVESTIGATOR_624639] . All measures required for AEmanagement must be recorded in the source 
document and reported according to sponsor instructions.
The sponsor assumes responsibility  for appropriate reporting of AEs to the re gulatory  authorities. 
The sponsor will also report to the investigator (and the head of the investigational institute where 
required) all S[LOCATION_003]Rs. The investigator (or sponsor where required) must report S[LOCATION_003]Rs to the 
appropriate IEC/IRB that approved the p rotocol unless otherwise required and documented by [CONTACT_12137]/IRB .A S[LOCATION_003]R will be reported to regulatory  authorities unblinded. Participating 
investigators and IEC/I RB will receive a blinded S[LOCATION_003]R summary , unless otherwise specified.
Each participant will be provided with a “ wallet ( study )card”and instructed to carry  this card for 
the duration of the stud y indicating the following:
Study number
Statement, in the local language(s), that the participant is participating in a clinical study
Investigator ’s name [INVESTIGATOR_1238] [ADDRESS_832171] telephone number
Local sponsor ’s name [INVESTIGATOR_1238] [ADDRESS_832172] telephone number (for medical staf f onl y)
Site number
Participant number
Any other information that is required to do an emergency  breaking of the blind
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 105
Approved , Date: 6 November 202012.3.2. Serious A dverse Even ts
SAEs related to the study  procedures or non-investigational (concomitant) Janssen products will 
be reported from ICF signature [CONTACT_624712] . All other SAEs will be reported 
from first vaccination throughout the rest of the study .
SAEs must be reported to the appropriate sponsor contact [CONTACT_170187] -site personnel within 
24hours of their knowledge of the event. During the long-term follow -up phase for participants 
from Groups 14 and 15 in Cohort 2, only SAEs related to study  vaccine ,study  procedures (ie, 
blood draws) , or non-investigational (concomitant) Janssen products , and all AEs leading to 
discontinuation will be collected.
Information regarding SAEs will be transmitted to the sponsor using the SAE Form, which must 
be compl eted and signed by a ph ysician from the study  site, and transmitted to the sponsor within 
24 hours. The initial and follow -up reports of a n SAE should be made by [CONTACT_6972] (fax).
All SAEs that have not resolved by [CONTACT_2054] , or that have not resolved upon 
discontinuation of the participant ’s participation in the study , must be followed until any of the 
following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the vaccine or to factors unrelated to study 
conduct
It becomes unlikely  that any additional information can be obtained ( participant or healthcare 
practitioner refusal to provide additional information, los t to follow -up after demonstration of 
due diligence with follow -up efforts)
Suspected transmission of an infectious agent by  a medicinal product will be reported as a n SAE . 
Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) that occur s during a 
participant ’s participation in a study  must be reported as an SAE , except hospi[INVESTIGATOR_43716]:
Hospi[INVESTIGATOR_624640](eg, social reasons such as 
pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the eCRF ). 
Note : Hospi[INVESTIGATOR_23743], and where the 
underly ing condition for which the hospi[INVESTIGATOR_624641] ,will not be 
considered as SAEs . Any AEthat results in a prolongation of the originall y planned 
hospi[INVESTIGATOR_23745] a new SAE .
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 106
Approved , Date: [ADDRESS_832173] be 
reported to the sponsor by [CONTACT_1758] -site personnel within 24 hours of their knowledge of the event 
using the appropriate pregnancy  notification form. Abnormal pregnancy  outcomes (eg, 
spontaneous abortion, fetal death, stillbirth, congenital anomal ies,andectopic pregnancy ) are 
considered SAEs and must be reporte d using the Serious Adverse Event Form .
Pregnancies in partners of male participant s included in the study  will be reported as noted above.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be requir ed.
12.4. Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23831] y issues or questions regarding the study  are listed in the Contact [CONTACT_23832](s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HA NDLING
A product qualit y complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , qualit y, 
durability , or reliabilit y of a product, including its labeling or package integrity . A PQC may  have 
an impact on the safety and immunogenicity of the product. Timely , accurate, and complete 
reporting and analysis of PQC information from studies are crucial for the protection of 
participant s, investigators, and the sponsor , and are mandated by [CONTACT_23824]. 
The sponsor has established procedures in conformity  with regulatory  requirements worldwide to 
ensure appropriate reporting of PQC information; all studies conducted by [CONTACT_443743].
13.1. Procedures
All initial PQCs must be reported to the sponsor by  [CONTACT_1758] -site personnel within [ADDRESS_832174] report the PQC to the sponsor 
according to the SAE reporting timelines ( seeSection 12.3.2 ). A sample of the suspected product 
should be maintained for further investigation if requested by  [CONTACT_456].
13.2. Contact[CONTACT_23834] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23835](s), which will be 
provided as a separate document.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 107
Approved , Date: 6 November 202014. VACCINE INFORMA TION
14.1. Physical Descripti on of the Vaccine s
A human replication -incompetent adenovirus -vectored vaccine candidate and RSV preF protein, 
manufactured and provided under the responsibility of the sponsor ,will be assessed in this study :
Ad26.RSV .preF (JNJ -64400141 )
Ad26.RSV.preF isa replication -incompetent Ad26 containing a DNA transgene that encodes the 
pre-fusion conformation- stabilized F protein derived from the RSV A2 strain.
For this study , Ad26.RSV.preF will beformulated asa solution for intramuscular injection andwill 
be supplied as a frozen liquid to be thawed prior to use.Ad26.RSV.preF will be supplied in single -
use vials (2×1011vp/mL). Refer to the I nvestigational Product Preparation Instructions for details 
on dosing preparation.
Refer to the Investigator ’s Brochure for details of the components of Ad26.RSV.preF and a list of 
excipi[INVESTIGATOR_840].18
RSV preF protein (JNJ -64213175 )
RSV preF protein is a pre-fusion conformation- stabilized F protein derived from the RSV A2 
strain.
For this study , RSV preF protein will be formulated as a solution for intramuscular injection. RSV  
preF protein will be supplied in a single -use vial. Refer to the Investigational Product Preparation 
Instructions for details on dosing preparation.
Refer to the Investigator ’s Brochure for details of the components of RSV  preF protein and a list 
of excipi[INVESTIGATOR_840].17
Note : RSV  preF protein clinical trial material will be labelled as “RSV-F Vaccine ”.
Placebo
Placebo for Ad26.RSV .preFand RSV preF protein will be supplied assterile saline for 
intramuscular injection in vials.
14.2. Packaging and Labelling
Vaccines will bemanufactured and packaged in accordance with Current Good Manufacturing 
Practice. Vaccines will be packaged and labeled under the responsibility  of the sponsor. Vaccine 
labels will contain information to meet the applicable regulatory  requirements.
No vaccine can be repacked or relabeled without prior approval from the sponsor.
Further details for vaccine packaging and labeling can be found in the Investigational Product 
Preparation Instructions.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 108
Approved , Date: [ADDRESS_832175] be stored in a secured location under controlled temperature with no access for 
unauthorized personnel. The study  refrigerator/freezer must be equipped with a continuous 
temperature monitor and alarm , and with back -up power system s. Ifa vaccine is exposed to 
temperatures outside the specified temperature range, all relevant data will be sent to the sponsor
to determine if the affected vaccine can be used or will be replaced. The affected vaccine must be 
quarantined and not used un til further instruction from the sponsor is received.
The vaccine swill be prepared by [CONTACT_624704], or other qualified individual and 
administered by  a vaccine administrator.
Note : The unblinded pharmacist, or other qualified individual, may also perform administration of 
the vaccine s, but will have no other stud y function following dosing.
Further details for vaccine storage, preparation, handling and stabilit y can be found in the 
Investigational Product Preparation Instructions .
14.4. Vaccine Accountability
The investigator is responsible for ensuring that all vaccine sreceived at the site is inventoried and 
accounted for throughout the study .All vaccine sadministered to the participant must be 
documented on the vaccine accountability  form. All vaccine swill be stored and disposed of 
according to the sponsor ’s instructions.
Vaccine smust be handled in strict accordance with the protocol and the container label, and must 
be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused vaccine smust be available for verification by [CONTACT_456] ’s 
study -site monitor during on-site monitoring visits. The return to the sponsor of unused vaccine s
will be documented on a vaccine return form. When the study  site is an authorized destruction unit 
and vaccine supplies are destroyed on-site, this must also be documented on a vaccine return form.
Potentially  hazardous materials such as used ampules, needles , syringes and vials contain ing 
hazardous liquids, should be disposed of immediately  in a safe manner and therefore will not be 
retained for vaccine accountability  purposes.
Vaccine sshould be dispensed under the supervision of the investigator or a qualified member of 
the study -sitepersonnel , or by a hospi[INVESTIGATOR_307]/clinic pharmacist. Vaccine swill be supplied only to 
participant s participating in the study . Vaccine smay not be relabeled or reassigned for use by [CONTACT_576691] s.The investigator agrees neither to dispense vaccine sfrom, nor store them at, any  sites
other than the stud y site agreed upon with the sponsor.
15. STUDY -SPECIFIC MATER IALS
The investigator will be provided with the following supplies:
Investigator’s Brochure for Ad26.RSV.preF18
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 109
Approved , Date: 6 November 2020Investigator ’sBrochure for RSV preF protein17
Investigational Product Preparation Instructions/Investigational Product Procedures Manual
Laboratory Manual (including procedures for collection of nasal samples)
Trial Center File
IWRS Manual
Electronic Data Capture (eDC) Manual/eCRF completion guidelines and randomization 
instructions
Sample I CF
Participant diaries
Ruler s
Thermometers
Nasal swab kits
RTI Symptoms Form s
Contact [CONTACT_160220](s)
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
Potential participant s will be fully informed of the risks and requirements of the study  and, during 
the study , participant s will be given any new information that may  affect their decision to continue 
participation. They  will be told that their consent to participate in the study  is voluntary  and may  be 
withdrawn at any time with noreason given and without penalt y or loss of benefits to which they 
would otherwise be entitled. Only participant s who are fully able to understand the risks, benefits, 
and potential AEs of the study , and provide their consent voluntaril y will be enrolled.
The total blood volume drawn from each participant will not exceed the US Department of Health 
and Human Services Office for Human Research Protections, and FDA guidelines of 550 mL in 
any 8-week period.36,37
Risks Related to Vaccin ation
Participant s may exhibit local signs /symptoms associated with vaccination, including erythema, 
swelling/induration, andpain/tenderness. These local reactions will be monitored, but generally 
are short -term and do not require treatment.
Participant s may exhibit general signs /symptoms associated with vaccination , including fatigue, 
headache, myalgia, arthralgia, chills ,nausea , and fever . These side effects will be monitored, but 
are generally  short -term and do not require treatment.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 110
Approved , Date: [ADDRESS_832176] an allergic reaction to the vaccination. An allergi c reaction may cause a 
rash, hives or even difficulty  breathing. Severe reactions, including anaphy laxis, are rare but can 
occur with anyvaccine. Participant s with a known allergy , or a history  of anaph ylaxis or other 
serious adverse reactions to vaccines or vaccine components (including any  of the constituents of 
the vaccine s) will be excluded from the study . Sites should have medical treatment available in 
case of severe allergic reactions following vaccine administration.
Risks Related to Adenoviral -vectored Vaccines
Safety  data available from completed clinical studies in adults with other Ad26 -vectored vaccine 
candidates, in which Ad26 with different inserts has been evaluated at dose levels ranging from 
1×109vp to 1×1011vp, indicate that no safety  concerns would be anticipated from vaccination with 
Ad26.RSV.preF at doses of 5×1010vp and 1×1011vp.14,15
Local AEs (moderate injection site pain/ tenderness, moderate to severe redness at the injection 
site) and systemic AEs (headache, chills, joint pain, muscle pain, tiredness/generall y not feeling 
well/fatigue ,fever) have been reported after vaccination with Ad26 -vectored vaccines. In a few 
participants, transient laboratory abnormalities have been observed , including changes in
neutrophils. Laboratory changes including decreased hemoglobin ,decreased platelets, and 
moderate elevations in liver transaminases were observed that were not associated with any clinical 
findings and appear to be transient based on no reported persistent abnormalities in any of the 
participant s.
For further details on the safet y profiles of other Ad26 -vectored vaccine candidates, see the 
Ad26.RSV.preF Investigator’s Brochure .[ADDRESS_832177] 
version of the Investigator’s Brochure for RSV preF protein .17
Risks from Blood Draws
Blood drawing may cause pain/tenderness, bruising, bleeding, lightheadedness, dizziness, 
vasovagal response, and, rarely, infection at the site where the blood is taken .
Risks from Collection of Nasal Samples
Collection of nasal samples may  cause a nosebleed.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 111
Approved , Date: 6 November 2020Participant s with Immuno -suppression/Reduced Immune Response
Limited evidence indicates that inactivated vacci nes (or non-replicating viral vaccines) generall y 
have the same safet y profile in immunocompromised patients and immunocompetent individuals. 
However, the magnitude, breadth, and persistence of the immune response to vaccination may  be 
reduced or absent inimmunocompromised persons. Participant s with abnormal function of the 
immune sy stem will be excluded from the study .
Concomitant Vaccination
Concomitant vaccination might have an influence on both thesafety  profile and immunogenicity 
ofAd26.RSV.preF and/or RSV preF protein. L ikewise, Ad26.RSV.preF and/or RSV preF protein
might have an influence on both the safet y profile and immunogenicity of any concomitant 
vaccination. As a result, vaccination with live attenuated vaccines within 28 days of a vaccinati on 
in this study  (ie, before and after) is prohibited. Other licensed vaccines (ie, not live: eg, influenza, 
tetanus, hepatitis A or B, or rabies) should be given at least 14days before or 14days after each 
study  vaccination to avoid potential confusion of adverse reactions and potential immune 
interference. If a vaccine is indicated in a post -exposure setting (eg, rabies or tetanus), it must take 
priority  over the vaccines in this study .
Potential Benefits
Ad26.RSV.preF and RSV preF protein areunder dev elopment for prophy laxis of RSV, however ,
vaccine efficacy  has not yet been evaluated. There is no direct medical benefit to the participant
for participation in this study . Although study  participants may benefit from clinical testing and 
physical examina tion, they may receive no direct benefit from participation. Others may benefit 
from knowledge gained in this study  that may  aid in the development of an RSV vaccine.
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
GCPis an international ethical and scientific qualit y standard for designing, conducting, recording, 
and reporting studies that involve the participation of human participant s. Compliance with this 
standard provides public assurance that the rights, safety , and well- being of study  participant s are 
protected, consistent with the principles that originated in the Declaration of Helsinki ,and that the 
study  data are credible.
16.2.2. Independent Ethics Committee or Institutional Review  Board
Before the start of the study , the investigator (or sponsor where required) will provide the IEC/I RB 
with current and complete copi[INVESTIGATOR_23747] (as required by  [CONTACT_427]) :
Final protocol and, if applicable, amendments
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 112
Approved , Date: 6 November 2020Sponsor -approved ICF(and any  other written materials to be provided to the participant s)
Investigator ’s Brochure s (or equivalent information) and amendments/addenda
Sponsor -approved participant recruiting materials
Information on compensation for study -related injuries or payment to participant s for 
participation in the study , if applicable
Investigator ’s curriculum vitae or equivalent information (unless not required, as documented 
by [CONTACT_6179]/IRB)
Information regarding funding, name [CONTACT_8152], institutional affiliations, other potential 
conflicts of interest, and incentives for participa nts
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/IRB has given full approval of the final protocol, 
amendments (if any, excluding the ones that are purely  administrative, with no consequences for 
participant s, data or study  conduct , unless required locally ), the ICF, applicable recruiting 
materials, and participant compensation programs, and the sponsor has received a copy of this 
approval. This approval letter must be dated and must clearly  identify the IEC/IRB and the 
documents being approved.
During the study ,the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for participants, data or stud y conduct)
Revision(s) to ICFand any  other written materials to be provided to participant s
If applicable, new or revised participant recruit ing materials approved by  [CONTACT_456]
Revisions to compensation for study -related injuries or payment to participant s for 
participation in the study , if applicable
New edition(s) of the Investigator ’s Brochure (s)and amendments/addenda
Summaries of the status of the study  at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of AEs that are serious, unlisted/unexpected, and associated with the vaccine
New information that may adversel y affect the safety  of the participant s or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the participant s
Report of deaths of participants under the investigator ’s care
Notification if a new investigator is responsible for the study  at the site
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 113
Approved , Date: 6 November 2020Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for participants, data or study conduct) , the amendment and applicable ICFrevisions 
must be submitted promptly to the IEC/IRB for review and approval before implementation of the 
change(s).
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where required.
At the end of the study , the investigator (or sponsor where required) will notify the IEC/IRB about 
the study  completion.
16.2.3. Informed Consent
Each participant must give written consent according to local requirements after the nature of the 
study  has been fully  explained. The ICF(s) must be signed before performance of any study -related 
activity . The ICF(s) that is/areused must be approved by [CONTACT_111177]/IRB and be in a language that the participant can read and understand. The informed conse nt 
should be in accordance with principles that originated in the Declaration of Helsinki, current ICH 
and GCP guidelines, applicable regulatory  requirements, and sponsor policy .
Before enroll ment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential participant s the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study ,and any discomfort participation in the study  may entail. 
Participant s will be informed that their partic ipation is voluntary  and that they may withdraw 
consent to participate at any time. They  will be informed that choosing not to participate will not 
affect the care the participant will receive. Finally , they will be told that the investigator will 
maintain a participant identification register for the purposes of long-term follow -up if needed and 
that their records may be accessed b y health authorities and authorized sponsor personnel without 
violating the confidentiality  of the participant , to the extent permitted by [CONTACT_6983](s) or 
regulations. By [CONTACT_624705]. It also denotes that the 
participant agrees to allow his or her study  physician to recontact [CONTACT_393407] y evaluations, if needed.
The participant will be given suf ficient time to read the ICF and the opportunity  to ask questions. 
After this explanation and before entry  into the study , consent should be appropriatel y recorded by 
[CONTACT_67824] ’s personally  dated signature. After having obtained the consent, a copy of 
the ICFmust be given to the participant .
Additional informed consent for participants progressing to the long-term follow -up phase 
(participants in Groups 14 and 15 in Cohort 2) will be required. Information relevant to 
participat ing in the follow -up phase of the study will be provided to the participant in a timely 
manner, and written informed consent for participation in this phase will be obtained. Additional 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 114
Approved , Date: [ADDRESS_832178]. 
Sponsor personnel whose responsibili ties require access to personal data agree to keep the identity 
of participant s confidential.
The informed consent obtained from the participant includes explicit consent for the processing of 
personal data and for the investigator /institution to allow direct access to his or her original medical 
records (source data/documents) for study -related monitoring, audit, IEC/I RB review, and 
regulatory  inspection. This consent also addresses the transfer of the data to other entities and to 
other countries.
The participant has the right to request through the investigator access to his or her personal data 
and the right to request rectification of an y data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into cons ideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
16.2.5. Long -Term Retention of Samples for Additional Future Research
Samples collected in this study  may be stored for up to 15 y ears (or according to local regulations) 
for additional research. Samples will only be used to understand Ad26.RSV.preF and RSV preF 
protein, to understand RSV, and to develop tests/assay s related to Ad26.RSV.preF and RSV preF 
protein and RSV .The research may begin at any time during the study  or the post-study  storage 
period. Included are samples from participants who were screened but not randomized which may 
also be used to develop tests/assays related to Ad26.RSV.preF, RSV preF protein, and RSV.
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Participant s may withdraw their consent for their samples to be 
stored for research ( seeSection 10.2).
16.2.6. Country Selection
This study  will only be conducted in those countries where the intent is to launch or otherwise help 
ensure access to the developed product.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 115
Approved , Date: [ADDRESS_832179] not be implemented witho ut prior IEC/IRB approval, or 
when the relevant competent authority  has raised any grounds for non-acceptance, except when 
necessary  to eliminate immediate hazards to the participant s, in which case the amendment must 
be promptly  submitted to the IEC/I RB and relevant competent authority . Documentation of 
amendment approval b y the investigator and IEC/IRB must be provided to the sponsor. When the 
change(s) involves only logistic or administrative aspects of the study , the IEC/IRB (where 
required) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact [CONTACT_90814] (s), which will be provided as a separate document . Except 
in emergency  situations, this contact [CONTACT_393404]. In all cases, contact [CONTACT_576696]. The data recorded in the eCRF and source 
documents will reflect any departure from the protocol, and the source documents will describe 
this departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory  
requirements ar e met.
17.2.2. Required Pre -study  Documentation
The following documents must be provided to the sponsor before shipment of vaccine sto the study
site:
Protocol and amendment(s), if an y, signed and dated by [CONTACT_978](s).
A copy of the dated and signed (or sealed, wher e appropriate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, participant compensation programs. This approval must clearly  identify  the 
specific protocol by [CONTACT_23850] (or sealed, where appropriate per 
local regulations) by [CONTACT_23851].
Name [CONTACT_23875]/IRB, including a current list of the I EC/I RB members and their 
function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, from 
the IEC/IRB, a general statement may be substituted for this list. If an investigator or a 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 116
Approved , Date: 6 November 2020member of the study -site personnel isa member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the vote/opi[INVESTIGATOR_66821] .
Regulatory  authority  approval or notification, if applicable .
Signed and dated statement of inv estigator (eg, Form FDA 1572), if applicable .
Documentation of investigator qualifications (eg, curriculum vitae).
Completed investigator financial disclosure form from the PI(s), where required.
Signed and dated Clinical Trial Agreement, which includes the financial agreement.
Any other documentation required by  [CONTACT_427].
The following documents must be provided to the sponsor before enroll ment of the first 
participant :
Completed investigator financial disclosure forms from all sub- investigators.
Documentation of sub -investigator qualifications (eg, curriculum vitae).
Name [CONTACT_67857] , and a dated copy  of 
current laboratory normal ranges for these tests, if applicable .
Local laboratory docume ntation demonstrating competence and test reliability  (eg,
accreditation/license), if applicable .
17.3. Participant Identification, Enroll ment, and Screening Logs
The investigator agrees to complete a participant identification and enroll ment log to permit easy  
identification of each participant during and after the study . This document will be reviewed by 
[CONTACT_43786] -site contact [CONTACT_23853].
The participant identification and enroll ment log will be treated as confidential and will be filed 
by [CONTACT_23854]. To ensure participant confidentiality , no copy  will be made. 
All reports and communications relating to the study  will identify  participants by [CONTACT_624706] . In cases where the participant is not randomized into the study , the 
date seen and date of birth will be used.
The investigator must also complete a participant screening log, which reports on all participant s 
who were seen to determine eligibility  for inclusion in the study .
17.4. Source Documentation
At a minimum, source document s consistent in the type and level of detail with that commonly  
recorded at the study  site as a basis for standard medical care must be available for the following: 
participant identification, eligibility , and study  identification; study  discussion and date of signed 
informed consent; dates of visits; results of safety  and immunogenicity parameters as required by  
[CONTACT_760]; record of all AEs and follow -up of AEs ; concomitant medication; vaccine
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 117
Approved , Date: 6 November 2020receipt/dispensing/return records; vaccine administration information ; and date of study 
completion and reason for early discontinuation of vaccine or withdrawal from the study , if 
applicable.
The author of an entry  in the source documents should be identifiable.
Specific details required as source data for the study  and source data collection methods will be 
reviewed with the investigator before the study and will be described in the monitoring guidelines 
(or o ther equivalent document).
The participant diary  used to collect information regarding solicited events after vaccination will 
be considered source data. At the visits at 7 days after each vaccination, information from the 
participant diary  will be reviewe d by [CONTACT_093]; diary  information will be transcribed by 
[CONTACT_3449] -sitepersonnel into the eCRF as described in the eCRF Completion Guidelines .
An electronic source (eSource )system may be utilized, which contains data traditionally 
maintained in a hospi[INVESTIGATOR_23749] (eg, electronic source 
documents) as well as the clinical study -specific data fields as determined by [CONTACT_760]. This 
data is electronically  extracted for use by [CONTACT_456]. If eSource is utilized, referen ces made to 
the eCRF in the protocol include the eSource system but information collected through eSource 
may not be limited to that found in the eCRF.
17.5. Case Report Form Completion
CRFs are prepared and provided by [CONTACT_624707]. All eCRF
entries, corrections, and alterations must be made by [CONTACT_70464] -site 
personnel. The investigator must verify  that all data entries in the eCRF are accurate and correct.
The study  data will be trans cribed by [CONTACT_3449]-sitepersonnel from the source documents onto an 
eCRF ,if applicable. Study -specific data will be transmitted in a secure manner to the sponsor.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF . Any 
such worksheets will become part of the participant’ s source document s. Data must be entered into 
the eCRF in English. The eCRF must be completed as soon as possible after a participant visit and 
the forms should be available for review at the next schedule d monitoring visit.
If necessary , queries will be generated in the eDC tool. If corrections to a neCRF are needed after 
the initial entry  into the eCRF , this can be done in either of the following ways:
Investigator and study-site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  [CONTACT_66832]) .
Sponsor or sponsor delegate can generate a query  for resolution by [CONTACT_70449] -
site personnel.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 118
Approved , Date: 6 November 202017.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -sitepersonnel before the study , and period ic monitoring visits by [CONTACT_456]. Written 
instructions will be provided for collection, handling, storage, and shipment of samples.
Guidelines for eCRF completion will be provided and reviewed with study -sitepersonnel before 
the start of the stud y.
The sponsor will review eCRF for accuracy  and completeness during on-site monitoring visits and 
after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designee, as appropriate. After upload of the data into the study database they  will be verified for 
accuracy  and consistency with the data sources.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF 
and all source documents that support the data collected fro m each participant , as well as all study 
documents as specified in I CH/GCP Section 8, Essential Documents for the Conduct of a Clinical 
Trial, and all study  documents as specified by [CONTACT_23859](s). The 
investigator/institution will take measures to prevent accidental or premature destruction of these 
documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contempl ated marketing applications 
in an I CH region or until at least [ADDRESS_832180]. These documents will be retained for a longer period 
if required by [CONTACT_66891]. It is the 
responsibility  of the sponsor to inform the investigator/institution as to when these documents no 
longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keepi[INVESTIGATOR_13274], custody  must be transferred to a person who will accept 
the responsibility . The sponsor must be notified in writing of the name [CONTACT_66903]. Under no circum stance shall the investigator relocate or dispose of any study documents 
before having obtained written approval from the sponsor.
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such reports.
17.8. Monitoring
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study -site visit log that will be kept at the study  site. The first post -
initiation visit will be made as soon as possible after enroll ment has begun. At these visits, the 
monitor will compar e the data entered into the eCRF with the source documents (eg,
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 119
Approved , Date: 6 November 2020hospi[INVESTIGATOR_307]/clinic/phy sician ’s office medical records) . The nature and location of all source 
documents will be identified to ensure that all sources of original data required to complete the 
eCRF are known to the sponsor and study -site personnel and are accessible for verification by [CONTACT_66886] -site contact. If electronic records are maintained at the study site, the method of 
verification must be discussed with the study -site personnel .
Direct access to source documents (medical records) must be allowed for the purpose of verifying 
that the recorded data are consistent with the original source data. Findings from this review will 
be discussed with the study -site personnel . The sponsor expects that, during monitoring visits, the 
relevant study -site personnel will be available, the source document swill be accessible, and a 
suitable environment will be provided for review of study -related documents. The monitor will 
meet with the investigator on a regular basis during the study to provide feedback on the study
conduct .
17.9. Study Completion/Termination
17.9.1. Study Completion /End of Study
The end of the study  will be the last participant ’s last visit 24months after the first vaccination
(Cohort 1 and Cohort 2 [Groups 11-13 and Groups 16-18]) or the last participant’s last visit 
36months after the first vaccination (Cohort 2 [Groups 14-15] and Cohort 3).The study  is 
considered completed with the last visit for the last participant participating in the study. The final 
data from the study site will be sent to the sponsor (or designee) after completion of the final 
participant visit at that study  site, in the time frame specified in the Clinical Trial Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor .Study sites will be closed upon study  completion. A
study site is considered closed when all required documents and study  supplies have been collected 
and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of a study site by [CONTACT_941] s ponsor or investigator may include but are not 
limited to:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor’ s procedures, or GCP guidelines
Inadequate recruitment of participa nts by [CONTACT_093]
Discontinuation of further study  vaccine development
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 120
Approved , Date: 6 November 202017.10. On-Site A udits
Representatives of the sponsor’ s clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection. Participant privacy  must, however, be 
respected. The investigator and study -site personnel are responsible for being present and available 
for consultation during routinely scheduled study -site audit visits conducted by  [CONTACT_66893] .
Similar auditing procedures may also be conducted by [CONTACT_23865], either as part 
of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify the sponsor if he or shehas
been contact[INVESTIGATOR_530] b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding Ad26.RSV.preF and RSV preF 
protein or the sponsor ’s operations (eg, patent application, formulas, manufacturing processes, 
basic scientific data, prior clinical data, formulation information) supplied by [CONTACT_170193], and any data generated as a result of this study , are
considered confidential and remain the sole property  of the sponsor. The investigator agrees to 
maintain this information in confidence and use this information only to accomplish this study , 
and will not use it for other purp oses without the sponsor ’s prior written consent.
The investigator understands that the information developed in the study will be used by [CONTACT_111181]26.RSV.preF and RSV preF protein , 
and thus may be disclosed as required to other clinical investigators or regulatory  agencies. To 
permit the information derived from the clinical studies to be used, the investigator is obligated to 
provide the sponsor with all data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by [CONTACT_624708]-protocol . Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator . Results of analy ses performed after 
the Clinical Study  Report has been issued will be reported in a separate report and will not require 
a revision of the Clinical Study  Report . Study  participant identifiers will not be used in publication 
of results. Any work created in connection with performance of the study  and contained in the data 
that can benefit from copy right protection (except any  publication by  [CONTACT_460482]) shall be the property  of the sponsor as author and owner of copy right in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, t he sponsor shall have the right to publish such primary  (multi- center ) data and 
information without approval from the investigator. The investigator has the right to publish study 
site-specific data after the primary  data are published. If an investigator wishes to publish 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 121
Approved , Date: [ADDRESS_832181] been 
submitted for publication, within 12months of the availability  of the final data (tables, listings, 
graphs), or the sponsor confirms there will be no multi- center study  publication. Authorship of 
publications resulting from this study  will be based on the guidelines on authorship, such as those 
described in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, which 
state that the named authors must have made a significant contribution to the design of the study 
or analysis and interpretation of the data, provided critical review of the paper, and given final 
approval of the final version.
Registration of Clinical Studies a nd Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as required 
by [CONTACT_2371].
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 122
Approved , Date: 6 November 202018. APPENDIX 1: GUIDA NCE ON STUDY C ONDUCT DURING THE CO VID-19 
PANDEMIC
It is recognized that the Coronavirus Disease 2019 (COVID -19) pandemic may  have an impact on 
the conduct of this clinical study due to, for example, self -isolation/quarantine by  [CONTACT_90830] -site personnel; travel restrictions/limited access to public places, including hospi[INVESTIGATOR_600]; study  
site personnel being reassigned to critical tasks. 
In alignment with recent health authority  guidance, the sponsor is providing options for study  
related participant management in the event of disruption to the conduct of the study . This guidance 
does not supersede any local or government requirements or the clinical judgement of the 
investigator to protect the health and well- being of participants and site staff. If, at any time, a 
participant’s safet y is considered to be at risk, study  intervention will be discontinued, and study 
follow -up will be conducted.
Scheduled visits that cannot be conducted in person at the study  site will be performed to the extent 
possible remotel y/virtually  or delayed until such time that on-site visits can be resumed. At each 
contact, participants will be interviewed to collect safet y data. Key efficacy endpoint assessments 
should be performed if required and as feasible. Participants will also be questioned regarding 
general health status to fulfill any  physical examination requirement . 
Every  effort should be made to adhere to protocol -specified assessments for participants on study 
intervention, including follow up. Modifications to protocol -required assessments may be 
permitted via COVID -19 Appendix after consultation with the partic ipant, investigator, and the 
sponsor. Missed assessments/visits will be captured in the clinical trial management system for 
protocol deviations. Discontinuations of study  interventions and withdrawal from the study  should 
be documented with the prefix “CO VID-19 -related” in the case report form (CRF). 
The sponsor will continue to monitor the conduct and progress of the clinical study , and any 
changes will be communicated to the sites and to the health authorities according to local guidance.
If a participa nt has tested positive for COVID 19, the investigator should contact [CONTACT_456]’s 
responsible medical officer to discuss plans for study  intervention and follow -up. Modifications 
made to the study  conduct as a result of the COVID -19 pandemic should be summarized in the 
clinical study  report.
GUIDANCE SPECIFIC TO THIS PROTOCOL : 
When site visits are not possible due to local/national guidelines, sites should collect the 
assessments via telephone visits or home -based visits, if the participant allows. The actual 
visit date and the type of visit (ie, telephone or home -based visit) should be captured in the 
eCRF. Procedures that cannot be performed during a home -based visit (eg, clinical 
assessments, blood samples, nasal samples and physical examination) ,should be excluded. 
The missed procedures should be recorded as “missed due to COVID -19”.
When planning for vaccination visits, local/national or institutional guidelines will be 
followed. The study  vaccine should be administered by [CONTACT_1629](unblinded) pharmac ist or other 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 123
Approved , Date: 6 November 2020qualified individual at the study  site. If this is not possible, a solution may be considered in 
consultation with the sponsor and taking into consideration participant safety . Of note, if a 
scheduled stud y vaccination is not possible at the s cheduled visit time, the vaccination should 
occur within 3 weeks after the scheduled visit.
A revised ICF arising from this amendment needs to be signed by [CONTACT_624709] a 
site visit or home -based visit, if the participant allows. When a site or home -based visit is not 
possible due to local/national guidelines, the participant can sign the paper ICF and mail the 
signed document to the site. 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 124
Approved , Date: [ADDRESS_832182] and 
polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med. 2010:181;1407 -1417.
2. Anderson L, Dormitzer P, Nokes D, et al. Strategic priorities for respi[INVESTIGATOR_4345] (RSV) vaccine 
development. Vaccine. 2013:[ADDRESS_832183] .2;B209 -215.
3. August A, Glenn G, Kpamegan E, et al. A Phase 2 randomized, observer -blind, placebo -controlled, dose-
ranging trial of aluminum -adjuvanted respi[INVESTIGATOR_4345] F particle vaccine formulations in healthy 
women of childbearing age. Vaccine. 2017;35(3 0):[ADDRESS_832184]-in-human evaluation of the safety and immunogenicity of a 
recombinant adenovirus serotype 26 HIV -1 Env vaccine (IPCAVD 001). J Infect Dis. 2013:207;240 -247.
5. Barouch D, Liu J, Peter L, et al. Characterization of humoral and cellular immune responses elicited by a 
recombinant adenovirus serotype 26 HIV -1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis. 
2013:207;248 -256.
6. Collins P, Chanock R, Murphy B. Respi[INVESTIGATOR_4345]. In: K nipe D, Howley P, Griffin D et al, 
editors. Fields Virology, Volume 1, Ed 4. Philadelphia: Lippi[INVESTIGATOR_4431] & Wilkins 2001:[ADDRESS_832185] Dis. 2017;216(11):1362 -1370. 
8. Falsey A, Hennessey P, Formica M, et al. Respi[INVESTIGATOR_153653] -risk 
adults. N Engl J Med. 2005:352;1749 -1759.
9. Falsey A, Walsh E. Respi[INVESTIGATOR_624642]. Clin Microbiol Rev. 2000:13;371 -384.
10. Gidudu J, Walco G, Taddio A, et al. Immunization site pain: case definition and guidelines for collection, 
analysis, and presentation of immunization safety data. Vaccine. 2012:30;4558- 4577.
11. Gilman M, Castellanos C, Chen M, et al. Rapid profiling of RSV antibody repertoires from the memory B 
cells of naturally infected adult donors. Sci Immunol. 2016:1. doi: 10.1126/sciimmunol.aaj1879.
12. Graham B, Modjarrad K, McLellan J. Novel antigens for RSV vaccines. Curr Opin Immunol. 2015:35;30 -
38.
13. Hall C, Weinberg G, Iwane M, et al. The burden of respi[INVESTIGATOR_153655]. N 
Engl J Med. 2009:360;588 -598.
14. Janssen Vaccines & Prevention B.V. Adenoviral Vaccine Safety Da tabase -Report December 2017. 
15. Janssen Vaccines & Prevention B.V. Adenoviral Vaccine Safety Database v 2.0. Addendum. September 
2017. 
16. Janssen Vaccines & Prevention B.V. Data on file. 
17. Janssen Vaccines & Prevention B.V. Investigator ’s Brochure: PreF Pro tein. Edition 4. 
18. Janssen Vaccines & Prevention B.V. Investigator ’s Brochure: Prophylactic RSV Vaccine. Edition 10. 
19. Janssen Vaccines & Prevention B.V. Study VAC18192RSV1001: A Phase 1, First -in-Human Study to 
Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With 
Ad26.RSV.FA2 in Healthy Adult Volunteers. Final Clinical Study Report. 
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 125
Approved , Date: 6 November 202020. Janssen Vaccines & Prevention B.V. Study VAC18192RSV1003: A Phase 1, First -in-Human Study to 
Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Follow ed by  [CONTACT_300092]35.RSV.FA2 in 
Healthy Adult Volunteers. Final Clinical Study Report. 
21. Kapi[INVESTIGATOR_327859] A, Mitchell R, Chanock R, et al . An epi[INVESTIGATOR_624643] (RS) virus infecti on in children previously vaccinated w ith an inactivated RS virus vaccine. Am J 
Epi[INVESTIGATOR_5541]. 1969:89;405 -421.
22. Kohl K, Walop W, Gidudu J, et al. Induration at or near injection site: case definition and guidelines for 
collection, analysis, and presentation o f immunization safety data. Vaccine. 2007:25;5839 -5857.
23. Kohl K, Walop W, Gidudu J, et al. Swelling at or near injection site: case definition and guidelines for 
collection, analysis and presentation of immunization safety data. Vaccine. 2007:25;5858 -5874.
24. Krarup A, Truan D, Furmanova -Hollenstein P, et al. A highly stable prefusion RSV F vaccine derived from 
structural analysis of the fusion mechanism. Nat Commun. 2015:6;8143.
25. Magro M, Mas V, Chappell K, et al. Neutralizing antibodies against the preactiv e form of respi[INVESTIGATOR_624644]. Proc Natl Acad Sci U S A. 
2012:109;3089 -3094.
26. Marcy S, Kohl K, Dagan R, et al. Fever as an adverse event following immunization: case definition and
guidelines of data collection, analysis, and presentation. Vaccine. 2004:22;551 -556.
27. Milligan I, Gibani M, Sewell R, et al. Safety and immunogenicity of novel adenovirus type 26 -and modified 
vaccinia ankara- vectored ebola vaccines: a randomized clinical trial. JAMA. 2016:315;1610 -1623.
28. Moghaddam A, Olszewska W, Wang B, et al. A potential molecular mechanism for hypersensitivity caused 
by [CONTACT_328057] -inactivated vaccines. Nat Med. 2006:12;905 -907.
29. Ngwuta J, Chen M, Modjarrad K, et al. Prefusion F -specific antibodies determine the magnitude of RSV 
neutralizing activity in human sera. Sci Transl Med. 2015:7;309ra162.
30. [No authors listed] Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit 
Protein Vaccine, VRC -RSVRGP084 -00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults. 
Available at: https://clinicaltrials.gov/ct2/show/record/[STUDY_ID_REMOVED]?term=nih&cond=rsv&rank=2. 
Accessed on 18 January 2018.
31. Ouedraogo A, Tiono A, Kargougou D, et al. A phase 1b randomized, control led, double -blinded dosage-
escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based 
circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS One. 
2013:8;e78679.
32. Shay D, Holma n R, Newman R, et al. Bronchiolitis -associated hospi[INVESTIGATOR_469022], 1980 -
1996. JAMA. 1999:282;[ADDRESS_832186] Dis J. 
2012:31;[ADDRESS_832187] presented at: 61st ASTMH 
Meeting, November 11 -15, 2012; Atlanta, GA, [LOCATION_003]. 
35. Thompson W, Shay D, Weintraub E, et al. Mortality associated w ith influenza and respi[INVESTIGATOR_624645]. JAMA. 2003:289;179 -186.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 126
Approved , Date: 6 November 202036. US Department of Health and Human Services. Office for Human Research Protections -OHRP Expedited 
Revie w Categories (1998). Available at: http://www.hhs.gov/ohrp/regulations -and-
policy/guidance/categories -of-research -expedited -review -procedure -1998/index html . Accessed on 18
January 201 8.
37. US Food and Drug Administration. Conditions for IRB Use of Expedited Revie w. Available at: 
https://www.fda.gov/ScienceResearch/SpecialTopi[INVESTIGATOR_1102]/Run ningClinicalTrials/GuidancesInformationSheetsan
dNotices/ucm118099 htm . Accessed on 18 January 201 8.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 127
Approved , Date: 6 November 2020Attachment 1: Toxicity Tables
Adapted from the FDA Guidance document “Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enroll ed in Preventive Vaccine Clinical Trials” (September 2007) .
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 128
Approved , Date: 6 November 2020A: Tables for Clinical Abnormalities
Local Reaction to
Injectable ProductMild
(Grade 1 )Moderate
(Grade 2 )Severe
(Grade 3 )Potentially Life -threatening
(Grade 4 )
Pain Does not interfere
with activityRepeated use of 
non-narcotic
pain reliever
> 24 hours or
interferes with
activityAny use of
narcotic pain
reliever or
prevents daily
activityEmergency room
(ER) visit or
hospi[INVESTIGATOR_624646]/redness* 2.5 –5 cm 5.1 –10 cm > 10 cm Necrosis or
exfoliative
dermatitis
Induration/swelling** 2.5 –5 cm and
does not interfere
with activity5.1 –10 cm or
interferes with
activity> 10 cm or
prevents daily
activityNecrosis
* In addition to grading the measured local reaction at the greatest single diameter, the measurement should be recorded as a
continuous variable.
** Induration/Swelling should be evaluated and graded using the functional scale as well as the actual measurement.
Vital Signs * Mild
(Grade 1 )Moderate
(Grade 2 )Severe
(Grade 3 )Potentially Life -threatening
(Grade 4 )
Fever** (°C)
Fever** (°F)38.0 –38.4
100.4 –101.138.5 –38.9
101.2 –102.039.0 –40
102.1 –104> 40
> 104
Tachycardia -beats per 
minute101 – 115 116 – 130 > 130 ER visit or hospi[INVESTIGATOR_106313] -beats per 
minute***50 –54 45 –49 < 45 ER visit or hospi[INVESTIGATOR_106314] (systolic) 
-mm Hg ****141 – 150 151 – 160 > 160 ER visit or hospi[INVESTIGATOR_624647] 
(diastolic) -mm Hg91 –95 96 –100 > 100 ER visit or hospi[INVESTIGATOR_624648] (systolic) 
-mm Hg85 –89 80 –84 < 80 ER visit or hospi[INVESTIGATOR_624649] -
breaths per minute17 –20 21 –25 > 25 Intubation
* Participant should be at rest for all vital sign measurements.
** Oral body temperature; no recent hot or cold beverages or smoking.
*** When resting heart rate is between 60 and100 beats per minute. Use clinical judgment when characterizing bradycardia 
among some healthy participant populations, for example, conditioned athletes.
**** Revised by [CONTACT_456] .
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 129
Approved , Date: 6 November 2020Systemic
(General)Mild
(Grade 1)Moderate
(Grade 2 )Severe
(Grade 3 )Potentially Life -threatening 
(Grade 4 )
Nausea/vomiting No interference 
with activity or
1 -2 epi[INVESTIGATOR_1841]/24 
hoursSome interference 
with activity or 
> 2epi[INVESTIGATOR_1841]/24 
hoursPrevents daily 
activity, requires 
outpatient IV 
hydrationER visit or hospi[INVESTIGATOR_106318] 2 -3 loose stools 
or < 400 gms/24 
hours4 -5 stools or
400 -800 gms/24 
hours6 or more w atery 
stools or 
>800gms/24 
hours or requires 
outpatient IV 
hydrationER visit or hospi[INVESTIGATOR_624650]-narcotic pain 
reliever > 24 hours 
or some 
interference with 
activitySignificant; any 
use of narcotic 
pain reliever or 
prevents daily 
activityER visit or hospi[INVESTIGATOR_93276]; 
prevents daily 
activityER visit or hospi[INVESTIGATOR_93277]; 
prevents daily 
activityER visit or hospi[INVESTIGATOR_624651]
(Grade 1 )Moderate
(Grade 2 )Severe
(Grade 3 )Potentially Life -threatening 
(Grade 4 )
Illness or clinical 
adverse event (as 
defined according to 
applicable regulations)Awareness of 
symptoms that 
are easily 
tolerated, causing 
minimal 
discomfort and 
not interfering 
with everyday 
activitiesSufficient 
discomfort is 
present to cause 
interference with 
norm al activityExtreme distress, 
causing 
significant 
impairm ent of 
functioning or 
incapacitation. 
Prevents norma l 
everyday 
activitiesSymptoms causing inability to 
perform basic self -care 
functions OR medical or 
operative intervention 
indicated to prevent permanent 
impairm ent, persistent 
disability
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 130
Approved , Date: 6 November 2020B: Tables for Laboratory Abnormalities
The grading scale used for laboratory assessments is based on the FDA Guidance document “Toxicity 
Grading Scale from Healthy Adult and Adolescent Volunteers Enroll ed in Preventive Vaccine Clinical 
Trials”. Any laboratory value shown as a “graded” value in the table that is within the central laboratory
normal ranges will not be graded for severity or recorded as an AE. For hemoglobin, both the actual value 
and the change from reference will be graded. For the change from reference, the corresponding actual 
value should also be at least Grade 1.
Serum * Mild
(Grade 1 )Moderate
(Grade 2 )Severe
(Grade 3 )Potentially Life -
threatening
(Grade 4 ) **
Sodium -
hyponatremia -mEq/L132 – 134 130 – 131 125 – 129 < 125
Sodium -
hypernatremia -
mEq/L144 – 145 146 – 147 148 – 150 > 150
Potassium -
hyperkalemia -mEq/L5.1 –5.2 5.3 –5.4 5.5 –5.6 > 5.6
Potassium -
hypokalemia -mEq/L3.5 –3.6 3.3 –3.4 3.1 –3.2 < 3.1
Glucose -
hypoglycemia -mg/dL65 –69 55 –64 45 –54 < 45
Glucose -
hyperglycemia fasting 
-mg/dL100 – 110 111 – 125 > 125 Insulin requirements 
or hyperosmolar 
coma
Random glucose -
mg/dL110 – 125 126 – 200 > 200
Blood urea nitrogen 
BUN -mg/dL23 –26 27 –31 > 31 Requires dialysis
Creatinine -mg/dL 1.5–1.7 1.8 –2.0 2.1 –2.5 > 2.5 or requires 
dialysis
Calcium -
hypocalcemia -mg/dL8.0 –8.4 7.5 –7.9 7.0 –7.4 < 7.0
Calcium -
hypercalcemia -mg/dL10.5 –11.0 11.1 –11.5 11.6 –12.0 > 12.0
Magnesium -
hypomagnesemia -
mg/dL1.3 –1.5 1.1 –1.2 0.9–1.0 < 0.9
Phosphorous -
hypophosphatemia -
mg/dL2.3 –2.5 2.0 –2.2 1.6 –1.9 < 1.6
CPK -mg/dL 1.25 –1.[ADDRESS_832188]*** 1.6 –3.[ADDRESS_832189] 3.1 –[ADDRESS_832190] > [ADDRESS_832191]
Albumin -
Hypoalbuminemia -
g/dL2.8 –3.1 2.5 –2.7 < 2.5 --
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 131
Approved , Date: 6 November 2020Serum * Mild
(Grade 1 )Moderate
(Grade 2 )Severe
(Grade 3 )Potentially Life -
threatening
(Grade 4 ) **
Total protein -
hypoproteinemia -
g/dL5.5 –6.0 5.0 –5.4 < 5.0 --
Alkaline phosphate -
increase by [CONTACT_12245]1.1 –2.[ADDRESS_832192] 2.1 –3.[ADDRESS_832193] 3.1 –[ADDRESS_832194] > [ADDRESS_832195] increase by 
[CONTACT_12245]1.1 –2.[ADDRESS_832196] 2.6 –5.[ADDRESS_832197] 5.1 –[ADDRESS_832198] > [ADDRESS_832199] increase 
by [CONTACT_12245]1.1 –1.[ADDRESS_832200] 1.26 –1.[ADDRESS_832201] 1.51 –1.[ADDRESS_832202] > 1.[ADDRESS_832203]
Bilirubin –when liver 
function test is normal; 
increase by [CONTACT_12245]1.1 –1.[ADDRESS_832204] 1.6 –2.[ADDRESS_832205] 2.0 –3.[ADDRESS_832206] > 3.[ADDRESS_832207]
Cholesterol 201 –210 211 –225 > 226 --
Pancreatic enzymes -
amylase, lipase1.1 –1.[ADDRESS_832208] 1.6 –2.[ADDRESS_832209] 2.1 –5.[ADDRESS_832210] > 5.[ADDRESS_832211]
* The laboratory values provided in the tables serve as guidelines and are dependent upon central laboratory normal parameters. 
Central laboratory normal reference ranges should be provided to demonstrate that they are appropriate.
** The clinical signs or symptoms associ ated with laboratory abnormalities might result in characterization of the laboratory
abnormalities as potentially life-threatening (Grade 4). For example ,a low sodium value that falls within a Grade 3 parameter (125-
129mE/L) should be recorded as a Grade 4 hyponatremia event if the participant had a new seizure associated with the low sodium 
value.
***ULN is the upper limit of the normal range.
VAC18193 (JNJ-64400141)
Clinical Protocol VAC18193RSV1004 Amendment 6
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 132
Approved , Date: 6 November 2020Hem atology * Mild
(Grade 1 )Moderate
(Grade 2 )Severe
(Grade 3 )Potentially Life -
threatening
(Grade 4 ) **
Hem oglobin ( female) -
gm/dL11.0 –12.0 9.5 –10.9 8.0 –9.4 < 8.0
Hem oglobin ( female) 
change from baseline 
value -gm/dLAny decrease –1.5 1.6 –2.0 2.1 –5.0 > 5.0
Hem oglobin ( male) -
gm/dL12.5 –13.5 10.5 –12.4 8.5 –10.4 < 8.5
Hem oglobin ( male) 
change from baseline 
value -gm/dLAny decrease –1.5 1.6 –2.0 2.1 –5.0 > 5.0
WBC increase -
cell/mm310,800 –15,000 15,001 –20,000 20,001 –25,000 > 25,000
WBC decrease -
cell/mm32,500 – 3,500 1,500 – 2,499 1,000 – 1,499 < 1,000
Lymphocytes decrease 
-cell/mm3750 –1,000 500 – 749 250 – 499 < 250
Neutrophils decrease -
cell/mm31,500 – 2,000 1,000 – 1,499 500 – 999 < 500
Eosinophils -cell/mm3650 –1,500 1,501 –5,000 > 5,000 Hypereosinophilic
Platelets decreased -
cell/mm3125,000 –140,000 100,000 –124,000 25,000 –99,000 < 25,000
PT -increase by [CONTACT_12245] 
(prothrombin time)1.0 –1.[ADDRESS_832212]** 1.11 –1.[ADDRESS_832213] 1.21 –1.[ADDRESS_832214] > 1.[ADDRESS_832215]
PTT -increase by 
[CONTACT_12245] (partial 
thromboplastin time)1.0 –1.[ADDRESS_832216] 1.21 –1.[ADDRESS_832217] 1.41 –1.[ADDRESS_832218] > 1.[ADDRESS_832219]
Fibrinogen increase -
mg/dL400 – 500 501 – 600 > 600 --
Fibrinogen decrease -
mg/dL150 – 200 125 – 149 100 – 124 < 100 or associated 
with gross bleeding 
or disseminated 
intravascular 
coagulation (DIC)
* The laboratory values provided in the tables serve as guidelines and are dependent upon central laboratory normal parameters. 
Central laboratory normal reference ranges should be provided to demonstrate that they are appropriate.
** ULN is the upper limit of the normal range.